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Novelty and Hypotheses of the Current Study 
Epithelial cancers are the most prominent in cancer history. In the present day scenario, 
a great deal of chemotherapeutic drugs are used; however, their efficiency and 
effectiveness are not reaching the standards because of their half-life and bioavailability 
at the tumour site(s). Hence, a new approach to treating the cancers is investigated with 
cancer cell targeted therapy. This thesis studies specified cancer cell surface markers, 
called epithelial cell adhesion molecule (EpCAM) and nucleolin. These cancer cell 
biomarkers were used in cancer cell specific targeted delivery for therapeutic 
applications by Neocarzinostatin and saporin as anti-cancer molecules in epithelial 
cancers such as breast cancer, retinoblastoma and liver cancers. The novelty and 
importance of the current study are listed below: 
 biophysical investigation of EpCAM aptamer-Neocarzinostatin and its 
interactions with the active site for enhancing EpCAM aptamer as a delivery 
vehicle to target Neocarzinostatin 
 developing EpCAM antibody and ribosomal inactivating protein (RIP) saporin 
conjugates for EpCAM positive tumours 
 investigating the role of Neocarzinostatin by conjugating with EpCAM aptamer 
as a therapeutic agent against epithelial cancers 
 using Neocarzinostatin-EpCAM aptamer conjugates to prepare novel 
nanoparticles and their use against epithelial cancers in-vitro and in-vivo. 
Knowledge gaps that this study aims to fill 
Chemotherapy is a common method for treating cancers; however, it has enormous 
disadvantages as chemotherapeutic drugs have many side effects, drug resistance and 
off-target delivery. Hence, targeted therapy is needed to treat the cancers without 
affecting the other tissues and organs. Molecular targets widely in the cancer research 
field are HER-2, BRAF, nucleolin and EpCAM. These cancer cell surface molecules or 
receptors are targeted by using antibodies, affibodies or diabodies. They deliver the 
drugs very efficiently and effectively; however, due to their macromolecular size, 
cytotoxicity and immunogenicity causing inflammation, they are extensively studied for 
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alternative strategies. In the case of epithelial tumours, chemotherapy, radiation therapy 
and surgery have been the only affordable means of treatment. A great deal of research 
has been carried out on targeted cancer therapy, as it is more effective than conventional 
methods of treatment. 
The aforementioned drawbacks will be addressed in this study by using molecular 
targets and different modes of targeted therapy in epithelial tumours as a proof of 
concept study. These include: 
1) examining the role of EpCAM in tumourigenesis, design the aptamer specific to 
EpCAM and find the interactions between the drug (Neocarzinostatin) and 
aptamer for better efficiency of the aptamer 
2) developing the antibody drug (saporin-RIP) conjugate to examine the effect of 
the conjugate in the epithelial cancer cells 
3) fabricating aptamer-Neocarzinostatin conjugate nanoparticles decorated with 
EpCAM and nucleolin aptamer for a double-targeted effect in epithelial 
tumours. The use of nucleolin in hepatocellular-carcinoma 
4) using aptamer-Neocarzinostatin nanoparticles in a liver cancer xenograft model. 
This can help in new therapeutic approaches to cancer therapy, especially in 
epithelial tumours. 
Aim and objectives of the study 
The targeting of drugs to specific cancer types without affecting healthy cells and the 
imaging of cancer cells by targeted ligands are still under research. At this juncture, 
using targeting ligands or markers that help in cancer cell therapy is of moral 
importance. New approaches in therapy and cancer cell biology include EpCAM, a 
protein that helps in cancer cell signalling and invasion and nucleolin, a protein 
involved in the transcriptional mechanism. Both of these molecules can be translocated 
between the cancer cell surface and the cytoplasm and help transfer drugs to achieve 
internalisation, avoiding drug resistant Poly-glycoproteins (Pgp) molecules. 
This study aims to construct the conjugates that are highly specific to EpCAM positive 
cancers for therapy and imaging. The objectives of this study can be achieved by 
fulfilling the following smaller objectives: 
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1) investigating the interaction between Neocarzinostatin and EpCAM aptamer for 
stability—a biophysical approach. Neocarzinostatin (NCS) is an antitumour, 
antibiotic chromophore-protein involved in DNA damage. The conjugation of 
NCS with the EpCAM aptamer might result in the degradation of the aptamer. 
Therefore, the physical interaction was studied using a biophysical approach. 
The secondary structure prediction of the EpCAM aptamer and NCS was 
investigated separately and the interaction between the NCS main protein vs. the 
aptamer and NCS-chromophore vs. the aptamer were studied to discover the 
stability of the aptamer to NCS to conjugate these two for therapeutic use. 
2) conjugating the EpCAM antibody-saporin conjugate and the EpCAM aptamer-
NCS conjugate to investigate the targeting potential of EpCAM and the 
effectiveness of drugs in epithelial cancers. This aim was achieved by 
conjugating the EpCAM antibody-saporin conjugate and the EpCAM aptamer-
NCS conjugate and characterising the conjugates for their conjugation 
efficiency. Thus, the conjugates are tested in-vitro for their effectiveness and 
therapeutic efficiency in cancer cells. This is followed by imaging of the cells 
using florescent-labelled aptamer to investigate the role of EpCAM in the 
prognosis of the epithelial tumours. 
3) fabricating nanoparticles and using EpCAM-aptamer-NCS conjugates decorated 
with LNA-modified EpCAM and nucleolin aptamers to examine the effect in 
Hepatocellular carcinoma and its effect in in-vivo liver cancer xenograft models. 
To achieve this aim we have objectives to be fulfilled, they are, fabrication of 
calcium phosphate alginate nanoparticles encapsulated with EpCAM-aptamer-
NCS conjugate. The nanoparticles were decorated with LNA-EpCAM and 
nucleolin aptamers for a double targeting effect. The nanoparticles were tested 
with the liver cancer cells in-vitro and further investigated in-vivo in liver cancer 
xenograft models and the efficiency of the drug conjugate was investigated. 
All of the objectives were achieved by screening the best aptamer sequence and 
conjugating with anti-cancer drugs for stable chimeric conjugate for in-vitro and in-vivo 




The hypotheses of the study were to develop novel anti-cancer drug-aptamer conjugates 
for targeted therapy to reduce the off-target effect of chemotherapy drugs to the cancers 
and its use in real-time imaging and therapy. 
Hypotheses by Chapter 
Chapter 2 
EpCAM is found to be the protein involved in tumourigenesis and cell proliferation and 
adhesion is overexpressed in cancer cells. Targeting EpCAM and designing an EpCAM 
aptamer to conjugate with antitumour drugs helps in reducing off-target effects. The 
interaction of antitumour drugs with the EpCAM aptamer is a major concern as the 
drugs have a tendency to degrade the aptamers. We hypothesise that studying the 
aptamer–drug interaction would help to understand the mechanism as to how to 
conjugate the aptamer–drug for targeted delivery. This study would help to better 
understand the chemistry between the drug and the aptamer that acts as a ligand for 
binding to the specific receptors on the cells. The interaction is processed in an in-silico 
model to depict the areas and chemistry. 
Chapter 3 and Chapter 4 
The conjugation of EpCAM antibody-saporin conjugate and NCS-aptamer conjugate 
shuts the off-target effects of the drugs, thus, increasing the efficiency only to the cancer 
cells. We hypothesise that the NCS-aptamer conjugate and the saporin-antibody 
conjugates would help to bind to the EpCAM positive tumour cells and reduce the off-
target effects both at the cell level and at gene level analysis. The mechanism involved 
in the regression of tumours with these conjugates at the cell level is to switch off 
cellular mechanisms such as cell cycle phase and the induction of the apoptotic genes. 
The degradation of the DNA double helix with the NCS and the ribosomal inactivation 
in the case of saporin would lead to tumour suppression and, ultimately, result in the 




The next study in this thesis is to additionally target cancer stem cells (CD44, EpCAM, 
and CD133) using NCS-aptamer conjugates. We hypothesise that alginate encapsulated 
chitosan calcium phosphate loaded NCS-EpCAM nanoparticles would deliver the drugs 
only to the cancer cells in-vivo and reduce the tumour volume in xenograft liver models. 
We also hypothesise that decorating these nanoparticles with a fluorophore-labelled 
EpCAM LNA and nucleolin LNA aptamers would help in live imaging of the tumours in-
vivo. Similar modifications can be done to increase the targeting efficiency of the drug-





Targeting chemotherapeutic drugs to the specific site of cancer has become an important 
aspect of cancer therapy. Many drugs that cause off-target effects are now available on 
the market. The need to investigate new combinations of ligand-based drugs is critical. 
Epithelial Cell Adhesion Molecule (EpCAM) is one important regulator that is 
overexpressed in epithelial cancers. In this study, we attempted to conjugate antitumour 
drugs with a combination of antibody and aptamer specific to EpCAM to evaluate the 
effect of drugs with and without ligands. We formulated the nanocarriers (NCs), 
decorated with locked nucleic acid (LNA) modified EpCAM and nucleolin aptamer, for 
double targeting effect. The best combination of drug conjugate with high efficiency in 
vitro was tested in vivo xenograft liver cancer models. 
Background 
Cancer is a global threat and is listed in diseases with a high mortality rate around the 
world. Treatment for cancer includes chemotherapy, radiation therapy and surgery. 
Most cases of cancer including breast cancer, pancreatic cancer, colon cancer, liver 
cancer and prostate cancer are treatable with chemotherapeutics. However, 
chemotherapeutics cannot exclude normal cells and tissues and affects these tissues and 
cells as well. Treating cancer without affecting normal tissues and cells by ligand 
molecules is called ‘Targeted Therapy’. The overexpressed protein in cancer helps as a 
biomarker when targeting the drugs to a specific site by ligands complementary to the 
protein present on the cancer cells. 
EpCAM is one type of transmembrane glycoprotein overexpressed in epithelial cancers. 
It helps to target the drugs that are specific to EpCAM positivity. EpCAM aids in 
regulating cell proliferation, adhesion and metastasis. EpCAM is a type I membrane 
protein with three domains, namely an epidermal growth factor-like (EGF) domain, a 
thyroglobulin repeat domain and a transmembrane domain. EpCAM was shown to be a 
putative stem cell marker for retinoblastoma T-cell mediated immunotherapy. 
 Neocarzinostatin (NCS) is an antitumour, antibiotic chromophore-protein extracted 
from Streptomyces Neocarzinostaticus. NCS can cleave the DNA. Hensens et al. (1979) 
Abstract 
xxv 
reported that the enediyne chromophore of NCS is toxic and is able to bind to the DNA. 
The bound chromophore induces double-stranded DNA cleavage. Given the favourable 
biochemical properties of apo-NCS and the firm evidence for internalisation of holo-
NCS, Moody, Paul et al. (2013) investigated the possibility that a recombinant apo-NCS 
could act as a cell-penetrating protein; therefore, providing a platform for the targeted 
intracellular delivery of therapeutic cargo. 
EpCAM is a transmembrane glycoprotein involved in tumourigenesis, cell proliferation, 
migration and adhesion. EpCAM is expressed in all the epithelial origin specifically 
overexpressed in cancers. Thus, it has gained interest as a crucial marker in cancer 
therapy. EpCAM-mediated targeted therapy helps in treating tumours efficiently 
without affecting normal cells. The stemness of EpCAM helps as a marker for cancer 
cell theranostics. Antibodies, affibodies, diabodies and ankyrins are synthesised against 
EpCAM protein to target the drugs to the cancers earlier; however, chemically 
synthesised antibodies and aptamers are regarded as better options for targeting. 
In this study, we extensively studied the biophysical aspect of NCS and EpCAM. NCS 
is a highly potent drug as it cleaves DNA; therefore, our first preference is to show that 
NCS does not affect the EpCAM RNA aptamer sequence. In silico analysis was 
performed to understand the interaction between NCS and EpCAM. We found that the 
NCS and EpCAM interaction does not affect the nature of the EpCAM sequence, 
because there is only hydrogen bonding between the chromophore and the EpCAM 
sequence. This investigation provides a clue as to how to conjugate NCS with an 
EpCAM aptamer. 
Initial studies were performed with an EpCAM antibody and saporin (SAP), an active 
antitumour drug said to inhibit the function of ribosomes. The conjugation of SAP with 
an EpCAM antibody has led to the conclusion that EpCAM is a good target for the drug 
loads. Hence, we achieved high levels of dead population in EpCAM-positive cancers— 
mostly in retinoblastoma and breast cancers. 
Chimerisation of EpCAM with NCS was performed, attaining the destruction of the 
cancer cells by DNA-double strand breaks. The conjugates were characterised and the 
efficiency of the conjugation was determined. In vitro studies with EpCAM-positive 
cells revealed the killing of cancer cells. Using these conjugates, retinoblastoma and 
breast cancer cells were tested and showed high cell death. This selection of EpCAM–
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NCS combination not only helps the efficiency of NCS, but also reduces off-target 
effects. The effect of NCS alone was minimal when compared with the NCS–EpCAM 
chimera. This study was performed using both a fluorescent-labelled aptamer and a non-
fluorescent aptamer. The fluorescent-labelled aptamer helped in tumour imaging as the 
high expression of EpCAM facilitates the binding of the aptamer. The insights of NCS–
EpCAM conjugates served to discover the gene level regulations related to apoptosis 
and EpCAM. 
Alternatively, NCS–EpCAM conjugate delivery using non-viral carriers such as 
alginate enclosed chitosan-calcium phosphate- (AEC-CP) loaded NCS–EpCAM 
conjugate were achieved and decorated with LNA EpCAM and LNA nucleolin 
aptamers. Targeting EpCAM using these novel nanoparticles (NPs) helped to achieve 
increased targeting efficiency, as they are altered to bind with EpCAM and nucleolin. 
NCS alone does not have specificity, whereas NPs are highly specific. The NPs were 
tested with liver cancer cells and were found to destroy the cancers. The NPs were 
tested in vivo in liver cancer xenograft model and we concluded that there was depletion 
of tumours in the treated group thus, showing high specificity to the EpCAM-positive 
liver cancer cells. 
Hence, the primary objective of this study is to synthesise novel NCS–EpCAM aptamer 
conjugates and observe the efficiency of the drug conjugate in vitro and in vivo. Most 
cancers such as breast cancer, liver cancer, prostate cancer, lung cancer and eye cancer 
do have cancer stem cell population. The most prominent markers in all of these cancers 
are CD44, CD133, ABCG2 and EpCAM. Targeting these markers would reduce the 
cancer stem cell population, thereby killing the cancer cells. An aptamer drug strategy 
against the cancer stem cell markers would increase the efficacy of the drugs. 
Methodology 
The native EpCAM expression in cancer cells (MCF-7 breast cancer and WERI-Rb1 
retinoblastoma) was found using Fluorescence Activated Cell Sorter (FACS) flow 
cytometry. The EpCAM aptamer was designed using MC-fold software and it was 
synthesised. NCS is a potent DNA degrading agent; therefore, in silico analysis was 
performed to find the interaction between NCS and the EpCAM aptamer. The 
secondary structure of the protein was determined using CD spectroscopy. Infra-red 
spectroscopy analysis of the 2F Modified EpCAM aptamer and NCS was performed to 
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analyse the interactions. RNA structure prediction and docking of the NCS protein 
complex and the EpCAM RNA aptamer complex was performed to discover the 
structure and interaction between NCS and the EpCAM aptamer for chimerisation of 
these two molecules. 
The aptamer drug conjugates using multiple approaches: 
1) SAP–EpCAM antibody conjugates were prepared using EDC-NHS chemistry 
for protein-protein covalent bonding 
2) the SAP conjugates were characterised using the Matrix Assisted Laser 
Desorption Spectroscopy-Time of Flight (MALDI-TOF) and Polyacrylamide 
Gel Electrophoresis (PAGE) 
3) NCS–EpCAM aptamer conjugates were prepared using heterobifunctional cross-
linker succinimidyl 3-(2-pyridyldithio) propionate (Sulfo-LC-SPDP) 
4) NCS–EpCAM drug conjugates were characterised using high-performance 
liquid chromatography (HPLC) and PAGE 
5) the AEC-CP-loaded NCS–EpCAM conjugate was synthesised and decorated 
with LNA EpCAM and LNA nucleolin aptamers and characterised using 
dynamic light scattering (DLS), Zeta potential, scanning electron microscopy 
and Fourier Transform Infra-red Spectroscopy (FTIR) 
6) AEC-CP NPs were characterised for drug release and encapsulation efficiency 
using protein estimation using spectroscopy. 
The aptamers and the aptamer drug conjugates were extensively studied for in vitro 
efficacy, in which: 
1) the expression of EpCAM in cancer cells using antibody and EpCAM aptamer 
were analysed using flow cytometry 
2) the functional activity of the drugs and drug conjugate were investigated using 
MTT assay 
3) gene expression studies with drug and drug conjugates were performed using the 
Affymetrix microarray analysis 
4) imaging of the cancer cells and real-time tracking was conducted using 
microscopy 
5) the cytotoxicity, or cell viability, was measured using trypan blue dye exclusion 
assay and calorimetry based MTT assay 
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6) cell death assay was performed using Annexin V-FITC and Propidium iodide 
(PI). Cell cycle analysis was performed using PI 
7) the NPs were tested in vitro for the efficiency of the drug and the drug 
conjugate. Spheroid assay and colony forming assay were performed to study 
the tumour regression 
8) MTT and trypan blue dye exclusion assay were performed to check the 
cytotoxicity of the NPs. 
In vivo studies were conducted by the better approach of targeted drug delivery using 
NPs, in which: 
1) a liver cancer xenograft model was induced in nude mice and tested for the 
efficiency of the drug conjugate by orally feeding the animal at regular intervals
2) the animals were monitored and their body weights and tumour volumes were 
recorded. Biochemical analysis was performed including blood, 




Figure 1: Schematic Representation of the Detailed Study Plan 
The study strategy shows the top to bottom approach to drug–aptamer interactions, conjugations and 
characterisation, using in vitro and in vivo studies to study the efficiency and gene and pathway analysis 
to understand the deregulated pathway that is affected by using these drug conjugates. 
Results 
This study focuses on novel drug conjugates for targeted therapy in cancers. Initial 
studies were performed on NCS and the EpCAM aptamer for interaction studies to 
understand stability and feasibility to conjugate. Ellipticity changes were observed in 
the region between 200 nm and 300 nm for the native NCS and the 2F Modified 
EpCAM aptamer. The Microweb analysis of CD spectra for native NCS showed peaks 
such as þ224 nm (helix pep*) 216 nm, and 210 nm (see Figure 10). The native 2F 
Modified EpCAM aptamer revealed peak at 210 nm, reflecting 60% GC content from 
the sequence. The physical mix of a 2F Modified EpCAM aptamer with the NCS 
showed the perturbation of β-sheets in NCS. The Dichroweb analysis of native NCS CD 
spectra revealed a broad negative peak at 205 nm indicating the presence of random coil 
and at 213 nm for the β-sheet. After the addition of a 2F Modified EpCAM aptamer 
with NCS, a peak shift was observed at 210 nm, suggesting a helix induction, and þ213 
nm and þ221 nm peaks of NCS disappeared favouring the helix structure induction. The 
docking program predicted that the aptamer binds to the same cavity in which the 
chromophore was linked to the NCS protein C strand that is hydrophobic in nature. 
Non-bonded interaction of the 2F Modified EpCAM aptamer at Phe52 of NCS was 
evident. From the results obtained, it was interpreted that the aptamer is in the same 
region where the chromophore is bound to the NCS. Non-bonded interactions were 
formed with residues Phe52 and Phe72 to which the pi-face of the chromophore 
interacts in the crystal structure. Non-bonded interactions were formed with strands of 
inner β-sheets C and D and one hydrogen bond formed with the ser54 of strand D. The 
loop region from 100 to 106 was also found to interact with the 2F Modified EpCAM 
aptamer, in which it forms a hydrogen bond with the Ala100 to stabilise the 
chromophore by maintaining the hydrophobic core. 
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Conjugation of SAP EpCAM with the Antibody 
A conjugation of SAP and the EpCAM antibody was performed using EDC-NHS. A gel 
retardation assay clearly showed the difference between the SAP and SAP–EpAB 
conjugate. A MALDI analysis revealed that the molecular mass of the conjugate was 
more than that of the native SAP and native EpCAM antibody. The EpCAM antibody 
showed a molecular mass of 24.24 kDa. The SAP molecule showed a molecular mass of 
31.32 kDa and the conjugate showed a molecular weight of ~75.23 kDa. The flow 
cytometric analysis revealed that the EpCAM antibody and the conjugate were bound to 
the MCF-7 breast cancer cells, WERI-Rb1 cells. MCF-7 cells showed binding 
efficiency of 75% with the EpCAM antibody and 75% with the conjugate. WERI-Rb1 
cells showed values of 42% and 31% for the EpCAM antibody and the conjugate, 
respectively. The fluorescence microscopy results showed membrane positivity for the 
EpCAM antibody and the conjugate in MCF-7 and WERI-Rb1 cells. The SAP–EpAB 
conjugate (1 μg) showed 45% cell death in WERI-Rb1 cells, whereas the SAP showed 
only 16% cell death at the same concentration (p<0.05). The MCF-7 cell showed 51% 
cell death with SAP–EpAB conjugate (1 μg), whereas the SAP revealed only 17% cell 
death (p<0.001). The apoptosis assay (Annexin V-FITC and PI) for conjugate treated 
cells revealed late apoptosis and necrosis in MCF-7 and WERI-Rb1 cell lines. SAP and 
the SAP conjugate treatment showed 22%, 89% of necrosis and 8% of late apoptosis in 
MCF-7 cells. The SAP and the SAP conjugate treatment showed 0% and 37% of 
necrosis in WERI-Rb1 cells. The conjugate showed 9.96% late apoptosis with the SAP–
EpAB conjugate and 6.07% early apoptotic cells. 
Conjugation of NCS with EpCAM Aptamer 
The conjugation of the NCS and the EpCAM aptamer was performed using Sulfo-LC-
SPDP. The appearance of the absorption peak at 340 nm confirmed the release of 
Pyridine-2-thione that was produced as a byproduct of the conjugation reaction. The 
HPLC results indicated that NCS was eluted from the Zorbax oligo column at the 12.5th 
minute, whereas the conjugate eluted at the 30.0th minute. The conjugation was further 
confirmed by SDS-PAGE. The native aptamer and the conjugate showed better binding 
profiles in MCF-7 breast cancer cells and WERI-Rb1 retinoblastoma cells, compared to 
MIOM1 Müller glial cells. The binding of the native aptamer and the conjugate were 
found to be 62% and 35%, respectively, for MCF-7 cells at the IC50 values. The native 
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aptamer and the conjugate were found to have a binding of 35% and 30%, respectively, 
for WERI-Rb1 cells at the IC50. MIOM1 cells (deprived of EpCAM expression) showed 
a feeble binding (i.e., 3% and 10%, respectively) for aptamer and conjugates at the IC50 
value. The results were confirmed through an immunofluorescence study that revealed 
that the native aptamer and conjugates were bound to the cell membrane. Both the 
FITC-labelled native aptamer and the aptamer conjugates showed higher levels of 
membrane positivity in MCF-7 cells than WERI-Rb1 cells. To find the gene interaction 
involved in cancer pathways a Kyoto Encyclopaedia of Genes and Genomes (KEGG) 
analysis was performed using online DAVID software. The analysis revealed highly 
deregulated genes participating in the cell cycle process including E2F2, E2F5, CDC20, 
MYC and genes involved in small lung cancer and TGF-beta signalling pathways. The 
KEGG pathway analysis revealed an increased expression of histone molecules such as 
H2AX and clearly indicated the activation of DNA damage repair mechanism. Cell 
cycle checkpoint genes were up-regulated including BCL2 and cyclins. The cell cycle 
assay revealed 78% of G2 phase arrest for NCS treatment and 86% for the NCS 
conjugate treatment in the MCF-7 cell line. Interestingly, WERI-Rb1 cells showed ‘S’ 
phase elongation leading to the phase arrest of 29% of NCS treatment and 45% of NCS 
conjugate treatment. 
AEC-CP NPs Loaded With NCS–EpCAM Conjugate and Decorated With LNA 
EpCAM and LNA Nucleolin Aptamers 
AEC-CP NPs showed a particle size of 250 nm ± 50 nm. The scanning electron 
micrographs showed that the particles were spherical in shape and, thus, dispersed in 
nature. The drug loading capacity was confirmed by the FTIR analysis. The N–H stretch 
and the C = O confirmed the presence of the aptamer and the protein in the NPs. 
Cytotoxicity of NPs in vitro showed the constant release of the drug in the media, 
promising cancer cell death with the NCS–EpCAM NPs. Spheroid assay with liver 
cancer showed a decreased tumour volume in the spheroid culture with an increase of 
time of incubation with NPs (p<0.001). The clonogenic assay revealed the reduction in 
colonies per plate with the NPs treatment in liver cancer cell lines (p<0.001). The in 
vivo studies using the liver cancer xenograft model showed tumour regression 
(p<0.001) with complete tumour growth inhibition—without any side effects or toxicity 
in the animals. Histopathological analysis showed there was no cytotoxicity to the cells 
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by the treatments given. The normal cells and tissues adjacent to the tumour site were 
not affected by the drug. 
Conclusion 
 The results from our study show for the first time that the interaction between 
NCS and aptamer does not degrade the efficiency of the aptamer and, hence, can 
be used for theranostic purposes. This study was conducted on an in silico-based 
bioinformatics analysis of both the NCS and the aptamer. 
 The results showed an increased efficiency in the drug when it was conjugated 
with the aptamer, thus sparing the normal cells and affecting only the cancer 
cells. The SAP–EpCAM antibody and the NCS–EpCAM aptamer conjugates 
showed a multimode delivery effect of anti-cancer drugs; therefore, helping in 
live cell imaging using the aptamer. 
 The conjugates showed target-specific delivery that aided in the imaging of 
various EpCAM-positive cell lines, such as WERI-RB1, MCF-7, HepG2 and 
Hep3B. 
 The AEC-CP NCs that were fabricated and decorated with EpCAM LNA and 
Nucleolin LNA aptamers delivered NCS to the target site in vivo, reducing 
tumour volume and, thereby, reducing off-target effects. 
 The histopathological investigations, along with the in vitro studies, proved that 
the NCS left no cytotoxicity and increased the apoptotic protein expressions that 
lead to cell death. The stem cell array with the tumour tissues proved that the 
NCS was specifically targeting the cancer stem cells that are the key molecules 
involved in tumourigenesis. 
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Chapter 1. Literature Review 
1.1 Cancer 
Cancer is a disease caused by the uncontrolled growth of cells that form a lump or a 
mass of tissue known as a tumour. In 2012, 14.1 million new cases of cancer were 
recorded worldwide. Out of this number, 8 million people from developing countries 
were affected. It is expected that, by 2030, more than 21.7 million new cases of cancer 
will be diagnosed and there will be 13 million deaths resulting from cancer (Ferlay et al. 
2015). In cancer cells, the control systems that prevent cell overgrowth and invasiveness 
of other tissues are disabled. Cancer cells grow and develop new characteristics 
including changes in the structure, decreased cell adhesion and the production of new 
enzymes. These changes allow cells to divide and grow. Such changes enable the cancer 
cells to invade and spread to other tissues. 
Mutations in cancer cells are observed in protein-encoding genes that regulate cell 
division (El-Deiry 1998). These mutations mean that genes that usually code for 
proteins that normally repair DNA cannot perform their function. Therefore, if the 
mutation begins to increase in the cell, abnormalities also increase in the daughter cells. 
These mutations may cause some cells to die; however, due to the other alterations, the 
abnormal cells proliferate much more rapidly than the normal cell cycle. These 
conditions enhance the growth of cancer cells. If the abnormal cells remain in their 
original location, they are called benign tumours. If the cells are invasive, they are 
called malignant tumours. Malignant tumours have a tendency to send the cancer cells 
to different parts of the body, where new tumours can develop. This condition is called 
metastasis. 
Tumours may be invasive or non-invasive. Invasive tumours can interfere with the 
digestive, nervous and circulatory systems. Based on the cell that is initially affected, 
there are over 100 different types of cancers—each of which is classified based on the 
nature of the cancer cell. 
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1.2 Current Cancer Treatments and Therapies 
Cancer treatment has various modalities; however, the traditional methods of treating 
cancers are as follows. 
1.2.1 Chemotherapy 
Chemotherapy is the classical method that is standard for treating cancer. Chemo drugs 
are chemicals that interfere with the cell division process, damaging proteins or DNA so 
that the cancer cells undergo apoptosis. Chemotherapy affects not only the cancer cells 
but also the healthy tissues and organs adjacent to the tumour site. Chemo drugs can be 
used to treat cancer that can spread through the body if the tumours are metastasised, as 
is the case with leukaemia and lymphoma. Treatment usually occurs in cycles, so that 
the body has time to heal between the doses. Some of the common side effects from 
chemo drugs include nausea, hair loss, fatigue and vomiting. Chemotherapy includes 
combination therapy in which multiple types of chemotherapy are combined with other 
treatment options. The current chemotherapy focuses on combination chemotherapy. 
The primary focus of combination therapy is to treat chemo-resistant cancers by giving 
the drugs in a combination of two or more. The combination of drugs has proven to be 
efficient at killing the cancer cells in most cancers including that of the eye, liver and 
breast (Assayag et al. 2016) (Lévi et al. 2016) (Zhang, Gu, et al. 2013). Chemotherapy 
is one of the foremost treatment methods for cancer and has its advantages and 
disadvantages. The advantages include the immediate relief and complete regression of 
tumour post-chemotherapy. The disadvantages include short-term and long-term side 
effects. Long-term or sustained side effects include premature ovarian failure, weight 
gain, long-term cardiac effects, chemotherapy-associated leukaemia, cognitive 
dysfunction and others (Partridge, Burstein, and Winer 2001). Some of the 
disadvantages even cause tight junction defects in the buccal mucosa of the subjects 
under the standard dose of chemotherapeutic agents (Wardill et al. 2016). Photo-
activated chemotherapy is a new line of therapy whose prodrug is inactive. Once the 
light is exposed, the drug gets activated based on the intensity of the light (Szymanski 
and Reessing 2016). One of the most prevalent cancers worldwide is cervical cancer, 
caused by papillomavirus type 16 (HPV16). Treating cervical cancer by already existing 
chemotherapeutics has been less successful. Hence, a vaccine was developed against 
HPV16 to help prevent this cancer. Although the vaccine works to prevent cancer, it 
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cannot work if the subject has an already established cancer. However, the combination 
of the vaccine and chemotherapy might help cervical cancer patients. Scientists are still 
researching this approach (Welters et al. 2016). The new combinations of platinum anti-
cancer drugs with photochemotherapeutic agents are among recent advancements in 
cancer therapy (Shaili 2014). Recent improvements in chemotherapeutics include the 
use of nanocarriers and ligand molecules to deliver the drugs (Kim et al. 2016) (Khdair 
et al. 2016) (Zhang, Ng, et al. 2016) (Estanqueiro et al. 2015) (Mohamed et al. 2014). 
1.2.2 Radiation therapy 
Radiation therapy uses high-energy radiation to make tumours shrink, leading to cancer 
cell death (Lawrence TS et al., 2008). Radiation such as X-rays, gamma rays and 
charged particles are used for cancer treatment. If the radiation is delivered outside the 
body, it is called external beam radiation therapy. If the radiation is radioactive material 
placed near the tumour, it is called internal radiation or brachytherapy. Systemic 
radiation therapy uses radioactive substances, such as radioactive iodine that kills the 
cancer cells by passing through the blood. Most cancer patients receive radiation 
therapy at some time during the course of their treatment. Radiation therapy kills cancer 
cells by damaging their DNA (Lawrence TS et al., 2008). Radiation therapy can either 
create free radicles within the tumour that can damage the DNA or directly damage the 
DNA. If the DNA is damaged beyond repair in a cancer cell it will stop dividing or die. 
When the damaged cells die, they are broken down and eliminated by the body’s natural 
processes. 
1.2.3 Immunotherapy 
Immunotherapy involves boosting the immune system. There are two types: local 
immunotherapy, whereby the treatment is injected into the affected area to cause 
inflammation that causes tumour shrinkage (Wang, Ye, and Gu 2016) and systemic 
immunotherapy that can treat the whole body through a drug such as a protein-
interferon alpha (Hiniker et al. 2016). Immunotherapy is sometimes considered non-
specific as it improves cancer-fighting abilities by stimulating the immune system of the 
body. It can also be considered a targeted therapy if the treatment specifically signals 
the immune system to destroy tumours. These therapies are under research and are 
coined ‘young’ therapies. Researchers have had success in treating breast cancer 
through introducing antibodies to the body that inhibit the growth of breast cancer cells. 
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Bone marrow transplantation (Hematopoietic stem cell transplantation) can also be 
considered an immunotherapy as the donor's immune cells often attack the tumour or 
cancer cells that are present in the host system. 
Recent developments in immunotherapy include engineered chimeric antigen receptor-
primary natural killer (NK) cells as an enhancement of the adoptive immunotherapy. 
Promising results have been shown by NK cells in their toxicity to the cancer cells 
(Temme and Schmitz 2016). Another advancement is killing the cancer cells by 
selectively removing the sialic acid (also called glycocalyx, or the outer sugar coat) 
from cancer cells. This method uses enzyme–antibody conjugates that help to remove 
the sugar from the cell surface and the antibody directs the immune cells to kill the 
cancer cells (Xiao et al. 2016). A new combination of ICD inducer (IGMI) along with 
immune checkpoint immunotherapy helps in Tumor Growth Inhibition (TGI) in CT26 
and 4T1 models. This model demonstrates high quality from the combination involving 
immunotherapy (Mckenzie et al. 2016). The level of cholesterol (high) in the cell 
membranes of T-Killer cells enhances the cell’s ability to react more on immune 
response against tumours in mice. This kind of immunotherapy not only enhances the 
levels of the immune cells but also enhances positive immunotherapy (Dustin 2016). 
Recent advances in immunotherapy have been important milestones. Great 
achievements have been made in some patients in the clinical therapeutics. One of the 
main disadvantages of immunotherapy includes resistance before or after therapy 
(Restifo, Smyth, and Snyder 2016). 
1.2.4 Targeted therapy 
Targeted therapy is the new generation therapeutics of cancer drugs. The drugs are 
designed to interfere with a specific tumour-associated protein known to play a critical 
role in tumour growth or proliferation (Seshacharyulu et al. 2012). This type of 
therapeutics contrasts with existing therapies such as chemotherapy and radiation 
therapy. The discovery of a cancer biomarker has opened new possibilities for the 
development of effective immunotherapy, antibody therapy and ligand-targeted therapy. 
Ligand-based targeted therapy has successfully improved the selective toxicity of anti-
cancer therapeutics (Zugazagoitia et al. 2016). This strategy helps in the targeted 
delivery of small molecule drugs or gene-based medicines such as antisense 
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oligonucleotides. These types of drugs may be added to chemotherapy or radiation 
therapy, or used in combination with vaccine therapy and immunotherapy. 
 
Figure 2: Overview of Targeted Therapy 
The possible receptor sited for targeted therapy such as tumour antigens, growth factors and intracellular 
signalling molecules. mRNA-based receptor-based antisense probes are also developed as a new class for 
targeted therapy. Apoptosis agonists, tyrosine kinase inhibitors such as Gefinitib and therapeutic 
antibodies and toxins such as gelonin and NCS are used as therapeutic molecules that can be targeted 
towards the receptors. 
1.2.4.1 Advantages of targeted therapy over other therapies 
 Targeted therapies act on specific molecular targets that are associated with 
cancer, whereas most standard chemotherapies act on all rapidly dividing, 
normal and cancerous cells. 
 Targeted therapies are deliberately chosen or designed to interact with their 
target, whereas many standard chemotherapies are identified because they kill 
cells. 
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 Targeted therapies are often cytostatic (i.e., they block tumour cell proliferation), 
whereas standard chemotherapy agents are cytotoxic (i.e., they kill tumour 
cells). 
 Targeted therapies are currently the focus of much anti-cancer drug 
development. They are a cornerstone of precision medicine, a form of medicine 
that uses information about a person’s genes and proteins to prevent, diagnose, 
and treat disease. 
1.2.4.2 Disadvantages of other therapies 
 Chemotherapy has unpleasant side effects such as nausea, hair loss and extreme 
discomfort. 
 Chemicals must be carefully selected depending on the type and the stage of the 
cancer. 
 There are no chemical drugs that specifically kill cancer cells. When 
chemotherapy kills cancer cells it also kills normal cells and will shorten the 
survival of patients over time. 
 Certain  tumours are not sensitive to the drug; the use of chemotherapy has no 
clinical value. 
 Chemotherapy cannot completely kill all the cancer cells in vivo. After time, the 
cancer will relapse or metastasis. 
 Radiation therapy equipment is expensive and treatment is even more expensive. 
 Radiation therapy takes a long time—normally one to two months. 
 Radiation can cause more complications, and even loss of function caused by 
sector. 
 Radiation treatment cannot completely eradicate cancer cells that would, over 
time, be long. 
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1.2.5 Oncogenes 
Oncogenes are key molecules that are involved in targeted therapy. More than 10 target 
oncogenes were validated in non-small cell lung cancer. ALK and ROS1 inhibition by 
crizotinib was reported to be highly effective and tolerable by patients (Ye et al. 2016). 
GI tumours are one of the most prominent cancers and many targets were altered in a 
variety of GI tumours. The main targets for therapy in GI tumours are HER2, epidermal 
growth factor receptor (EGFR) and vemurafenib (BRAF). The alteration was validated 
based on the next generation sequencing and the patients receiving the standard dose of 
trastuzumab+pertuzumab (HER2), BRAF and erlotinib, an EGFR. Combination 
targeted therapy showed positive results in these tested groups. The EGFR antibody was 
predicted to have sensitivity towards the alterations in the markers in colorectal cancer 
(CRC). The antibody has the highest sensitivity against EGFR immunotherapy (Rankin 
et al. 2016). CRC is also a significant cause of mortality. Some of the chemo drugs 
prolonged the survival rate in metastatic CRC. The target used to treat CRC is vascular 
endothelial growth factor (VEGF) and EGFR. As a first and a second line of treatment, 
a combination of VEGF and cetuximab and panitumumab-EGFR have shown promising 
results in therapy. The novel targets in CRC are still under investigation for higher 
therapeutic efficiency (Ohhara et al. 2016). Recent immune-targeted therapy has found 
Gai1/3 to be a better target for hepatocellular carcinoma (Zhang, Wu et al. 2016). 
The key role of targeted therapy is to discover possible targets or target antigens. 
Several targets have been identified for targeted therapy by researchers. Targets studied 
intensively include EGF (Schneider-Merck et al. 2010), HER2 (Vu and Claret 2012), 
EpCAM (Spizzo et al. 2011b) (Gaiser et al. 2012), p53 (Jackson et al. 2012) (Jeay et al. 
2015) and CD44 (Yan, Zuo, and Wei 2015). The target antigens may be approached by 
fabricating oligonucleotide-based modalities such as ssRNAs, siRNAs, miRNAs and 
functional aptamers to target specific tumour antigens, thereby suppressing the 
tumourigenic effect. Various methods of therapeutics have been investigated to target 
tumour antigens such as antibodies, affibodies, ankyrins and aptamers (chemical 
antibodies). 
1.2.5.1 EpCAM 
EpCAM is highly expressed in epithelial tumours. Its type1 transmembrane 
glycoprotein shows overexpression in stem cells, progenitor cells and less expression in 
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differentiated cells (Maetzel et al. 2009). In normal cells, the EpCAM expression is 
observed only in the basolateral membrane, in contrast to tumour cells. EpCAM 
expression levels decrease when cells are differentiated to neoplastic cells (Schnell, 
Cirulli, and Giepmans 2013a; Ogura et al. 1998; Trzpis et al. 2007). These 
characteristics provide a preference for Aptamer Drug Conjugate (ADC) to bind 
efficiently to tumour cells compared to normal cells. EpCAM played a substantial role 
in tumourigenesis and metastasis and was expressed in most of the epithelial tumours. 
Hence, targeting EpCAM may provide a valuable approach for treating cancers (Lin et 
al. 2012). The specificity of EpCAM aptamers has already been reported in the previous 
literature (Subramanian et al. 2012) (Subramanian, Kanwar, Athalya et al. 2015). 
EpCAM is known to be involved in tumourigenesis through the activation of various 
proteins in the Wnt signalling pathway (Gostner et al. 2011). The EpCAM protein is 
cleaved by TACE/ADAM17 and γ-secretase containing presenilin2 into EpEX 
(extracellular domain) and EpICD (intracellular domain) (Imrich, Hachmeister and 
Gires 2012). EpICD on cleavage into the cytosol interacts with various proteins and 
brings about up-regulation of c-myc, e-fap and cyclin-E genes (Denzel et al. 2009). 
EpEX released into the ECM (extracellular matrix) acts as a soluble ligand in cleavage 
of other EpCAM proteins (Maetzel et al. 2009). 
 
Figure 3: EpCAM Signalling Pathway 
The link between E-cadherin and actin cytoskeleton may become weakened by the EpCAM E-cadherin 
mediated adhesion. This can increase the availability of non-bound β-catenin and can be stabilised 
associated with EpICD. Adopted from EpCAM: structure and function in health and disease, Biochimica 
et Biophysica Acta (BBA)— Biomembranes (Schnell, Cirulli and Giepmans 2013b). 
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1.2.6 Ligand-based based targeted therapy 
Most cancer cells have features in common with the normal host cells from which they 
are isolated or derived. High levels of toxicity cannot be achieved with anti-cancer 
drugs because of the lack of molecular targets to differentiate the regular cells. 
Targeting the molecular targets can increase the toxicities against the normal cells and 
tissues such as the gastrointestinal tract, bone marrow and hair follicle tissues. Selective 
toxicity of anti-cancer drugs can be increased by either increasing the amount of the 
drug that reaches the cancer tissue or by decreasing the concentration of the drug that 
may reach the normal tissue. Ligand-based targeted therapy makes the drug more 
tumour-specific and increases cytotoxicity. Ligand-based drugs can take high doses of 
the drug to the tumour site and overcome the obstacles involved in cytotoxic chemo 
drugs. Barriers include drug resistance, cancer stem cells and high tumour interstitial 
fluid pressure (IFP). Recently, research has been conducted on the use of monoclonal 
antibodies (Gerber and Ferrara 2003) (Reff et al. 1994) (Willett et al. 2004) and small 
molecules (Capdeville et al. 2002) (Graham, Mushin, and Kirkpatrick 2004) to inhibit 
tumour growth. Tumour-targeting ligands need to specifically deliver the drugs for 
specificity. About 90% of human cancers are solid tumours. Recognising the antibodies 
for tumour-specific antigens helps in the drug delivery, as some immunoconjugates 
cannot easily penetrate into the tumour tissue (Dvorak, Nagy and Dvorak 1991) 
(Shockley et al. 1991). Liposomes and NPs are other types of drug carriers that can 
carry higher dosages of drugs to the tumour sites and overcome some obstacles to 
effective cancer therapy. 
1.2.7 Antibody-based targeted therapy 
One hundred years ago, German chemist Paul Ehrlich proposed antibody-based 
therapies could be a ‘magic bullet’ in treating disease. According to this concept, 
targeting a toxin specifically to a disease-causing agent eradicates the disease. Antigens 
present on the tumour cells act as targets for antibody therapy. This requires a 
comprehensive analysis of normal tissue expression and tumour expression including 
homogeneity of expression as well as understanding the biological role of the antigen in 
tumour growth. The mechanism of action may be engaged with the cell surface 
receptors, or activate antibody-dependent cell mediated cytotoxicity (ADCC), or 
complement dependent cytotoxicity (CDC). It is desired that the antigen monoclonal 
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antibody complex should not rapidly internalise. When delivering toxins to the tumour 
cells, the antibody, whose function is to down-regulate the cell surface receptors, should 
be internalised (Van den Eynde and van der Bruggen 1997). Antigens that are 
differentiated by hematopoietic cells are usually glycoproteins associated with CD 
grouping including CD20, CD30, CD33 and CD52 (Weiner, Surana and Wang 2010) 
(Chan and Carter 2010) (Cheson and Leonard 2008). 
Growth factors as targets for antibodies include CEA (Cheson and Leonard 2008) and 
epidermal growth factors such as EGFR, also known as Erb1 (Van Cutsem et al. 2009), 
HER2, also known as Erb2 (Hudis 2007), Erb3 (Schoeberl et al. 2009), MET (Canadas 
et al. 2010) ephrin receptor A3 (Eph A3) (Vearing et al. 2005), insulin-like growth 
factor 1 receptor (IGF1R) (51), apoptosis-inducing ligand receptor 1 TNF (TRAIL R1) 
and TRAIL R2. Receptors involved in angiogenesis are usually proteins or growth 
factors that support the formation of the new microvasculature including VEG), VEGF 
receptor (VEGFR) and stromal and extracellular matrix antigens that include the 
fibroblast activation protein (FAP) and tenascin (Deckert 2009) (Scott, Allison and 
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1.2.8 Peptides-based targeted therapy 
Peptides have had a tremendous influence in current cancer treatment and diagnosis. 
Along with peptide-based cancer therapies already available for cancer patients, positive 
results are expected from clinical trials of peptide-based vaccines, tumour-targeting 
cytotoxic drugs and radioisotopes and anti-angiogenic peptides. Primovax (peptide 
cancer vaccine Pharmexa), Cilengitide (Glioblastoma, Merck), Stimuvax 
(Thundimadathil 2012), and Melanotan (precancerous actinic keratosis Clinuvel) are 
good examples of potential peptides in recent clinical trials. Combination therapy has 
emerged as a key strategy to fight cancer, as chemotherapy using a single drug cannot 
cure the disease completely or prevent recurrence (Foy et al. 2012). To achieve a 
synergistic effect, combinations of anti-angiogenesis with classical chemotherapy are 
currently being trialled (Retter, Figg, and Dahut 2003) (Andersen et al. 2010) (Retter, 
Figg and Dahut 2003) (Stupp et al. 2010). A phase I/IIa trial of a combination of 
temozolomide and cilengitide with radiotherapy for newly diagnosed glioblastoma 
patients is showing better overall survival (OS) rates (Thundimadathil 2012). 
1.2.9 Aptamer-based targeted therapy 
Aptamers are short oligonucleotide sequences such as deoxyribonucleic acid (DNA), 
ribonucleic acid (RNA), single-stranded deoxyribonucleic acid (ssDNA) and small 
peptide molecules that can bind to a specific receptor on the cell surface due to their 
specific three-dimensional structures. Primarily, RNA and ssDNA aptamers can differ 
from each other in sequence and folding pattern, although they bind to the same target. 
The concept of joining nucleic acids with proteins began to emerge in the 1980s from 
research on the human immunodeficiency virus (HIV) and adenovirus. The research 
indicated that these viruses encode a number of small structured RNAs that bind to viral 
or cellular proteins with high affinity and specificity (Dollins, Nair and Sullenger 2008). 
For more than three decades, antibodies have been the most popular class of molecules 
for molecular recognition in a wide range of applications. Aptamers are widely known 
as a substitute for antibodies because the molecules overcome the weaknesses of 
antibodies. The advantages of aptamers compared with antibodies include: 
 high stability—aptamers can recover confirmation upon annealing 
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 can bind to the targets (Centi et al. 2009). Thus, aptamers can be used under a 
wide range of assay conditions, varying temperatures and other parameters 
 synthesis is less laborious. Antibodies need to undergo a number of 
immunoassays to confirm activity (Birch and Racher 2006), whereas aptamers 
are nuclease resistant and can be easily modified based on requirements for 
chemical reactions (Ferreira et al. 2008) (Jayasena 1999) 
 can introduce fluorophores such as FITC and CY3 that are signal moieties, 
greatly facilitating the fabrication of biosensors 
 low immunogenic, as the human immune system does not recognise the nucleic 
acids as foreign bodies. Antibodies are more immunogenic and need repeat 
doses (Lakhin, Tarantul and Gening 2013) (Jayasena 1999). The Eyetech Study 
Group demonstrated that a VEGF-specific aptamer displayed little 
immunogenicity when given to monkeys in 1,000-fold higher doses (Eyetech 
Study 2002) (Eyetech Study 2003) 
 targets are greater for the oligo sequence. Antibodies are more prone to immune 
response and are very difficult to produce. Aptamers are less immunogenic and 
can be produced in sufficient numbers. The aptamer sequence has greater 
affinity towards the target. 
A short RNA ligand, called the trans-activation response (TAR) element in HIV, 
promotes transactivation and viral replication by binding to the Tat protein (Sullenger et 
al. 1990). The adenovirus also has a short RNA aptamer called virus-associated (VA)-
RNA that regulates translation (O'Malley et al. 1986) (Burgert et al. 2002). There have 
been substantive studies on aptamers since the in vitro selection process SELEX. 
SELEX was first reported in 1990 (Ellington and Szostak 1990) (Tuerk and Gold 1990). 
It is a basic technique to isolate aptamers, in which aptamers can be selected against 
multiple targets from biomolecules to proteins and even cells (Han, Kim and Shon 
2010). Aptamers are termed as biomaterials in most studies and investigations 
concerning their use as a diagnostic and therapeutic tool and biosensing probe and in the 
development of new drugs and drug delivery systems. There have been attempts to 
search for aptamers that are specific to targets in various diseases, such as cancer and 
viral infection. Aptamers that have developed have been primarily used as diagnostic or 
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therapeutic tools. In 2004, approval was gained from the Food and Drug Administration 
of Macugen (Querques et al. 2008) (Huang et al. 2016) (Spitzer et al. 2007) for the use 
of a VEGF-specific aptamer for the treatment of neovascular (wet) age-related macular 
degeneration (AMD). This is a major milestone in the application of aptamers (Bunka 
DH et al. 2006). Aptamer technology is regarded as more efficient and more 
authoritative and the number of studies on the applications of aptamers is rapidly 
increasing. There are many fields in which aptamers may be applied. 
 
Figure 4: Schematic Illustration of SELEX Process for Aptamer Synthesis 
The process begins with the synthesis of a large oligonucleotide library that consists of random sequences 
of fixed 5' and 3' end lengths that act as primers. The target sequence is immobilised on the bead and then 
subjected to the nucleotide library, usually by affinity chromatography. The bound sequences are eluted 
and amplified by polymerase chain reaction (PCR) for the selection of the tightest-binding sequences by 
setting up the stringency of elution, cloned and sequenced. 
RNA aptamers, small oligonucleotides derived by SELEX, are prominent candidates for 
therapeutic and diagnostic applications. RNA aptamers have high affinity and 
specificity for their target molecules (Biroccio et al. 2002). In this review, we describe 
methods for generating RNA aptamers and therapeutic applications for diseases such as 
neovascular AMD, inflammatory diseases and obesity. Aptamers are a promising 
chemical antibody for cancer therapy (Zhou et al. 2016). A recent advancement in 
aptamer technology has led to the development of an electrochemical aptamer 
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cytosensor that can detect human liver cancer using high sensitivity and selection (Sun 
et al. 2015). DNA aptamers have become an advanced method of aptamer technology. 
DNA aptamers generated through SELEX have shown promising results in the 
molecular recognition of liver cancers (Xu, Teng et al. 2015). 
Various studies have been performed using aptamers to target most cancers. Nucleolin 
aptamer-based therapy to treat retinoblastoma was performed and the resultant aptamer 
helped as an imaging marker through mass-spectrometry-based imaging (Subramanian 
et al. 2016). LNA has a greater stability and has been used against EpCAM for the 
preparation of Fe3O4-saturated lactoferrin NCs for triple positive (EpCAM, CD33, 
CD44) colon cancer therapeutics for the imaging of cancers (Roy, Kanwar, and Kanwar 
2015). A few studies have been conducted using aptamers against the epithelial cancers 
by using chimerised EpCAM aptamer-EpCAM siRNA for the silencing of the EpCAM 
gene to regress the progression of EpCAM-positive cancers including retinoblastoma 
cell line and breast cancer cell line (Subramanian, Kanwar, Kanwar, et al. 2015). 
Similar studies have been performed by synthesising NPs using EpCAM aptamer and 
EpCAM siRNA for the specific delivery of siRNA to cancer cells (Subramanian, 
Kanwar, Athalya, et al. 2015). The TLS11a aptamer has been conjugated to nanoprobes 
against the diagnosis using real-time imaging in liver cancer cells (HepG2) (Wei et al. 
2016). 
1.2.10  Toxin based anti-cancer therapeutics 
Toxins used in targeted therapy consist of polypeptide covalently linked to the peptide 
toxin. The ligands may be antibodies or antibody fragments, such as a single chain 
antibody. These are called as immunotoxins. If the targeting molecule on the cell 
surface is a growth factor (cytokine or peptide hormone), it is called a fusion protein 
toxin (Frankel, Kreitman and Sausville 2000). The ligand molecule directs the toxin to 
the cell surface receptors and the toxin molecule enters the cell and induces apoptosis by 
inactivating the protein synthesis, or by damaging the DNA. Highly potent toxins can 
kill cancer cells with as few as one molecule or cell extracted from plants, bacteria or 
fungi. Significant challenges in the synthesis of clinically active toxins include 
identifying the ligand that selectively targets every malignant cell in the body and 
modifies the toxin so that it will no longer bind to normal tissues. The ligand molecules 
and the toxin are linked together, either genetically or chemically. These conjugates, or 
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fusion proteins, are purified by chromatographic techniques. The purified toxin 
conjugates have demonstrated selective toxicity to malignant cells, both in tissue culture 
and animal models. The toxins need to be modified to remove normal tissue binding 
sites and to link the tumour-selective ligand. Plants and fungi produce many molecules 
with defensive functions to protect themselves against pathogens such as 
microorganisms and predators such as insects. These defence proteins include 
ribosome-inactivating proteins that are capable of inhibiting RNA translation. A broad 
spectrum of activities have been attributed to these proteins, encompassing 
antiproliferative, antitumour, immunomodulatory, antiviral, antifungal and anti-insect 
activities. 
In 1970, antibody–toxin conjugates for targeting cancer cells were first investigated 
(Moolten et al. 1975). The researchers employed an antibody–toxin conjugate against 
the viral antigens overexpressed on the surface of monkey kidney cells. They succeeded 
in demonstrating that antibody–toxin fusion proteins could be used to target neoplastic 
cells. Immunotoxins, also known as cytotoxins, are recombinant molecules that 
specifically bind to antigens overexpressed on the surface of a cancer cell (Pastan et al. 
2007). These recombinant molecules consist of a specific antibody, or ligand, coupled 
to a toxin protein. The toxins used in this process are natural by-products of plants, 
bacteria and fungi that inactivate eukaryotic protein synthesis (Chandramohan et al., 
2012). 
The most commonly used toxins in the construction of immunotoxins include bacterial 
toxins Pseudomonas aeruginosa exotoxin A (PE), diphtheria toxin (DT) and plant toxin 
ricin. Apart from these toxins, Gelonin toxin (Gelonium multiflorum), SAP toxin (seeds 
of Saponaria officinalis) and NCS toxin (Streptomyces macromomyceticus) are often 
used in cancer therapy and primary research. 
1.2.10.1 Pseudomonas exotoxin A 
Pseudomonas exotoxin A is expressed as a single 638-amino-acid polypeptide by the 
Gram-negative bacterium Pseudomonas aeruginosa. Upon synthesis, a 25-amino-acid 
segment is clipped off the N-terminus of the pro-protein and a 613-amino-acid mature 
toxin is secreted (Weldon and Pastan 2011). The 66 kDa mature toxin comprises three 
major functional domains (Weldon and Pastan 2011) (Hwang et al. 1987). The N-
terminal domain I, subdivided into domains Ia (residues 1–252) and Ib (365–404), is the 
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receptor-binding domain. It targets the low-density, lipoprotein-receptor-related protein 
(LRP1), or the closely related variant LRP1B expressed in the plasma membrane of 
mammalian cells for subsequent cellular internalisation by receptor-mediated 
endocytosis (Kounnas et al. 1992) (Pastrana et al. 2005). Domain II is composed of 
residues 253–364 and is involved in toxin translocation and intracellular trafficking. 
The remaining C-terminal residues (405–613), along with a portion of domain Ib 
(residues 395–404), make up the catalytically active domain. They catalyse the 
adenosine diphosphate (ADP) ribosylation and inactivation of EF2 that leads to 
inhibition of protein synthesis, followed by cell death (Siegall et al. 1989). The earliest 
PE-based therapeutics application was generated by the chemical coupling of full-length 
PE with antibodies. Elucidation of the structure and the function of the PE led to the 
development of recombinant immunotoxins, in which the receptor-binding domain of 
PE was substituted with the Fv portion of an antibody, a growth factor or a cytokine, to 
generate a higher binding affinity to cancer cells through chemical conjugation or 
recombinant DNA technology (Zhang et al. 2007). 
1.2.10.2 DT 
DT is secreted by the Gram-positive bacterium Corynebacterium diphtheria as a single 
polypeptide chain of 535 amino acids (Greenfield et al. 1983). The functional DT is 
composed of two major domains: amino-terminal domain A (1–193 amino acids) that 
carries the active site for ADP-ribosylation of EF2, and carboxyl-terminal domain B 
(194–535 amino acids) that promotes the binding of the toxin to the cells and the entry 
of domain A into the cytosolic compartment. The human heparin-binding epidermal 
growth factor-like precursor (HB-EGF) acts as a receptor for DT on the plasma 
membrane of human cells (Naglich et al. 1992). Once internalised by receptor-mediated 
endocytosis, an arginine-rich segment connecting the A and B domains is readily 
cleaved by trypsin-like enzymes to yield active fragments A and B (Tsuneoka et al. 
1993). In the acidic conditions of the late endosome, domain A is translocated into the 
cytosol (Sandvig and Olsnes 1980) to catalyse the transfer of the ADP-ribose moiety of 
nicotinamide adenine dinucleotide (NAD+) to a highly conserved diphthamide residue 
(modified histidine) on the EF2 polypeptide chain, thereby inactivating it (Collier and 
Pappenheimer 1964) (Honjo, Nishizuka, and Hayaishi 1968) (Van Ness, Howard, and 
Bodley 1980). The modified EF2 can no longer make a new protein and the cell dies 
through apoptosis. Recombinant DT-based immunotoxins are constructed by mutating 
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or replacing the carboxyl-terminal cell binding domain and fusing the engineered toxin 
with a ligand to a cancer cell surface receptor, or the Fv fragment of an antibody. 
1.2.10.3 Ricin 
The plant toxin ricin, extracted from the seeds of Ricinus Communis, belongs to a group 
of toxins called ribosome-inactivating proteins (RIPs) Type II (Siegall et al. 1994). 
Ricin is synthesised as a precursor protein of 565 amino acids, consisting of a 24-
amino-acid N-terminal signal sequence followed by the A chain (267 amino acids) that 
is attached to the B chain (262 amino acids) by a 12-amino-acid linker (Lamb II et al. 
1985). During biosynthesis, the signal sequence is co-translationally removed from the 
preproricin to generate proricin and the 12-amino-acid linker is cleaved post-
translationally to yield the mature protein held together by a disulfide bond. The toxic 
action of ricin is associated with the A chain, while the B chain functions as a carrier 
moiety to bind the toxin to the galactose-containing receptors on the cell surface (Olsnes 
and Pihl 1973) (Newton et al. 1992). Once the A chain reaches the cytosol of the target 
cell, it enzymatically attacks the 28S rRNA in the 60S ribosomal sub-unit and disrupts 
protein synthesis (Olsnes, Pappenheimer, and Meren 1974) (Sperti et al. 1973). 
Immunotoxins are generated by the chemical cross-linking of the intact ricin or the 
recombinant ricin A chain to antibodies directed to antigens overexpressed on the 
tumour cell surface. 
1.2.10.4 SAPORIN 
Thirty years ago, the type 1 RIP SAP-S6, also known as SAP, was isolated from the 
seeds of Saponaria officinalis L. Since then, the properties and mechanisms of action of 
SAP-S6 have been well characterised and it has been widely used in the construction of 
conjugates and immunotoxins. These immunotoxins have shown many interesting 
results when used in cancer therapy, particularly in haematological tumours. The high 
enzymatic activity, stability and resistance to conjugation procedures and blood 
proteases make SAP-S6 a very useful tool in cancer therapy. High efficacy has been 
reported in clinical trials with SAP-S6 containing immunotoxins, at dosages that 
induced only mild and transient side effects—mainly fever, myalgias, hepatotoxicity, 
thrombocytopenia and vascular leak syndrome. Moreover, SAP-S6 triggers multiple cell 
death pathways, rendering impossible the selection of RIP-resistant mutants. This 
review reports some aspects of SAP-S6, such as its chemico-physical characteristics, 
Chapter 1: Literature Review 
20 
structural properties, endocytosis, intracellular routing and the pathogenetic 
mechanisms of the cell damage. In addition, recent progress and developments of SAP-
S6 containing immunotoxins in cancer immunotherapy are summarised, including in 
vitro and in vivo preclinical studies and clinical trials. A Phase 1 Study of Substance P-
SAP in terminal cancer patients with intractable pain was conducted at the University of 
Texas (Polito et al. 2013b). In a single-blind controlled study, 70 companion dogs with 
bone cancer pain were randomised to either standard-of-care analgesic therapy alone 
(control, n=35), or intrathecal SP-SAP (20 μg–60 μg) in addition to standard-of-care 
analgesic therapy (n=35). Activity, pain scores and videography data were collected at 
baseline, two weeks post-randomisation and then monthly until death (Brown and 
Agnello 2013). Although efficacy results at the two-week post-randomisation point 
were equivocal, the outcomes evaluated beyond two weeks revealed a positive effect of 
SP-SAP on chronic pain management. Significantly, more dogs in the control group 
(74%) required unblinding and adjustment in analgesic protocol or euthanasia within six 
weeks of randomisation, than dogs that were treated with SP-SAP (24%, p<0.001). 
Overall, dogs in the control group required unblinding significantly sooner than dogs 
that had been treated with SP-SAP (p<0.01). 
RIPs are plant-derived toxins. They have N-glycosidase activity and cause the 
depurination of a particular adenine residue at position 4324 in the ricin/α-sarcin loop of 
eukaryotic 28S rRNA (Narayanan et al. 2005). These RIPs are classified into three types 
based on their structure. Type 1 includes single chain amino acids of approximately 30 
KDa, Type 2 includes RIPs with two domains: a lectin binding domain and an N-
glycosidase domain. Type 3 is poorly characterised and has been found in maize and 
barley. These pro-RIPs become active on proteolytic cleavage (Nielsen and Boston 
2001). The RIPs are internalised through clathrin-coated vesicles or receptor-mediated 
endocytosis by binding to specific substrates on the cell surface. The internalised 
proteins are then transported to the cytosol through the Endoplasmic-reticulum-
associated protein degradation (ERAD) pathway from ER, where they exert their 
cytotoxic effect (Nielsen and Boston 2001) (Puri et al. 2012). RIP-induced apoptosis 
through Reactive Oxygen Species (ROS), loss of mitochondrial membrane potential and 
DNA fragmentation has also been observed (Narayanan et al. 2005). SAP is a type 1 
RIP. There are nine isoforms of the protein that can be obtained from different plant 
tissues (Polito et al. 2013a). SAP-S6 is the well-characterised isoform of the protein 
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with its hydrophobic nature and a negative charge at the active site consisting of Glu176, 
Arg179 and Trp208 residues (Polito et al. 2013a). 
1.2.10.5 NCS 
The NCS compound is derived from by Streptomyces carzinostaticus. It is a 12-kDa 
protein (Kuromizu et al. 1986) bound to an enediyne chromophore ligand (Napier et al. 
1979). The enediyne chromophore (Kappen, Napier, and Goldberg 1980) has been 
attributed to the binding of the chromophore to DNA, in which it induces double-
stranded DNA cleavage (Moody et al. 2013) (Hensens et al. 1994). The SMANCS 
construct in which NCS is conjugated to poly (styrene comaleic acid) (Oda and Maeda 
1987) (Maeda, Takeshita, and Kanamaru 1979) has been used clinically to treat 
hepatomas in humans (Konno 1992) (Konno et al. 1994). 
The Nuclear Magnetic Resonance spectroscopy (NMR) (Takashima et al. 2005) 
(Caddick et al. 2006) and crystal (Kim et al. 1993) (Teplyakov et al. 1993a) structures 
of NCS have been elucidated, revealing a hydrophobic groove that binds the 
chromophore with nanomolar affinity (Povirk and Goldberg 1980). The considerable 
stability of apo-NCS to reduction and denaturation (Meienhofer et al. 1972) (Sudhahar 
and Chin 2006) and its ability to bind a wide range of synthetic ligands have stimulated 
efforts to develop ligands for NCS for use as chemotherapeutics (Caddick et al. 2006). 
Such activity could be coupled with the ability of NCS to display functional 
complementarity determining region loops from antibodies (Nicaise et al. 2004). 
Holo-NCS can induce chromosomal DNA damage, found after analyses of DNA 
replication rates (Kappen, Napier, and Goldberg 1980) and gene transcription (Schaus, 
Cavalieri, and Myers 2001), following incubation of live cells with holo-NCS damage. 
Hence, the chromophore can enter the nucleus. The chromophore is highly unstable in 
its ‘free’ form and it has been suggested that it is protected from degradation in the 
cytoplasm by the NCS protein (Kappen, Napier, and Goldberg 1980). In addition, 
microscopy of living cells treated with fluorescently labelled holo-NCS suggests that 
holo-NCS can internalise and accumulate in the nucleus (Takeshita, Maeda, and Koike 
1980) (Oda and Maeda 1987). 
Given the favourable biochemical properties of apo-NCS, and the strong evidence for 
internalisation of holo-NCS, we have investigated the possibility that a recombinant 
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apo-NCS could act as a cell-penetrating protein and; therefore, provide a platform for 
the targeted intracellular delivery of therapeutic cargo. 
 
Figure 5: The Structure of NCS 
Demonstrating the chromophore attached to the protein and the chromophore showing the interaction of 
the phenyl ring edges of the Phe52 and Phe78 of pi-face. The picture was adopted from Protein 
Engineering, Design and Selection and the European Journal of Biochemistry (Valerio-Lepiniec et al. 
2002) (Teplyakov et al. 1993a). 
Many clinical trial approaches have been investigated previously by different groups. 
The drug has undergone extensive clinical trials in Japan and has been reported active 
against a variety of human tumours (Dedrick et al. 1978). In the Japanese trials, 22 
patients who were in relapse with acute nonlymphocytic leukaemia refractory to other 
agents were given two dose schedules of NCS. In schedule 1, 12 patients were given 
2000 units/m2/day–8000 units/m2/day by continuous infusion for five to 10 days. In 
schedule 2, 10 patients were given 2000 units/m2/day–6000 units/m2/day by intravenous 
(IV) bolus every eight hours (Griffin et al. 1978). Another study was performed with 
NCS in which the drug was given to 47 patients who had cancer and leukaemia. 
Tolerance to two schedules was investigated—a single dose as a two hour infusion and 
a continuous infusion over five days. Immediate reactions, including fever, chills, rigor, 
hypertension and mental confusion, were dose-limiting for the two-hour infusion 
schedule, occurring at 3000 units/m2 and higher. While continuous administration for 
five days eliminated the immediate reactions, haematological toxicity often prolonged 
leukopenia and thrombocytopenia became dose-limiting (Ohnuma et al. 1978). Another 
study was performed with 53 patients who received intensive treatment with NCS in 
doses of 3500 units/m2 by IV bolus infusion daily for five to 14 days. The response rate 
was 9% for 22 patients with leukaemia. One complete and one partial remission were 
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observed among nine patients with chronic myelogenous leukaemia in blast cell crisis 
(McKelvey et al. 1981). NCS was administered by both continuous and intermittent IV 
infusion to 76 patients who had a variety of malignant diseases. Doses ranged from 500 
units/m2 to 6500 units/m2 for five days. With levels greater than or equal to 1800 
units/m2, bone marrow suppression (particularly thrombocytopenia) was the dose-
limiting toxicity (McKelvey et al. 1979). 
NCS is a new anti-cancer drug developed by Japanese researchers. To delineate the 
potential usefulness of this drug, we reviewed the preclinical data and summarised the 
Japanese clinical data on 462 patients. The bulk of these patients had carcinoma of the 
stomach or pancreas and acute leukaemia. NCS was administered intravenously in a 
daily dose of 2 mg–3 mg for 5–15 day periods. Significant antitumour activity was 
observed in acute leukaemia. A few responses were also reported in pancreatic 
adenocarcinoma; however, the drug was inactive against gastric carcinoma. The side 
effects observed included nausea, vomiting, myelosuppression, fever and occasional 
hypersensitivity reactions. The Investigational Drug Branch of the National Cancer 
Institute has recently sponsored an investigational new drug application with the Food 
and Drug Administration and phase I studies are expected to begin soon in the United 
States (US) (Legha, VonHoff, et al. 1976). 
1.2.10.6 Mechanism of action 
NCS protein is made up of 113 amino acids comprising 7 β-strands (inner and outer) 
and a loop region (Meienhofer et al. 1972). The arrangement of β-strands are in such a 
way that the outer β-sheet contains strands A (residues 5–8), B (residues 17–24) and E 
(residues 62–69), while the inner β-sheet contains strands C (residues 31–39), D 
(residues 45–56), H (residues 93–98) and I (residues 107–109). Strand D is separated 
into sub-strands D1 and D2 by a short loop (Loop 47–53) (Wang and Merz 2010) 
(Izadi-Pruneyre et al. 2001). The apo-NCS is bound to the enediyne chromophore 
(Affinity Kd=0.1nM) and thus protects the chromophore’s functional activity (Mohanty, 
Sieker, and Drobny 1994; Heyd et al. 2000). Recent studies suggest that apo-NCS has 
cell penetrating properties and also releases chromophore into the cell (Schaus, 
Cavalieri, and Myers 2001) (Shanmuganathan et al. 2009). Generally, apo-NCS and 
chromophore are tightly bound and found to protect each other against damage (Kappen 
and Goldberg 1980). The apo-NCS protein is highly stable with its seven β-sheets 
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(Moody et al. 2013) and the formation of the hydrophobic cluster by internal β-sheets is 
similar to IgG structure (Valerio-Lepiniec et al. 2002). The dynamics of the NCS lies in 
the loop region (Wang and Merz 2010) that primarily facilitates the release of 
chromophore from the protein structure. Based on an earlier Molecular Dynamics (MD) 
study, it is inferred that the β-sheets possess restricted movement, while the loop region 
(residue 99–104) has more flexibility and movement by which the chromophore 
released is facile. The cleft formation and chromophore binding are formed by three 
loop regions such as residues 40–44, 76–83 and 99–104 (Wang and Merz 2010). The 
cluster is formed by the residues val7, Thr8 of A strand, Val18, Leu20 of B strand, Leu 67, 
Thr 68 of E strand, Val34, Gln36 of C, Val108 and Ala109 of G strand. Moreover, the FG 
loop showed maximum flexibility and movement and the residue Gly35 provided more 
plasticity for the structure. 
NCS has a marked nonlinearity of triple bonds. The chromophore interacts with the 
phenyl ring edges of the Phe52 and Phe78 of pi-face. The carbonate groups and the 
amino sugar present in the chromophore are solvent exposed, whereas the acetyl groups, 
epoxide and carbon C-12 of the nucleophilic thiol addition during chromophore 
activation reaction are unexposed. The amino acid group’s position in the chromophore 
carbohydrate relative to C-12 reveals that the amino acid plays an important role in thiol 
activation reaction. 
 
Figure 6: Mechanism of DNA Cleavage by NCS 
Adopted from http://nptel.ac.in/courses/104103068/4. 
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NCS contains an active naphthoate ester that intercalates in DNA, positioning the diyne 
in the minor groove. The folding of the seven-stranded β-sandwich protein is similar to 
that of the variable domains of immunoglobulins. Activation with a thiol, followed by a 
Bergman rearrangement, produces a diradical that is somewhat different to those 
produced by other enediynes (i.e., it is not a 1,4-dehydrobenzene diradical, but it is 
thought to behave similarly). The reactive diradical affects DNA strand scission by 
reacting with the C4′- and the C5′-atoms of the deoxyribose sugar, usually at 
deoxyadenosine and thymidine residues, consuming one equivalent of O2 per strand 
break (Valerio-Lepiniec et al. 2002). 
1.2.10.7 Clinical significance of NCS 
NCS is a potent DNA damaging agent that can be used in clinical trials. It is a cell cycle 
phase arrest agent that reduces cell proliferation and induces apoptosis in cancerous 
conditions. Clinical trials were performed with 53 patients and the doses were 
maintained at 3500 units/m2 by IV bolus every day for 15 consecutive days. Twenty-
two patients with leukaemia (9%) and 31 patients with solid tumours did not respond to 
the treatment (9%). Side effects including prolonged thrombocytopenia and bone 
marrow toxicity were observed along with allergic reactions (28%) (McKelvey et al. 
1981). The Japanese group clinical trials were performed in 1971 and the treatment was 
used against S–180, Ehrlich tumour, L1210, Yoshida sarcoma and a range of ascitic 
hepatomas. The study was a failure due to the limitations of the side effects and the 
response (Kimura 1978). 
A phase I clinical trial was performed with NCS and tolerance levels observed for the 
two-hour infusion and the continuous infusion in a group of 47 patients with leukaemia. 
Haematological toxicity was observed with bone marrow toxicity that limited the dose 
and remission was observed (Kimura 1978) (Legha, Von Hoff, et al. 1976). NCS has 
been extensively studied in phase II clinical trials (Kimura 1978). NCS conjugated with 
the antibody and the immune response of the toxin conjugates was found to be 
contradictory (Kikuchi et al. 1983). The immune response of the patients was allergic 
and the study was stopped. The reason behind the failure of the antibody–toxin 
conjugate is that antibodies are prone to immune reactions that can lead to adverse 
effects. Hence, conjugation of the NCS with the aptamer may reduce the body’s 
immune reactions and help to treat cancer with fewer side effects. 
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1.2.11 Nanocarrier-based targeted therapy 
Nanocarrier-based drugs are a new range of therapeutic under research. NCs can be 
polymer based, dendrimers, polymer-lipid combinations or polymer micelles. NCs can 
be engineered according to the level of targeting efficiency, with targeting moieties such 
as aptamers, antibodies and peptides. Although drug resistance to the chemotherapeutic 
drugs has been a problem in treating cancers, multifunctional and multi-
targeted NPs have been developed to overcome barriers of drug resistance in human 
cancers (Dawar et al. 2013). NPs have been developed against survivin in colon cancer 
xenograft models. The lactoferrin-based natural molecule has the anti-cancer effect and 
Fe-bLf nano formulation was synthesised to target survivin, kill colon cancer stem cells 
and maintain absorption of iron, calcium and zinc (Kanwar et al. 2015). Fe-bLf nano 
formulations were synthesised for oral administration of iron-saturated bovine 
lactoferrin-loaded ceramic nanocapsules for breast cancer therapy and its influence on 
iron and calcium metabolism (Mahidhara et al. 2015). NCs have been developed against 
triple positive colon cancer (EpCAM, CD133, CD44). These NPs have been decorated 
with LNA aptamer-targeting tumour for NIRF, MRI and CT imaging (Roy, Kanwar, 
and Kanwar 2015). Biodegradable Eri silk NPs were synthesised against MDA-MB-231 
and MCF-7 breast cancer cells (Roy et al. 2016). An EpCAM aptamer-mediated cancer 
cell specific delivery of EpCAM siRNA using polymeric nanocomplex was synthesised 
against retinoblastoma cell lines and breast cancer cell types (Subramanian, Kanwar, 
Athalya, et al. 2015). 
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Figure 7: Illustration of Nanoparticle Synthesis 
The core nanoparticle is made of polymeric, organic or inorganic compounds that will be encapsulated, 
upon addition of drugs. The process will then continue for decorating the nanoparticle with the ligand of 
choice according to the application (i.e., antibodies, aptamers and so forth) to achieve the targeting effect. 
The then-formed nanoparticle is fully functional—a functional nanoparticle. 
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Chapter 2. Materials and Method 
2.1 In Vitro Materials 
Dulbecco’s Modified Eagle Medium (DMEM), Rowell Park Memorial Institute (RPMI) 
1640 medium, Fetal Bovine Serum (FBS) and Trypsin-EDTA solution were purchased 
from Invitrogen, Thermo Fisher Scientific (Carlsbad, California, US). Acrylamide, bis-
acrylamide, Tris base, glycine, sodium chloride and sodium hydroxide were purchased 
from SRL Biotech (Chennai, India). Trizol reagent, TEMED, Ammonium Persulfate 
(APS), Sodium Dodecyl Sulphate (SDS), Diethyl Pyrocarbonate (DEPC) and 
biotechnological grade DNase and RNase free water were purchased from Sigma-
Aldrich (Bangalore, India). Cell culture consumables including cell culture flasks (T25, 
T75), serological pipettes, 60 mm dishes, cell culture plates (96, 24, 12 and 6) and 0.22 
μm syringe filters were purchased from Sigma-Aldrich and BD Biosciences (Bangalore, 
India). The other chemicals were purchased from Sigma-Aldrich (Bangalore, India), 
unless otherwise stated. 
NCS (NCC-catalogue 69856) and SAP (S-9896) were purchased from Sigma-Aldrich 
(St. Louis, MO). Sulfo-LC-SPDP (sulfosuccinimidyl 6-(3'-(2-pyridyldithio) 
propionamido) hexanoate) was purchased from Invitrogen, Thermo Fisher 
Scientific (Carlsbad, California, US). EpCAM aptamer with 2ʹF pyrimidines with the 
sequence (5ʹ-GCGACUGGUUACCCGGUCG-3ʹ), was purchased from Thermo Fisher 
Scientific (Lafayette, CO). The EpCAM sequence was purchased with and without 
Fluorescein-labelled (FITC). Sephadex PD MidiTrap G-10 columns were purchased 
from GE Healthcare Life Sciences (Bangalore, India). 
The MTT reagent, trypan blue dye, was purchased from Sigma-Aldrich (Bangalore, 
India). EpCAM antibody (Catalogue no: EpCAM 2929) was purchased from Cell 
Signaling Technology (Danvers, MA, USA). The apoptosis kit (Catalogue No.556419) 
and the cell cycle kit were purchased from BD Biosciences (Bangalore, India). 
Biotechnological grade water was used in all experiments to eliminate the DNase and 
RNase. 3 KDa MWCO centrifugal spin filters were used for protein desalting and 
concentrating the conjugates. HPLC analysis was done using an Agilent system with 
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Zorbax oligo column for the purification of the conjugates. Mass spectroscopy was done 
through the MALDI-TOF system, using the oligo matrix 3ʹ-hydroxypicolinic acid. 
EpCAM, Nucleolin LNA aptamer sequences 5ʹ-GCGACUGGUUACCCGGUCG-3ʹ and 
5ʹ-GGTGGTGGTGGTTGTGGTGGTGGTGG-3ʹ with and without Cy5.5 labelling with 
modifications at 3ʹ position were purchased from Exiqon, Denmark. The DAPI and all 
other regents for microscopy and tissue culturing were purchased from Sigma-Aldrich. 
2.2 Secondary Structure Prediction of NCS and EpCAM Aptamer 
Using CD Spectroscopy 
Equimolar concentrations of NCS (20uM) (NCS, Sigma-Aldrich) and 2F Modified 
EpCAM RNA aptamer (IKA gene technologies) were mixed in a 1.5 ml tube at room 
temperature (RT). The interactions were studied in different physiological buffers 
including Tris Acetate EDTA (TAE) (pH 7.6), PBS (pH 7.6) and MES (pH 5.5). The 
CD spectra were measured using a spectropolarimeter, model J-710 (Jasco, Japan), 
equipped with a Neslab RTE-110 temperature controller (Neslab Instruments, US). The 
instruments were calibrated with a standard solution of (+)–10-camphorsulfonic acid. 
The results were analysed through the Dichroweb online tool 
(http://dichroweb.cryst.bbk.ac.uk/html/home.shtml). 
2.3 Infra-Red Spectroscopy Analysis of 2F Modified EpCAM Aptamer 
and NCS Toxin 
Equal concentrations of NCS (20 μM) and 2F Modified EpCAM aptamer (20 μM) were 
mixed and taken for Attenuated Total Reflection (ATR) FTIR analysis. Individual 
samples of 2F Modified EpCAM aptamer and NCS toxin were spotted on ATR–FTIR 
(Bruker Alpha, and Bruker TENZOR 27, Germany). The spectra were measured in an 
absorbance mode between 400 cm–1 and 4000 cm–1. 
2.4 RNA Structure Prediction 
The secondary and tertiary structures of the aptamer were predicted using MC-FOLD 
and MC-SYM pipeline tools, respectively (Parisien and Major 2008). The secondary 
structure was predicted by MC-FOLD and validated using centroid fold (Sato et al. 
2009). Further, the validated secondary structure was taken as input for MC-SYM to 
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predict the RNA tertiary structure. The maximum number of models was set to 100 and 
the best structure was chosen, based on the lowest potential energy after energy 
minimisation. Finally, molprobity was used to assess the stereochemical quality of the 
predicted structure (Davis et al. 2004). 
2.5 Molecular Dynamics Simulations and Docking 
2.5.1 RNA simulation 
MD simulation was conducted for the predicted RNA structure in explicit water solvent 
using Groningen Machine for Chemical Simulation (GROMACS) (Pronk et al. 2013; 
Garcia and Sanbonmatsu 2002). The system was set up with the nucleic acid solvated in 
TIP3P water model in a cubic box with nucleic acid placed at the centre. An 
AMBERGS force field (Garcia and Sanbonmatsu 2002) (Meienhofer et al. 1972) was 
applied for energy calculation. The system was neutralised by adding Na+ ions and 
energy was minimised using the steepest descent algorithm with short-range 
electrostatic and the Van der Waals cut-off point was set to 1.0 nm. The energy 
minimised system was equilibrated using NVT and NPT ensembles for 100 ps. The 
temperature (300 K) and pressure (1bar) of the system were equilibrated with modified 
Berendsen thermostats and a Parrinello-Rahman barostat, respectively. Particle Mesh 
Ewald was used to calculate long-range electrostatics. Lincs algorithm was used to 
constrain all atoms to follow the Newtonian motion. The final production run was 
carried out for 50 ns with the coordinates sampled at every 2 ps. 
2.5.2 Docking 
The structural coordinates of the antitumour protein complex (co-crystallised with 
chromophore) (NCS) were downloaded from the Protein Data Bank (PDBID: 1NCO) 
(Meienhofer et al. 1972). Docking of the 2F Modified EpCAM RNA aptamer with the 
structure of NCS was performed using a Hex protein docking server (Macindoe et al. 
2010) (Ritchie and Venkatraman 2010). The RNA aptamer was chosen as a receptor and 
the optimised NCS complex structure was taken as a ligand. Finally, molecular docking 
was carried out using default parameters with shape-only correlation type. The 
interaction plot for the docked complex was calculated using Nucplot (Ritchie and 
Venkatraman 2010) from pbdsum server (Laskowski 2001). 
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2.5.3 Docked complex simulation 
Simulations were performed, with and without RNA, for the protein chromophore 
complex. GROMACS topologies for the Protein–RNA complex were made using the 
pdb2gmx program. The protein chromophore topology was generated by antechamber 
(Wang et al. 2006; Wang et al. 2004) and openbabel (O'Boyle et al. 2011) using 
ACPYPE (Sousa da Silva and Vranken 2012). ACPYPE-generated topology was based 
on the general amber force field (GAFF) that is highly compatible with amber force 
field-based calculations. Further, the system was neutralised and energy minimised with 
optimal parameters similar to RNA simulations as discussed above. The system was 
equilibrated with NVT–NPT ensembles with coupling groups made by grouping the 
protein, chromophore and RNA into a single unit to treat them as an integral part of the 
complex. Do_dssp program was used to compare secondary structure deviation within 
the simulation (Kabsch and Sander 1983) and g_mdmat program of GROMACS was 
used to plot interatomic distance. G_mindist program was used to calculate the distance 
and contacts between the strands. The final production run was carried out for 20 ns. 
2.6 Conjugation of SAP with EpCAM Antibody 
The conjugation reaction was performed using the EDC-NHS coupling reaction. First, 1 
mg/ml of SAP was prepared in an activation buffer (0.1 M MES (2-[morpholino] ethane 
sulfonic acid), 0.5 M NaCl, pH 6.0). A 10-fold molar excess of EDC (N-(3-
dimethylaminopropyl)-N’-ethyl carbodiimide hydrochloride) was then added to the 1 ml 
SAP solution and NHS (0.6 mg) was added to the reaction mixture (5 mM final 
concentration). The reaction mixture was incubated for 15 minutes at RT. EDC was 
inactivated by the addition of 1.4 μl of 2-mercaptoethanol (20 mM final concentration 
in the reaction mixture) to the mixture. Unreacted EDC, or byproducts, were removed 
using desalting filter columns. An EpCAM antibody 1mg/ml dissolved in PBS (amine-
free buffer pH 7.40) was added to the activated NHS-ester. The reaction components 
were mixed and allowed to react for two hours at room temperature. The reaction was 
quenched using hydroxylamine (10 mM final concentration). The conjugate was 
purified using 3 kDa spin filter columns (Amicon) and stored at –20°C. 
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2.7 Characterisation of SAP–EpCAM Conjugates 
2.7.1 MALDI-TOF analysis 
To confirm the conjugation reaction the molecular mass of the conjugate was measured 
using MALDI-TOF. SAP 31 kDa (SAP), EpCAM antibody (EpAB) 25 kDa and SAP–
EpCAM antibody conjugate (SAP–EpAB) were prepared individually with the MALDI 
matrix (Sinapinic Acid). The matrix solution TA (33% Acetonitrile, 0.1% TFA) was 
mixed with equal volumes of the test sample solutions, then the mixture was spotted on 
the matrix and dried. The spectra were recorded individually for all three components 
and analysed using AutoFlex II TOF / TOF, Bruker Daltonics (Shrimpex Biotech 
Services Pvt. Ltd, Chennai, India). 
2.7.2 Gel retardation assay 
Gel retardation was performed to find the difference in the retention time for the native 
proteins and the conjugate. SAP and SAP–EpAB were taken individually and mixed 
with 1X protein loading buffer (50mM Tris pH 7.5; 2% SDS; 8% glycerol; 0.5% 
bromophenol blue) and denatured at 95°C for five minutes. The samples were loaded 
onto 12% SDS-PAGE and electrophoresed in Tris-Glycine running buffer (pH 8.3) for 
one hour at 100 V. 
2.8 In Vitro Evaluation of SAP–EpAB Conjugates 
2.8.1 Cell culture 
The WERI-Rb1 cells were grown in RPMI 1640 (GIBCO, Rockville, MD). MCF-7 
MIOM1 cells were cultured in DMEM (GIBCO, Rockville, MD) supplemented with 
10% FBS and 1X penicillin–streptomycin antibiotics (Himedia, Bangalore, India). The 
cells were maintained in 5% CO2 in a 37°C saturated humidified incubator (Thermo 
Scientific, US). 
2.8.2 Assessment of SAP–EpAB conjugates binding with cells 
First, 2 × 106 cells of MCF-7, WERI-Rb1 and MIOM1 cells were taken and fixed using 
4% PFA (paraformaldehyde), washed twice with 1X PBS and permeabilised using 0.1% 
Triton x–100 (93443, Sigma-Aldrich, USA). The cells were washed twice with 1XPBS 
Chapter 2: Materials and Method 
33 
and treated with 1 μg of EpCAM antibody and 1 μg of SAP–EpAB conjugate and 
incubated overnight at 4°C. The cells were washed twice with 1X PBS and incubated 
for two hours with an anti-mouse IgG monoclonal secondary antibody labelled with 
FITC. The cells were washed twice with 1XPBS and acquired through flow cytometry. 
2.8.3 Fluorescence microscopy 
In a 24-well plate, 1 × 105 cells/ well of MCF-7, WERI- Rb1 and MIOM1 were cultured 
on Poly-L-Lysine coated coverslips. The cells were then washed twice with 1X PBS 
and fixed with 4% PFA for 20 minutes. They were washed twice with 1X PBS and 
permeabilised using Triton x–100. The cells were washed twice with 1X PBS and 
incubated with a native EpCAM antibody 1 μg and the SAP–EpAB 1 μg conjugate 
overnight at 4°C. The cells were washed twice with 1X PBS and incubated for two 
hours with an anti-mouse secondary IgG antibody labelled with FITC. The cells were 
washed twice with 1X PBS and counterstained with DAPI for 10 minutes. The images 
were acquired by fluorescence microscopy (Zeiss) and analysed using Axio Vision 
software. 
2.9 Gene Expression by Microarray 
2.9.1 Cell culture 
In a 6-well plate, 2 × 106 cells of MCF-7 cells were grown. The media was replaced 
with fresh medium containing SAP, EpAB and SAP–EpAB conjugated at their IC50 
value and incubated for 48 hours. The cells were then washed twice with 1X PBS, and 
the total RNA was isolated using Qiagen (RNeasy mini kit, Qiagen) for control (C1, 
C2), SAP treated cells (S1, S2), and SAP–EpAB conjugate treated cells (SC1, SC2). 
The quality of RNA was assessed using Nanodrop (Bio-Nanospec, Shimadzu) and Gel 
Electrophoresis. Quality controlled RNA samples were taken for the microarray 
analysis. 
2.9.2 Microarray experimental setup 
Total RNA was isolated from control, SAP treated and SAP–EpAB conjugate treated 
cells. 100 ngs of isolated total RNA was used for double-stranded cDNA synthesis by 
reverse transcription using poly-A RNA controls, according to the manufacturer's 
protocol. The in vitro transcription was performed using 3ˈ IVT PLUS Reagent Kit 
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(902416, GeneChip 3ˈ IVT PLUS Reagent Kit) to synthesise biotin labelled aRNA. The 
aRNA was purified, fragmented and observed using 1% agarose gel electrophoresis. To 
make the hybridisation cocktail, 15 μg of fragmented aRNA was used. A volume of 130 
μl hybridisation cocktail was loaded on to the Gene Chip Prime View Human Gene 
Expression Array cartridges. The loaded cartridges were hybridised for 16 hours at 60 
RPM at 45°C in the GeneChip Hybridization Chamber. After hybridisation, the 
cartridges were washed and stained using Affymetrix Fluidic station 450. The stained 
cartridges were scanned at 570nm using the Affymetrix Gene Chip scanner (3000 7G). 
2.9.3 Data analysis 
The raw files (.chp) generated from the scanner were processed with Affymetrix 
Expression Console using Robust Multi-array Average (RMA) algorithm to generate 
the .CEL files. Normalised raw data files were submitted to the NCBI Gene Expression 
Omnibus (Accession number GSE70745). The microarray data analysis was performed 
using Gene Spring software (Version 13.0). The experiments were conducted in 
duplicates—control (C1, C2), SAP alone (S1, S2) and SAP–EpAB conjugate (SC1, 
SC2)]. The data was imported to Gene Spring and grouped as C1, C2; S1, S2 and SC1, 
SC2. Quality control was performed on the samples by the filter probe set by expression 
and, further, with the filter probe set by error. 
Statistical analysis for fold change was done for all three samples in duplicates 
including the control, SAP and SAP–EpAB conjugate. A moderate t-test was performed 
using the Benjamini-Hochberg algorithm to calculate the statistical significance of the 
biological interpretations of control v. SAP and control v. SAP–EpAB conjugate. 
2.10 Cell Viability Assay 
In a 96-well plate, 6000 cells/well of MCF-7, WERI-Rb1 and MIOM1 were cultured. 
The cells were washed twice with 1X PBS and incubated with SAP and SAP–EpAB 
(0.1 μg–1 μg) for 48 hours. The cells were washed twice with 1X PBS after incubation 
and 0.1% MTT was added to 100 μl media and incubated for four hours. The 
supernatant was removed and the formazan crystals were dissolved in DMSO (Sigma-
Aldrich, Bangalore, India). The absorbance was read at 570 nm using a multimode plate 
reader (Spectra Max M4, Molecular Devices). 
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2.11 Apoptosis Assay 
In a 6-well plate, 2 × 106 cells of MCF-7, WERI-Rb1 and MIOM1, were grown and 
washed twice with 1X PBS. The cells were replaced with the media containing SAP (1 
μg), EpAB (1 μg) and SAP–EpAB (1 μg) conjugate and incubated for 24 hours and 48 
hours. The cells were washed twice with 1X PBS followed by trypsinisation and 
treatment with Annexin V-FITC and PI staining, according to the manufacturer’s 
instructions, for one hour at 4°C. The cells were then washed twice with 1X PBS, 
resuspended with sheath fluid and acquired through flow cytometry. 
2.12 Conjugation of NCS with EpCAM Aptamer 
The heterobifunctional cross-linker Sulfo-LC-N-succinimidyl-3-(2-pyridylodithio) 
propionate (Sulfo-LC-SPDP, Thermo Scientific, US) was used to conjugate NCS with 
EpCAM aptamer [29]. Briefly, EpCAM aptamer 5ˈS-S-
GCGACUGGUUACCCGGUCG-3ˈ (Dharmacon Inc, Lafayette, CO, USA), with and 
without fluorescein (FAM), was diluted using RNAse- and DNAs-free water to make 
100 μM concentration. The aptamer was reduced using 2 mM Dithiothreitol (DTT, 
Sigma-Aldrich, Bangalore, India). Excess DTT was removed using Sephadex columns 
(NAP-5 columns, G25-DNA grade column, GE Healthcare, Bangalore, India). The NCS 
solution was treated with the SPDP cross-linker for one hour at RT using constant 
stirring. The unreacted SPDP was removed using Zeba micro spin desalting columns 
(Thermo Scientific, USA). The NCS-SPDP solution was added drop-wise to a fivefold 
molar excess of reduced EpCAM aptamer and reacted overnight at 4⁰C. To block the 
unreacted aptamer, 2 mM iodoacetamide (Sigma, Bangalore, India) was added to the 
reaction mixture. The conjugation reaction was monitored through the appearance of 
pyridine 2-thione at 340nm using a multimode microplate reader (Spectramax, 
Molecular Devices M4, USA). The unconjugated aptamer was washed with PBS (10 
mM sodium phosphate, 150 mM NaCl [pH 7.2]), and the conjugate was eluted with 10 
mM sodium phosphate, 1 M NaCl, as it was in previous reports [29]. The conjugates 
were then subjected to the spin filtration (Spin Filter columns, Millipore, Bangalore, 
India) to remove the unreacted salts and reactants and to concentrate. Filtered 
conjugates were then stored at –80⁰C until required for in vitro studies. 
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Figure 8: NCS–EpCAM Aptamer Conjugation Through Sulfo-LC-SPDP Cross-
Linker 
2.13 Characterisation of Conjugates 
2.13.1 Gel retardation assay 
The Ep–NCSFi conjugates were identified using SDS-PAGE (Polyacrylamide gel 
electrophoresis). NCS alone 5 μM, NCS-SSEpFi conjugate 5 μM and the DTT-reduced 
NCS-SSEpFi 5 μM were diluted with 1X protein loading buffer (50 mM Tris pH 7.5, 
2% SDS, 8% glycerol and 0.5% bromophenol blue) and the samples were run on 18% 
gel. The samples loaded were the native NCS, the native aptamer, the prepared 
conjugate and the DTT-reduced conjugate. 
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2.13.2 High-performance liquid chromatography analysis 
The NCS–EpCAM aptamer conjugates were analysed through a reversed phase–HPLC 
(Kavimandan et al. 2006). Purification of the Ep–NCSFi conjugate was carried out 
using an Agilent Zorbax oligo column (1200 series). The mobile phase contained 20% 
acetonitrile (A) and 80% 0.02 M sodium phosphate (monobasic, B) pH7.0, (B-A) + 2.0 
M NaCl. For separation, a linear gradient of 0% B to 100% B in 120 minutes with a 
flow rate of 0.5 ml/min was used. The gradient was controlled by the Agilent software. 
The column temperature was maintained at 25ºC. Fractions were collected at one-
minute intervals and absorbance measured at 260 nm and 480 nm using a Diode Array 
Detector (DAD). The fractions were concentrated using spin filter columns (Amicon-3 
KDa). The purified conjugates were also checked for the excitation and emission at 480 
nm and 520 nm using a multimode plate reader. 
2.14 In Vitro Evaluation of Ep–NCSFi Conjugates 
2.14.1  Cell culture 
WERI-Rb1 retinoblastoma cells (RIKEN BioResource Center, Ibaraki, Japan) were 
maintained in RPMI 1640 (GIBCO, Rockville, MD), supplemented with 10% FBS 
(FBS-GIBCO, Rockville, MD) and 0.1X penicillin–streptomycin antibiotics (Himedia, 
Bangalore, India). MCF-7 breast cancer (ATCC, USA) and the MIOM1 Müller glial 
cell line (a gift from Dr GA Limb [UCL Institute of Ophthalmology, London, England]) 
were maintained in DMEM 1640 (GIBCO, Rockville, MD) and supplemented with 10% 
FBS and 0.1X penicillin–streptomycin antibiotics (Himedia, Bangalore, India). All cell 
lines were maintained in a 5% CO2 saturated humidified incubator at 37°C. 
2.14.2  Flow cytometry analysis 
The binding efficiency of the aptamer and the Ep–NCSFi conjugate with the EpCAM 
cells was measured using a flow cytometer (BD, Life Sciences). First, 2 × 106 cells 
WERI-RB1, MCF-7 and MIOM1 cell lines were washed twice with 1X PBS and 
incubated with 0.1 μM–1 μM of native aptamer and Ep–NCSFi conjugates in 100 μl 
DMEM media for one hour. A control sample of all three cell lines was then maintained 
to gate the cells for flow cytometry analysis. The cells were centrifuged at 1500 RPM 
post-incubation for five minutes and the pellet was washed twice with 1X PBS and 
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suspended in sheath fluid. Cells were acquired using a green laser (480 nm) and 
analysed for FITC expression based on the histogram obtained. 
2.14.3  Fluorescence microscopy 
Fluorescence microscopy was used to study the aptamer and the Ep–NCSFi conjugates 
binding in cancer and normal cells. Approximately 1 × 103/well WERI-Rb1, MCF-7 
and MIOM1 were seeded on Poly-L-Lysine coated coverslips placed in 24 well plates. 
Post-seeding, cells were incubated with 150 nM concentrations of SSEpFi alone, Ep–
NCSFi conjugate and NCS alone at 37°C for one hour. Post-incubation, cells were 
washed twice with 1X PBS and fixed with cold 4% PFA. Cells were then washed twice 
with 1X PBS and counterstained with DAPI for 10 minutes. Images were acquired with 
a Zeiss fluorescence microscope and analysed using Axio Vision software. 
2.15 Gene Expression Study by Microarray Analysis 
2.15.1 Cell culture and RNA isolation 
In 6-well plates, 2 × 106 MCF-7 cells/well were seeded and allowed to grow overnight. 
The cells were treated with NCS alone (100 nM) or NCS-EpFI conjugated (50nM) and 
incubated for 24 hours. Cells were trypsinised after incubation and washed twice with 
1×PBS. Total RNA was isolated from the untreated control cells (C1, C2), NCS (N1, 
N2) and NCS conjugate- (NC1, NC2) treated cells in duplicates using the Qiagen 
RNeasy mini kit (Qiagen, USA). RNA was checked for quality and quantity using Bio-
nano spec (Shimadzu). Total RNA was diluted according to the requirement for further 
microarray analysis. 
2.15.2 Microarray analysis 
An Affymetrix microarray platform was used for the gene expression study. Double-
stranded cDNA was synthesised from 100 ng total RNA using poly-A RNA controls by 
reverse transcriptase PCR Further in vitro transcription was done to synthesise biotin 
labelled amplified RNA (aRNA) using a 3ˈ IVT PLUS Reagent Kit (902416, GeneChip 
3ˈ IVT PLUS Reagent Kit). The aRNA was purified and quantified using Bio-nano spec 
(Shimadzu Corp.). Further, it was fragmented and observed in 1% Agarose gel for the 
fragmentation pattern. 15 μg of labelled fragmented aRNA was used to prepare the 
hybridisation cocktail. 130μl of hybridisation cocktail was loaded on to the GeneChip 
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PrimeView Human Gene Expression Array cartridges and hybridised for 16 hours in 
rotation at 60 rpm and 45°C using the GeneChip Hybridization Oven 640. After 
hybridisation, the array cartridges were washed and stained using the Affymetrix 
Fluidic station 450. Stained arrays were scanned using the Affymetrix GeneChip 
scanner (3000 7G) at 570 nm. 
2.15.3 Microarray data analysis 
The Raw Expression Array feature intensity data (.CEL file) generated from the scanner 
was processed initially with the Affymetrix Expression Console software (version 4.0) 
using the RMA algorithm to generate probeset summarisation values .chp files. 
Normalised raw data was submitted to the NCBI Gene Expression Omnibus (Accession 
number GSE69160). Further microarray statistical analysis, fold change analysis and 
biological interpretation was done using Gene Spring (version 13.0) software. The 
analysis was conducted on three different samples in biological duplicates (i.e., control, 
NCS treated cells and NCS conjugate treated cells [C1, C2, N1, N2, NC1, and NC2]). 
The .CEL files were imported to the Gene Spring software (Version 13.0-GX). Quality 
control was performed based on filtration of the probe set by expression and by error. 
The interpretation was done individually between control v. NCS treated, control v. 
NCS conjugate treated and NCS v. NCS conjugate averaged samples of duplicate 
treatments. Statistical analysis was also performed separately between the three groups. 
Statistics were applied using a moderate t-test with the asymptotic computation of p-
value and multiple testing correlations using Benjamini-Hochberg false discovery rate 
(FDR). The downstream entities with a fold change of >2.0 with a p-value of <0.05 
were taken further for fold change interpretation. The fold change threshold was kept 
twofold. The gene list of fold change for both the control v. NCS and control v. NCS-
conjugate treated cells was analysed for a common gene set of differentially expressed 
genes using Venn diagram. Further biological interpretation on the differentially 
expressed gene list of NCS v. NCS conjugate analysis was performed to understand the 
differential expression upon NCS conjugate treatment. The differentially expressed gene 
set data was taken further for Gene Ontology (GO) analysis with a p-value of 0.05. 
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2.16 BrdU, H2AX and Poly (ADP-ribose) Polymerase Assay 
Bromodeoxyuridine (BrdU) incorporation assay was performed using the BrdU assay 
kit (BD Pharmingen 562253). In a 6-well plate, 2 × 106 cells (MCF-7 and WERI-RB1) 
were grown. The cells were treated with the NCS and Ep–NCSFi conjugates and 
incubated for 12 hours and 24 hours. The cells were then washed twice with 1XPBS and 
processed with a 10 μM final concentration of BrdU in cell culture media. The cells 
were incubated for a further 12 hours, washed twice with 1X PBS and treated according 
to the standard protocol (given in the manufacturer’s kit). The cells were washed and 
fixed with BD Perm wash buffer and incubated with anti-BrdU, anti-H2AX and cleaved 
anti-Poly (ADP-ribose) Polymerase (PARP) antibodies. The cells were incubated for 45 
minutes at RT, washed twice with 1X BD wash buffer and acquired through a flow 
cytometer. 
The vells were grown on the coverslips and the same procedure was followed for the 
microscopic analysis. The cells were fixed and stained with the DAPI mountant to 
enable the images to be recorded. The images were acquired with a Zeiss fluorescence 
microscope and analysed using Axio Vision software. 
2.17 Cell Cycle Assays by Flow Cytometry 
MCF-7 and WERI-Rb1 cells were cultured in 6-well plates, incubated with native NCS 
(200 nM), and Ep–NCSFi conjugates (100 nM) for 24 hours. Post-incubation, cells were 
collected, washed twice with 1X cold PBS and fixed with 70% cold ethanol. Cells were 
washed twice with 1XPBS and incubated with RNase (10 μg/ml) and Propidium Iodide 
(PI-50 μg/ml) at 37°C for three hours. Post-incubation, cells were washed twice with 
1XPBS, suspended in sheath fluid and acquired through flow cytometer. 
2.18 Apoptosis Assay 
MCF-7 and WERI-Rb1 cells were grown at a confluence of 60%–75% for 24 hours, 
then incubated with NCS alone (200 nM) and Ep–NCSFi conjugates (100 nM) for 24 
hours. Post-incubation, the cells were washed twice with 1X PBS and fixed with 4% 
PFA. The cells were incubated with Annexin V FITC and PI according to the 
manufacturer’s protocol (556547, BD Pharmingen™) for one hour at 4°C. The cells 
were then washed twice with PBS and acquired through a flow cytometer. 
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Table 2: Annexin V-PI Staining of the Cells 
Sample Contents 
Unstained Untreated cells + 1X binding buffer 
Annexin alone Untreated cells + 4 μL of Annexin 
Propidium Iodide alone Untreated cells + 2.5 μL of Propidium Iodide 
Control Untreated cells + 4 μL of Annexin + 2.5 μL of Propidium Iodide 
Test Treated cells + 4 μL of Annexin + 2.5 μL of Propidium Iodide 
2.19 Trypan Blue Exclusion Analysis of Cell Viability 
MCF-7 and WERI-Rb1 cell lines were seeded in a 96-well plate at a cell density of 
6000/well. Different concentrations (100 nM, 200 nM, 300 nM, 400nM and 500 nM) of 
both NCS and NCS-SSEPFi treatments were prepared and added to the cells in 
triplicates. The samples were incubated at 37°C in a humidified incubator for 24 hours. 
Trypan blue dye (100 μl) was added to the cells and the number of dead cells that were 
taken up by the dye was counted in the hemocytometer under a compound microscope. 
The procedure was repeated for all the wells and the triplicate value and the percentage 
cytotoxicity was calculated using the standard formula. 
2.20 Statistical Analysis 
The statistical analysis for microarray was conducted using Gene Spring software. The 
correlation between the NCS and the conjugate was performed using the Benjamini-
Hochberg algorithm, in which duplicates of control, NCS and the conjugates were 
considered and the statistics were performed between the control v. NCS and control v. 
conjugate. The p-value was set to be p<0.05 and deemed to be significant. The statistics 
for the binding assay, cell cycle assay, apoptosis assay and the trypan blue assay were 
performed with the student t-test and the values, p <0.05, p<0.001 and p<0.05, were 
considered significant. 
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2.21 LNA-Modified Aptamer Decorated Alginate Enclosed Chitosan 
Coated Calcium Phosphate NCs Encapsulating NCS–EpCAM 
Aptamer Conjugate 
The locked nucleic alginate enclosed chitosan coated calcium phosphate NCs 
encapsulating the NCS–EpCAM aptamer conjugate (AEC-CP-NCSEpDT3) was 
prepared according to our methods described earlier (Kanwar, Mahidhara, and Kanwar 
2012) (Kanwar et al. 2015) (Mahidhara et al. 2015) (Gupta et al. 2015). Calcium 
phosphate (Sigma-Aldrich) 1% w/v alone was stirred at 800 rpm for one hour at RT. 
The calcium phosphate slurry was then subjected to centrifugation at 4000 rpm for 20 
minutes. Calcium phosphate (prepared in acetate buffer) was resuspended in 0.0.1% 
w/w low molecular weight chitosan (Sigma-Aldrich). NCSEpDT3 conjugate was added 
to 0.01% tri-poly phosphate (STPP) (Sigma-Aldrich) and stirred at 800 rpm. The STPP-
drug solution was added drop-wise and stirred at 4°C for 24 hours. The solution was 
spun at 4000 rpm for 20 minutes and the pellet was dissolved in calcium chloride slurry. 
The LNA EpCAM (LNA EpDT3) and LNA nucleolin (LNA Ncl) were added in a 
known concentration to the mixture and incubated for two hours at 4°C. Finally, 2% 
w/v sodium alginate was added drop-wise and stirred overnight to obtain the uniform 
size and shape of the NCs. Two sets of NCs were synthesised: the particles with 
EpCAM and Ncl aptamers and the NCs without the drugs as void NCs. 
2.22 Physico-Chemical Characterisation of AEC-CP-NCSEpDT3 NCs 
2.22.1  FTIR 
FTIR analysis was performed on the void NCs, EpCAM, NCS and the NCS-EpDT3 
conjugate. All the samples were lyophilised and the powder was mixed with KBr. The 
pellet was loaded onto the sample holder and the scans were performed from 400 cm¯1 
to 4000 cm¯1. The Bruker TENZOR 27 series was the instrument used for the analysis. 
2.22.2  Particle size analysis by DLS 
The lyophilised powder of all the NCs was suspended with PBS and the solutions were 
diluted to 1:100. The approximately 1 ml samples were loaded onto the quartz sample 
holder. The samples were then placed in the Malvern Zetasizer Nano ZS model and the 
size of the particles was analysed. 
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2.22.3  Encapsulation efficiency 
Drug encapsulation efficiency in the NCs was calculated as the ratio of the bound 




2.22.4  Electron microscopy 
SEM was performed to analyse the morphology of the particles. Different nano 
preparations were fixed onto the stub by double-sided adhesive tape. The particles were 
coated with gold sputtering for 60 s. by a SC7620 sputter coater (Quorum technologies, 
UK) and the images were acquired in the scale of 200 nm. 
2.22.5  Drug release assay 
A controlled release study was performed for the NCs. An in vitro drug release assay 
was performed for the nanoformulations, in which different pH PBS were used: pH 2, 
pH 6, pH 7 and pH 8. The nanoformulation was incubated under constant stirring and 
maintained at a temperature of 37°C. At different time intervals, from one hour to 24 
hours, each sample was centrifuged, supernatants were collected and the pellets were 
dispersed in the fresh solution. Supernatants were then analysed for protein 
concentration. To estimate the protein concentration, the Better Bradford™ assay 
(Pierce) was performed with Bovine serum albumin (BSA) protein standards. 
2.23 In Vitro Anti-Cancer Efficacy of NCs 
First, 1 × 103 cells of HepG2 and Hep3B were added in an agarose- (100 μL at 0.1%) 
coated 96-well plate. Cells were then incubated for seven days at 37°C with 5% CO2 
and left to form uniform spheroids in all the wells (Vinci et al. 2012). The spheroids 
were further treated with AEC-CP-NCSEpDT3 NCs (9.01 × 105) corresponding to 100 
mg/mL, 200mg/ml of NCS and nano-free NCS protein (3.3 mg/mL) for up to 96 hours. 
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Next, 6 × 103 cells each of HepG2 and Hep3B were added to a 96-well plate and post-
incubation cells were treated with AEC-CP-NCSEpDT3 NCs (9.01 × 105) 
corresponding to 100 mg/mL, 200mg/ml of NCS and nano-free NCS protein (3.3 
mg/mL) for 24 hours. Cell viability analysis of the HepG2 and Hep3B cells was 
determined using the MTT assay kit, according to the manufacturer’s instructions. The 
IC50 values were determined by the equation derived from the respective logarithmic 
curves. 
The clonogenic assay was performed at a plate density of 6 × 103 cells of HepG2 and 
Hep3B. The cells were treated for 24 hours with AEC-CP-NCSEpDT3 NCs (9.01×105) 
corresponding to 100 mg/mL, 200 mg/ml of NCS and nano-free NCS protein (3.3 
mg/mL). Post-incubation, the cells were trypsinised using a 0.01% trypsin-EDTA 
solution (Sigma) and washed twice with 1X PBS. The cells were then placed in a new 
plate and allowed to form colonies for up to 96 hours. The cells were washed 
thoroughly and stained with crystal violet. The colonies were washed off from excess 
dye and were counted using a microscope. The number of colonies for each treatment 
was then counted and a graph was plotted against the time. 
2.24 Preparation of Oral Feed for In Vivo Studies 
The animals’ diet was prepared as described earlier (Roy, Kanwar, and Kanwar 2015) 
[25]. The dose of AEC-CP-NCSEpDT3 NCs was calculated based on previous reports 
in which 500 μgs of NCS/kg of diet prevented tumour development. The diet was 
checked for the compatibility and stability of the NCs. The amount of nano-diet 
consumed by each mouse daily was also calculated. 
2.25 Animal Studies and Experimental Procedures 
2.25.1  Animal ethics 
Animals were purchased in accordance with Australian animal ethics and Deakin 
University rules and regulations. The animal ethics for carrying out the study was 
approved by Deakin University and was also approved by the Animal Ethics 
Committee, Geelong (AECG) under ethics application G19-2015. 
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2.25.2  Animal housing and feeding 
The animals were caged in groups (three to a cage) with autoclaved corncob as bedding 
material. All the animals were fed with an AIN93G diet that contained soymeal, barley, 
vegetable oils, canola oil, salt, magnesium oxide, vitamins, wheat, dicalcium phosphate 
and trace amounts of minerals. The animals were maintained in a humidified (50±20%) 
environment with a temperature of 22±3°C. Twelve hour dark and light cycles were 
maintained, with fresh air iNCut using controlled filters. All the animals were given 
freshly autoclaved drinking water throughout the study period. Water was filled in 
autoclaved bottles fitted with a nozzle. Two-thirds of the animals were individually 
pierced on their ears. Animals whose left ear was pierced were categorised as 1, animals 
with the right ear pierced were categorised as 2 and animals without ear-piercing were 
categorised as 3. The cages were labelled according to the group to which the animals 
belonged. Each animal’s health was routinely checked each day and their feed and cages 
were changed on a regular basis. 
2.25.3  Preparation of cells for tumour induction 
The cells were prepared in a sterile laminar hood. Hep3B cells were grown to a 
confluency in a T-75 flask, the cells were trypsinised and the pellet was collected. The 
cells were checked for viability and those with viability >90% were chosen for the 
study. Approximately 1 × 107 cells were resuspended in 200 μl of serum deficit media 
containing 50% of Matrigel (Sigma-Aldrich) and kept on ice prior to tumour induction. 
2.25.4 Tumour induction 
Athymic nude mice (aged five weeks to six weeks), males (n = 6) and female (n = 6), 
were used for tumour induction. The 1 × 107 sorted (CD44, CD133 and EpCAM) 
Hep3B cells (Kanwar et al. 2015) were injected subcutaneously into the left flank using 
Matrigel. The tumour volume was calculated on a regular basis by using the formula 
(1/2 L [mm] × W2), where L is the length of the tumour and W is the width of the 
tumour (measured using Vernier calipers). Once the tumour reached 0.5 cm3 for 60 
days, the mice were fed an NCs diet with all combinations. Tumour volumes were noted 
and changes were observed. Once tumour regression was observed, the diet was 
changed to a normal AIN93G diet for 30 days to observe any changes in the tumour 
volume. Body weight was observed and noted every day, while tumour volume was 
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observed and noted on alternate days. The control animals whose tumour volume 
reached approximately 1.0 cm3 in diameter were killed humanely according to animal 
ethics. All the treated mice were humanely killed post-treatment and their organs were 
harvested for histopathological investigations. The harvested organs were snap frozen at 
–80°C. Blood samples were collected and stored for whole blood analysis. 
2.25.5  Imaging for cancers and bio-distribution of AEC-CP-NCSEpDT3 using 
near–infra-red fluorescence 
The bio-distribution and the cancer localisation was imaged using a NIRF imaging 
system (IVIS-2 Lumina Imaging System), according to the animal ethics of Deakin 
University. Before imaging, the animals were fed a diet with different NCs containing 
fluorescent for 48 hours. After 48 hours, the animals were anesthetised using 4% 
isofluorane for approximately two to three minutes. The AEC-CP-NCSEpDT3 
containing VivoTag 680 XL was detected by the signal of the fluorescein in the range of 
675 nm–740 nm and the images were clicked and saved by IVIS. The images obtained 
were then analysed for tumour localisation and the bio-distribution patterns of the 
treatment in the animal’s body. The organs ex vivo mice were also imaged and analysed 
to check the bio-distribution of NCs in individual organs. 
2.25.6  Apoptotic array to detect the expression of apoptotic proteins in the 
tumours 
The Proteome Profiler Apoptosis Kit (R&D Systems) was used to perform the apoptotic 
array. The expression of 35 key apoptosis proteins were analysed. The tumours of the 
mice post-euthanising were collected and the tissue lysate was prepared using the buffer 
in the kit according to the manufacturer’s protocol. All the reagents were prepared and 
kept at RT. The tissue lysate was analysed for protein concentration using the Bradford 
reagent. The arrays were blocked and the tissue lysates (300 μg) were added to 1.25 ml 
of array buffer 1. The arrays were incubated overnight at 2°C–8°C on a rocking shaker. 
Post-incubation, the arrays were washed with a wash buffer three times for 10 minutes. 
Next, 15 μl of detection antibody cocktail was added to 1.5 ml of array buffer 2/3 and to 
each array. The arrays were then incubated for one hour on a rocking shaker. Washing 
was carried out as described earlier and the streptavidin–horse radish peroxidase (HRP) 
antibody was diluted in the array buffer 2/3 using the dilution mentioned on the vial. 
The arrays were carefully placed in a plate and 2 ml of the diluted streptavidin–HRP 
Chapter 2: Materials and Method 
47 
antibody was added and incubated for 30 minutes. The arrays were then developed 
using a chemi reagent mix (HRP substrates) provided by the manufacturer and imaged 
using ChemiDoc with an XRS camera. The band density was analysed using Image J 
software and the corresponding graphs were plotted in Microsoft Excel as band density 
(pixels) to corresponding proteins. 
2.25.7  Stem cell array for the detection of expression of stem cell markers 
The Proteome Profiler Pluripotent Stem Cell Array Kit (R&D Systems) was used to find 
the expression of the 15 established pluripotent stem cell markers. The tumour lysates 
were incubated with the stem cell arrays overnight at 2°C–8°C, according to the kit 
protocol. The unbound proteins were washed three times and incubated with the 
biotinylated detection antibodies cocktail. The streptavidin–HRP was counter-incubated 
and imaged using ChemiDoc with an XRS camera. The band intensity was analysed 
using Image J software. The intensities of the bands were measured in pixels and the 
graph was plotted against each marker protein. 
2.25.8  Angiogenesis and cytokine profile array 
An angiogenesis array was performed to find the expression of 55 important 
angiogenesis proteins using an Angiogenesis Array Kit (R&D Systems) according to the 
manufacturer’s instructions. The tumour lysates were diluted and incubated with the 
cocktail of biotinylated detection antibodies. The sample was then incubated with the 
human angiogenesis array. The detection antibody complex was bound to the 
immobilised antibody on the array. The unbound material was washed with a wash 
buffer and streptavidin–HRP. Chemiluminescence detection reagents were used to 
detect and capture the picture using ChemiDoc with an XRS camera. The band intensity 
of each sample was analysed using Image J software and corresponding graphs were 
plotted as in previous studies (Roy, Kanwar, and Kanwar 2015). 
Mouse cytokine array was performed using the Proteome Profiler Cytokine Array Kit 
(R&D Systems) according to the manufacturer’s protocol. The blood from the 
euthanised mice was collected using cardiac puncture and transferred into unheparinised 
vials. The blood was kept at RT for 20 minutes to clot. To remove the clot, the vials 
were centrifuged for 10 minutes at 4°C and the supernatant was transferred to the new 
vial and stored at –80°C. The mouse cytokine profile was determined in control, LNA 
Chapter 2: Materials and Method 
48 
EpCAM and void NCs-fed mice as in the previous studies (Roy, Kanwar, and Kanwar 
2015). 
2.25.9  Quantitative real-time polymerase chain reaction studies 
The RNA was extracted using TRizol Reagent (Invitrogen Inc., US), according to the 
manufacturer’s protocol. Purity of the RNA was checked using 1% agarose gel 
electrophoresis. The RNA was then converted to cDNA by the SuperScript III First-
Strand Synthesis System (Invitrogen Inc., US) according to the manufacturer’s protocol. 
The survivin splice variants, apoptosis markers, stem cell markers and signalling 
markers for the control, void, LNA EpCAM NC, NCS NC and NCSEpDT3 NC 
conjugated samples were analysed using real-time PCR using primers obtained from 
Sigma-Aldrich (with Bio-Rad Inc., US). 
2.25.10 Tissue processing and embedding: haemotoxylin and eosin staining for 
histopathological investigations 
All the tissues were thawed and washed thoroughly with 1X PBS from inside (Lumen) 
and fixed with 4% PFA. A tissue processor was used to dehydrate the tissue and the 
tissue was fixed. The processed tissues were then wax-embedded and the sectioning was 
done using microtome for 5 μm thin sectioning. The sections were then fixed onto the 
glass slides and stained. 
The slides were first fixed with ice-cold acetone solution (1:1 mixture of acetone and 
distilled water). The slides were then subjected to rehydration with distilled water, 
stained with hematoxylin and counterstained with eosin for immune-histopathological 
investigations (Kanwar et al. 2015) (Samarasinghe, Kanwar, and Kanwar 2014). 
2.25.11 Blood analysis 
The blood samples collected from the animals were directly analysed for whole blood 
composition using ABX Micros ES 60 (Horiba Medicals). The red blood corpuscles 
(RBCs), white blood corpuscles (WBCs), platelets and haemoglobin content were 
analysed using this technique. 
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2.26 Statistical Analysis 
Statistics were performed wherever they were required. The results were expressed as 
mean values ±SD of the best of three experiments, unless otherwise stated. The 
student’s t-test was performed to analyse the significant value for the statistical analysis 
of numerical data. The value p>0.05 was non-significant, p<0.05* was significant, 
p<0.01** was highly significant and p<0.001*** was very highly significant. The 
statistical data was analysed using GraphPad Prism software. 
Table 3: Treatment Groups and Their Corresponding Feeding Schedule 
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Chapter 3. NCS and EpCAM RNA Aptamer 
Biophysical Interaction 
3.1 Summary 
This chapter focuses on unravelling the interactions between the NCS and the EpCAM 
aptamer. These new findings could help in developing novel bioconjugates for targeted 
therapy. This study provides knowledge on the interaction mechanisms of potent DNA 
degrading agents towards the ligand molecule for cancer theranostics. The 2F Modified 
EpCAM RNA aptamer is a 23-mer that specifically targets EpCAM protein, a cell 
adhesion molecule highly expressed on the surface of epithelial tumour cells. 
Understanding the residues interacting between NCS and the targeting ligand will help 
to improve targeted tumour therapy. We investigated the biophysical interactions 
between the NCS toxin and 2F Modified EpCAM RNA aptamer using CD spectroscopy 
and infra-red spectroscopy. The aromatic amino acid residues spanning the β-sheets of 
NCS were found to participate in intermolecular interactions with the 2F Modified 
EpCAM RNA aptamer. In silico modelling and simulation studies corroborate with the 
CD spectra data. Further, it also strongly reinforces the involvement of the C and D1 
strand of NCS in intermolecular interactions with the EpCAM RNA aptamer. This is the 
first report exposing the fundamental interactions involved in the stabilisation of NCS–
EpCAM aptamer complex formation and will aid in the development of therapeutic 
modalities towards targeted cancer therapy. 
3.1.1 Results 
3.1.1.1 CD spectra of interaction between 2F Modified EpCAM aptamer and NCS 
CD spectra were recorded to study the interaction between the 2F Modified EpCAM 
RNA aptamer and NCS. The changes in the ellipticity were observed in the region 
between 200 nm and 300 nm for the native NCS and the 2F Modified EpCAM aptamer. 
The interactions were monitored in a PBS buffer due to the absorption interference 
below 200 nm in the aforementioned buffers. The CD spectra for the native NCS 
showed peaks such as +224 nm (helix π-π*), –216 nm and –210 nm. The native 2F 
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Modified EpCAM aptamer revealed a peak at –210 nm, reflecting 60% GC content 
from the sequence (Clark et al. 1997). The physical mix of the 2F Modified EpCAM 
aptamer showed the perturbation of β-sheets in NCS (see Figure 9). The Dichroweb 
analysis of the native NCS CD spectra revealed a broad negative peak of 205 nm of 
random coil and 213 nm of the β-sheet (see Figure 10). The addition of the 2F Modified 
EpCAM aptamer with NCS indicated the presence of induced α helix at –210 nm and 
the disappearance of +213 nm and +221 nm peak strongly favours the helix structure 
induction. 
 
Figure 9: Structure of NCS 
The arrangement of β-sheets in the protein responsible for the change in the structure of the protein. 
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Figure 10: Dichroweb Analysis of the Native NCS CD Spectra 
(A) NCS CD spectra analysis. (B) NCS–EpCAM mix CD spectra analysis. (C) EpCAM Aptamer CD 
spectra analysis (respective to NCS). (D) Molecular Ellipticity of NCS, EpCAM aptamer and mix. 
3.1.1.2  Infra-red spectroscopy of NCS–2F Modified EpCAM aptamer interaction 
FTIR of 2F Modified EpCAM aptamer and NCS revealed characteristic vibrations. The 
2F Modified EpCAM aptamer vibrations included the hydroxyl group (out of stretch) 
765 cm–1, Phosphoester (P-O-C out of stretch) 1060 cm–1, arene 1517 cm–1, 1632 cm–1 
(C = C stretch), Amine 3428 cm–1 (N–H stretch) (see Table 1). NCS also showed 
signature vibrations such as 773 cm–1 (O = H twist), 905 cm–1 (CN-Stretch), 1300 cm–1 
(C–O stretch carboxylic acid), 1412 cm–1 (Indole N–H) and 1640 cm–1 (amide bond). 
During the physical interactions between NCS and 2F Modified EpCAM aptamer, we 
observed sharp changes in 2432 cm–1 corresponding to hydroxyl-containing amino acids 
(Serine [11], Threonine [13] and tyrosine). These amino acids are major parts of strands 
C and D in which maximum perturbations were observed in both CD and in silico 
dynamics. The 2F Modified EpCAM aptamer and NCS revealed a new peak at 688 cm–1 
(Cyclic amide bend, NH deformation), 1194 cm–1, (P = O out of phase stretch), 1436 
cm–1 –Tryptophan (NH vibration), 2342 cm–1 (O–H stretch) and 2383 cm–1 (amide 
vibration) during the interaction (see Figure 11).
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Table 4: Infra-Red Spectroscopy Analysis of NCS, Aptamer and NCS-Aptamer 
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Figure 11: FTIR Analysis Performed at a Wave Number of 500 nm to 4000 nm 
The samples were scanned for the spectra including the NCS alone, the EpCAM aptamer alone and the 
mix. The analysis showed the new peak at 688 cm–1 (Cyclic amide bend, NH deformation), 1194 cm–1, (P 
= O out of phase stretch), 1436 cm–1 –Tryptophan (NH vibration), 2342 cm–1 (O–H stretch) and 2383 cm–
1 (amide vibration) during the interaction. 
3.1.1.3 RNA structure prediction 
MC-FOLD software predicted the secondary structure of RNA would form a hairpin 
loop between U9 and C12 with unpaired bases at 5’ G1 (see Figure 12). The predicted 
secondary structure was validated by the centroid fold server that also predicted the 
exact secondary structure for the input sequence. Three-dimensional (3D) coordinates 
for the predicted secondary structure were generated using MC-SYM (see Figure 12). A 
total of 100 models were produced by the MC-SYM and were sorted based on energy 
calculated by the steepest descent algorithm using refining options. The structure that 
was formed with the lowest energy of –17.22 Kcal/mol was chosen as the final optimal 
structure. Further, the stereochemical aspect of the predicted structure was assessed 
using molprobity. An all-atom clash score predicted by molprobity for the predicted 
structure was 4.78, indicating 97th percentile (100th percentile is the maximum quality). 
In addition to the clash score, the tools also predicted the structure to have zero wrong 
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sugar puckers, all the backbone conformations had fallen within recognised rotamers 
and all the bonds formed within the allowed distance. 
 
Figure 12: Secondary Structure Topology 
As predicted by MC-FOLD and centroid fold. 3D structure predicted by the MC-SYM. 
3.1.1.4 RNA molecular dynamics 
For the predicted structure of RNA, a molecular dynamics simulation was carried out 
using GROMACS. The simulation was performed on the timescale of 50 ns to sample-
wide conformations of RNA structure to delineate the stable conformation that can be 
used for further molecular interaction studies. The Root Mean Square Deviation 
(RMSD) plot (Figure 13A) was used to study the structural deviation throughout the 
simulation. It was observed that the highly flexible RNA molecule tended to fluctuate in 
the initial frames of the simulation and deviated up to 5Å. After 30 ns, the RNA 
structure gained stable conformation as it showed deviation within 1Å (0.4 nm–0.5 nm) 
and a 30 ns–50 ns period (Figure 13B). The final frame structure from molecular 
dynamics simulation was used as the starting structure for interaction studies. 
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Figure 13: RMSD Plot Aptamer Structure Throughout the Simulation 
The RMSD of the aptamer observed was between 30 ns–50 ns where the aptamer gains a stable 
conformation. 
3.1.1.5  RNA interaction with the NCS 
The interaction between the 2F Modified EpCAM native aptamer and the complex NCS 
was predicted by docking the refined structure of the RNA with the antitumour protein 
complex using a hex protein docking server. The docking program also predicted that 
the aptamer would bind to the same cavity in which the chromophore linked to the NCS 
protein C strand that is hydrophobic in nature. Non-bonded interaction at Phe 52 was 
evident. From the results obtained, it can be interpreted that the aptamer is in the same 
region in which the chromophore is bound to the NCS. Non-bonded interactions were 
formed with residues Phe52 and Phe72 to which the pi-face of the chromophore interacts 
in the crystal structure (Meienhofer et al. 1972). Non-bonded interactions were formed 
with strands of inner β-sheets C and D and one hydrogen bond formed with the ser54 of 
the strand D. The loop region 100–106 was also found to interact with the 2F Modified 
EpCAM aptamer, in which it forms a hydrogen bond with the Ala100, to stabilise the 
chromophore by maintaining a hydrophobic core (Takashima et al. 2005) (see Figure 
14). 
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Figure 14: Interaction Plot for the Predicted Complex Structure 
As predicted by Nucplot. In which blue represents the hydrogen bonds and the dotted red lines indicate 
the non-bonded contacts within 3.35 Å. 
3.1.1.6  Docked complex simulation 
A comparative molecular dynamics simulation was performed to observe the structural 
deviations formed between NCS complex, with and without the 2F Modified EpCAM 
aptamer. The mean of the smallest distance formed by the atoms of the complex was 
plotted using the g_mdmat program to find the interactive residues. The smallest 
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distance plot suggested that the two terminal (3' and 5') regions of the 2F Modified 
EpCAM aptamer are in proximal distance to the area between 30–45 and 31–39 of 
strand C. Docking studies revealed the interaction between strand C, strand D and the 
2F Modified EpCAM aptamer. The dynamics study showed that strand C maintained 
interaction throughout the simulation, particularly in the amino acid position 39, in 
which the mean smallest distance was almost zero (see Figure 15). Strand D is 
composed of two sub-strands, D1 and D2, separated by a loop region at 47–53. Regions 
of the sub-strand D1 were found to be closer in distance to the 2F Modified EpCAM 
aptamer than the sub-strand D2. 
 
Figure 15: Secondary Structure Changes at All Frames During MD of the 
Complex 
As calculated by the DSSP program. (A) Without the aptamer. (B) With the aptamer. 
3.1.1.7 Secondary structure analysis 
Since the interactions were found in the strands of the inner β-sheet, secondary structure 
compositions of the protein at all frames were analysed to understand the changes that 
occurred due to the interaction. The secondary structures were generated with the 
do_dssp program for both the NCS complex, with and without the RNA, and the 
changes in the secondary structure components were evaluated. The results (see Figure 
16A) showed that residues 31–33 of strand C were not part of the interaction after 3000 
ps with 2F Modified EpCAM aptamer complex (see Figure 16B). Conversely, three 
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residues were part of strand C in the complex without the 2F Modified EpCAM 
aptamer. The number of residues forming the sub-strand of strand D were also found to 
be reduced in the complex with the 2F Modified EpCAM aptamer, compared to the 
complex without the 2F Modified EpCAM aptamer, especially at the end of the sub-
strand D2 region (54–56) in which the loss of sheet can be observed after 3000 ps. The 
turn region connecting strands D and E increased in the complex with the 2F Modified 
EpCAM aptamer, compared to the complex without the 2F Modified EpCAM aptamer. 
 
Figure 16: Secondary Structure Analysis 
(A) The mean smallest distance between the residues of the complex. (B) Root mean square fluctuation 
(RMSF) plot with the green and red lines indicating the observed fluctuations of the complex with and 
without the aptamer, respectively. 
The inner β-sheet was formed by the two β-hairpins C and D and H and I, in which the 
lengthy strand C made hydrogen bonds with both strands D and H, making the strands 
integral components of the inner β-sheet. The sub-strands of D, D1 and D2 made 
hydrogen bonds with strand C, in which the D2 hydrogen bonds with amino acids 30, 
32 and 34. From the dssp calculation, it was observed that the number of residues that 
participated in the formation of strand D2 was reduced. Hydrogen bonds formed 
between these strands were compared and plotted for the two complexes (with and 
without the 2F Modified EpCAM aptamer) (see Figure 17). The comparison suggested 
that there was a decrease in some hydrogen bonds in the complex with the 2F Modified 
EpCAM aptamer, especially when the hydrogen bonds were compared for strand B and 
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D2. This correlated with the secondary structure calculation by the dssp that showed 
some reduction in residues of D2 (53–57) and was complemented in strand B (31–34) 
(Fig 16A). Loss of hydrogen bonds between these strands caused sheet perturbations 
that resulted in the extension of the loop region connecting strands D and E into the D2 
region. The RMSF plot study revealed that the residues at D2 (53–57) and the loop after 
strand D attains higher variation, while the region (35–41) where the RNA interacts had 
lower change (see Figure 16B). The more moderate variation at the region of the 
interaction suggested that the 2F Modified EpCAM aptamer interaction restricts the 
movement of the interacting strand (B). Thus, it disturbs the complementarity of strand 
B and D2 by forming fewer hydrogen bonds within the sheets that made the D2 region 
highly flexible. Further, the atomic contacts between the strands calculated and 
compared using g_mindist program (GROMACS) showed that strand D made more 
contacts with strand E during the 2F Modified EpCAM aptamer complex than without 
the 2F Modified EpCAM aptamer (see Figures 18 and 19). 
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Figure 17: Hydrogen Bonds Formed Within the Main Chain Atoms of Strands C 
and D 
In which red = the number of hydrogen bonds formed within the sheets of the complex without the RNA 
and green = the number of hydrogen bonds formed within the sheets of the complex with the RNA. 
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Figure 18: Number of Contacts Formed Within Strands C and D 
In which green = contacts between strands C and D complex with aptamer, red = contacts between 
strands C and D without the aptamer, blue = contacts between strands D and E with the aptamer and 
orange = contacts between strands D and E without the aptamer. From these comparisons it can be 
observed that, in the complex without the aptamer, strand C makes fewer contacts with strand E, but 
makes more contacts with strand D. In the complex without the aptamer it can be observed that strand C 
makes more contacts with strand E, but fewer contacts with strand D. 




Figure 19: Number of Hydrogen Bonds Formed Between Strands D and E in the 
Complex 
(A) With the aptamer. (B) Without the aptamer. 
The results were also correlated with some of the hydrogen bonds formed between 
strands D and E for both complex. The complex with the 2F Modified EpCAM aptamer 
showed a greater number of hydrogen bonds compared to the complex without the 2F 
Modified EpCAM aptamer. In our study, Asp33, Ser54, Phe52, Phe78, Trp 39 and Gly102–107 
displayed as interacting residues with the chromophore and the 2F Modified EpCAM 
aptamer, in agreement with earlier studies. 
3.2 Discussion 
The CD spectra of NCS has signature peaks at –210 nm, –190 nm and +225 nm 
(Kandaswamy et al. 2008) by CD spectroscopy. With the exception of the –190 nm 
peak, the +225 nm and –210 nm peaks were in agreement with earlier reports. In our 
study, a hydrophobic cluster of inner sheet was found to participate when the 
chromophore of the NCS interacts with the 2F Modified EpCAM aptamer residues. 
Since NCS has a structure close to an IgG molecule, the 2F Modified EpCAM aptamer 
interaction with the NCS is similar to the interaction between the IgG and the antigen 
(Valerio-Lepiniec et al. 2002), revealing the similarities between the secondary structure 
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of the IgG molecule and the NCS. The NCS chromophore complex attains stability due 
to the presence of the hydrophobic cluster from the inner sheets,. The chromophore 
binding site on apo-NCS consists of three pockets: a hydrophilic pocket containing 
Asp33, Ser54 and Asp99, a medium hydrophobic cavity containing pro49, phe52, phe76 and 
phe78 and a large hydrophobic cavity of trp39, Leu 45, Gln94, Ser 98 and Gly102–107 
(TEPLYAKOV et al. 1993b). The interaction between the NCS and the 2F Modified 
EpCAM aptamer reveals the appearance of a peak at 205 nm, indicating that the helix 
structure is induced in the NCS by the 2F Modified EpCAM aptamer. This observation 
resembles Trifluoroethanol activity, in which β-sheets are perturbed and α helix is 
induced in protein (Christopher et al. 2000). The major peak observed at –225 nm for 
native NCS was completely perturbed during the interaction, indicating changes in the 
β-sheets. The key residues Tyr 32, Trp 39 and Phe 52 (Zhao et al. 2010) were also 
perturbed in our CD spectra analysis showing similar profiles of interaction. 
In our FTIR study, we observed peak perturbation corresponded to the β-sheet of NCS 
when it interacted with the 2F Modified EpCAM aptamer. The hydroxyl-containing 
amino acid residues of NCS displayed sharp perturbation when interacting with the 2F 
Modified EpCAM aptamer. During these interactions, sharp changes were observed in 
2432 cm–1 corresponding to the total number of hydroxyl-containing amino acid (Serine 
[11], Threonine [13] and Tyrosine [1]). The hydroxyl-containing residues Thr 30, Tyr 32, 
Ser 53, Ser 54 and Thr 56 are part of strands C and D in which maximum perturbations 
were observed in both CD spectra and MD simulations. CD spectra also revealed the 
perturbation in the aromatic amino acid residues of strands C and D, such as Tyr 32, Trp 
39 and Phe 52. A major peak was observed at –225 nm for native NCS and was 
completely perturbed during the interaction, indicating changes in the β-sheets. When 
the 2F Modified EpCAM aptamer interacted with the NCS it was also found to induce α 
helix at –210 nm and rapidly disappear at 213 nm, while appearing at 221 nm peak, 
strongly favouring the helix structure induction. 
This was well corroborated with our in silico prediction, in which the NCS residues 31–
33 of strand C were not part of the interaction with strand D after 3000 ps (Fig 6B) 
during the dynamics study with 2F Modified EpCAM aptamer complex. Conversely, 
three residues were part of strands C and D in the complex without the 2F Modified 
EpCAM aptamer. This clearly demonstrates that the three residues from strand C are 
perturbed during the 2F Modified EpCAM aptamer interaction. Perturbation of β-sheets 
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during the interaction is in agreement with earlier reports (Tomioka et al. 2006). 
Moreover, a secondary structure calculation by the dssp showed a reduction of some 
residues in D2 (53–57) and it was complemented in strand B (31–34). Loss of hydrogen 
bonds between these strands caused by β-sheet perturbations resulted in the extension of 
the loop region connecting strands D and E into the D2 region. An earlier report (Izadi-
Pruneyre et al. 2001) revealed residue 39 Tryptophan had maximum perturbation. Trp39 
is an important residue that is a part of the binding cavity and makes larger amplitude in 
the dynamics of NCS by in silico analysis (Izadi-Pruneyre et al. 2001), in agreement 
with our present study. Strand C undergoes maximum perturbation from residues Tyr32 
Asp33 and Ser98 and is also involved in dihedral angle fluctuations. 
3.3 Conclusion 
We report perturbation of hydroxyl-containing amino acid residues Thr 30, Tyr 32, Ser 53, 
Ser 54 and Thr 56 of strands C and D during the 2F Modified EpCAM aptamer–NCS 
interaction by infra-red spectroscopy. The CD spectroscopy also revealed changes in 
aromatic amino acid residues such as Trp39 and Tyr 32 and Phe 52 that are part of strands 
C and D becoming perturbed during the interaction. In silico analysis also revealed 
interacting residues of NCS with the 2F Modified EpCAM aptamer found to be in 
strand C (Tyr 32, Asp 33 and Trp 39) and strand D (Phe 52, Ser 53, Ser 54 and Thr 56) and 
was complemented with strand B during the interaction. Hence, we conclude that 
strands C and D are involved in the interaction between the NCS and the 2F Modified 
EpCAM aptamer. Therefore, this study would help in targeting EpCAM-positive cells 
with a NCS drug using a 2F Modified EpCAM aptamer. 
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Chapter 4. EpCAM-Drug Conjugates for 
Targeted Therapy 
4.1 Summary 
The interaction between the EpCAM aptamer and the NCS was summarised in Chapter 
3. We have further studied various drug conjugates with the EpCAM antibody and the 
EpCAM aptamer that specifically deliver to the EpCAM-positive tumour cells. For our 
initial understanding, we investigated the role and expression of the EpCAM by 
conjugating the EpCAM antibody with an SAP molecule as an initial report. We report 
the role of the SAP as the inactivator of ribosomes, thereby killing the cancer cells using 
the EpCAM antibody as a ligand molecule. Whole genome sequencing was done and 
the corresponding pro-apoptotic genes were found to be up-regulated, leading to cancer 
cell death. The previous chapter showed that the NCS being a potent DNA damaging 
agent does not affect the function of the EpCAM RNA aptamer. We conjugated the 
EpCAM aptamer–NCS conjugate for the first time to show the non-specificity of the 
NCS leading to the targeted delivery of the NCS with the EpCAM aptamer as ligand. 
The proof of this concept was tested in WERI-Rb1 retinoblastoma and MCF-7 breast 
cancer cell lines. 
4.2 Targeting EpCAM Tumour Cells with Ribosomal Inactivating 
Protein Using Antibody Conjugate 
4.2.1 Results 
4.2.1.1 Conjugation and characterisation of the SAP–EpCAM antibody conjugate 
The conjugation reaction was performed using the EDC-NHS coupling reaction. First, 1 
mg/ml of SAP was prepared in an activation buffer (0.1 M MES (2-[morpholino] ethane 
sulfonic acid), 0.5 M NaCl and pH 6.0). A 10-fold molar excess of EDC (N-[3-
dimethylaminopropyl]-N’-ethylcarbodiimide hydrochloride) was then added to the 1 ml 
SAP solution and NHS (0.6 mg) was added to the reaction mixture (5 mM final 
concentration). The reaction mixture was incubated for 15 minutes at RT. EDC was 
Chapter 4: Epcam-Drug Conjugates for Targeted Therapy 
67 
inactivated by the addition to the mixture of 1.4 μl of 2-mercaptoethanol (20 mM final 
concentration in the reaction mixture). The unreacted EDC and byproducts were 
removed using desalting filter columns. The EpCAM antibody, 1 mg/ml dissolved in 
PBS (amine-free buffer pH 7.4), was added to the activated NHS-ester. The reaction 
components were mixed and allowed to react for two hours at RT. The reaction was 
quenched using hydroxylamine (10 mM final concentration) and the conjugate was 
purified using 3 kDa spin filter columns (Amicon) and stored at –20°C. 
4.2.1.2 Gel retardation for conjugate 
The gel retardation assay clearly showed the difference between the SAP and SAP–
EpAB conjugate. The difference in the retention between SAP and conjugate was 
observed in 12% gel (see Figure 20). 
 
Figure 20. PAGE Showing the Difference Between the Native SAP and the 
Conjugated SAP 
The experiment was run in a Tris-Glycine buffer at 120 V for 45 minutes. The protein was not denatured 
prior to loading on to the gel. 
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4.2.1.3 MALDI analysis 
The MALDI analysis revealed that the molecular mass of the conjugate was more than 
that of the native SAP and the native EpCAM antibody. The EpCAM antibody showed 
a molecular mass of 24.24 kDa. The SAP molecule showed a molecular mass of 31.32 









Figure 21: MALDI Analysis 
(A) The clear peak at 24 kDa represents the EpCAM antibody. (B) The peak at 31 kDa it represents SAP. 
(C) The peak at 75 kDa represents the SAP–EpCAM antibody conjugate. 
4.2.1.4 Assessment of conjugate binding by flow cytometry and fluorescence 
microscopy 
The flow cytometry analysis revealed that the EpCAM antibody and conjugates were 
bound to the MCF-7 breast cancer cells and WERI-Rb1 cells. The MCF-7 cells showed 
binding positivity of 75% with the EpCAM antibody and 75% with the conjugate (see 
Figure 22). The WERI-Rb1 cells showed 42% and 31% for the EpCAM antibody and 
the conjugate, respectively. MIOM1 (Müller glial) cells were used as a control that has 
not showed binding of the antibody. 
The fluorescence microscopy results showed the membrane positivity for the EpCAM 
antibody and the conjugate in the MCF-7 and the WERI-Rb1 cells. The membrane 
positivity for both the EpCAM antibody and the SAP–EpAB conjugate was higher in 
MCF-7 than in WERI-Rb1 cells (see Figure 23). MIOM1 cells were used as a control 
that showed no positivity. 
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Figure 22: Flow cytometry analysis of MCF-7, Weri Rb1 and MIOM1 cells 
showing EpCAM positivity of antibody and conjugate 
The antibody and conjugate binding assay was performed using flow cytometry. The EpCAM primary 
antibody and the conjugate were treated, followed by the FITC-labelled secondary antibody. The 100 nM 
concentration of the EpCAM and the EpCAM conjugate showed 75.65% and 31% of FITC positivity in 
MCF-7 and WERI-Rb1 cells, respectively. FITC positivity in MIOM1 was found to be negligible. 
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Figure 23: Antibody Binding Assay Using the Fluorescence Microscope 
The EpCAM antibody and the conjugates were treated in MCF-7, WERI-Rb1 and MIOM1 cells. MCF-7 
cells showed membrane positivity with the EpCAM antibody and the conjugates. A similar pattern was 
observed in WERI-Rb1 cells. No positivity was observed in the MIOM1 cells. 
4.2.1.5 Microarray analysis 
Microarray gene expression analysis was performed using Gene Spring software and the 
data was averaged between the duplicate samples. The total number of normalised 
genes in both groups was 1,235. Past the threshold of false discovery rate (FDR) 
adjusted p<0.05 of these 903, 561 genes showed a fold change of >2.0. Individual 
analysis was performed for the control v. SAP and control v. SAP conjugate. Quality 
control was performed by expression and by error and the statistics were applied using 
the moderate t-test and a p-value computation by Benjamini-Hochberg FDR. The results 
revealed 1,706 genes with a p-value of 0.2 from a total of 18,089 genes. A total of 
12,535 entities were matched with the control probeset of 22,245 entities with a p-value 
of 0.05 for further statistical and fold change analysis. Fold change was measured 
individually with a cut-off value of two-fold. From this, 1,464 genes were qualified for 
control v. SAP and 5,184 genes were qualified for control v. SAP conjugate. There were 
found to be 903 overlapping genes between the control v. SAP and the control v. SAP 
conjugate (i.e., commonly expressed genes). There were 561 differentially expressed 
genes for control v. SAP and 4,281 for control v. SAP conjugate. The biological 
interpretation was done individually for control v. SAP and control v. SAP conjugate. 
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Cluster analysis was performed based on the entity list with SAP and SAP–EpAB 
conjugate and the difference in the GO was listed (see Figure 24). The major 
differentially expressed genes for control v. SAP showed biological processes that are 
involved in translation initiation, mRNA metabolic process, post-transcriptional 
regulation of gene expression, RNA processing, cell cycle and regulation of RNA 
metabolic process. The differential cellular processes involved were found to be in the 
nucleoplasm, organelle lumen, membrane-enclosed lumen, cystol and ribonucleoprotein 
complex (see Figure 25). The differential molecular functions involved were RNA 
binding, translation initiation factor activity, nucleotide binding and transcription 
activator activity. 
 
Figure 24: Differentially Expressed Genes Between the SAP and the SAP 
Conjugate Treated Cells in MCF-7 
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Figure 25: Gene Spring GO Analysis 
The GO terms involved in the protein inhibition process, the biological process, cellular component and 
the metabolic components. 
In the control v. SAP conjugate, the differentially expressed genes showed the 
biological processes that were involved in post-transcriptional regulation of gene 
expression, cell cycle, regulation of translation, RNA processing, translation, cell cycle 
process, negative regulation of macromolecular metabolic process, regulation of 
apoptosis and cell death. The cellular components involved were cytosol, a 
ribonucleoprotein complex and ribosome. The molecular functions included RNA 
binding, translation initiation factor activity, translation factor activity, nucleic acid 
binding, protein dimerisation activity, GTPase activity, identical protein binding and 
single-stranded RNA binding. 
KEGG pathway anaysis using DAVID sofware revealed that the conjugate was 
involved in the cell cycle process, pathways related to cancer, TGF-beta signalling 
pathway and ribosomal inactivation, further leading to cell apoptotic pathways. 
4.2.1.6 Cell viability assays by MTT 
The MTT assay revealed less toxicity to WERI-Rb1 and MCF-7 cells by native SAP 
treatment, whereas the conjugate showed cell death with an increase in the 
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concentration (0.1 μg–1 μg). The SAP–EpAB conjugate (1 μg) showed 45% cell death 
for WERI-Rb1 cells; however, the SAP showed only 16% cell death at the same 
concentration. MCF-7 cells showed 51% cell death with the SAP–EpAB conjugate (1 
μg), whereas the SAP revealed only 17% cell death with the same concentration. 
Control experiments were performed with the MIOM1 cells (see Figure 26). 
4.2.1.7 Apoptosis assay 
The apoptosis assay (Annexin V FITC and PI) for the conjugate treated cells revealed 
late apoptosis and necrosis in MCF-7 and WERI-Rb1 cell lines. The SAP and SAP 
conjugate treatment showed 22%, 89% of necrosis and 8% of late apoptosis in MCF-7 
cells. The SAP and SAP conjugate treatments showed 0% and 37%, respectively, of 
necrosis in WERI-Rb1 cells. The conjugate showed 9.96% late apoptosis with the SAP–
EpAB conjugate and 6.07% early apoptotic cells (see Figure 27). Control experiments 
were performed with the MIOM1 cells. 
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Figure 26: Cytotoxic Assay 
(A) and (C) Shows an increase in cell death with an increase in the concentration of conjugate in breast 
cancer cells MCF-7 and retinoblastoma (WERI-Rb1) cells. (B) The apoptosis assay by Annexin V and PI 
reveals a high amount of necrosis and late apoptosis in MCF-7 cells. (D) A similar pattern was observed 
in WERI-Rb1 cells. (E) The cytotoxic assay in MIOM1 cells with SAP conjugate treatment showed 
minimal cell death and more viability. (F) The same pattern was observed with Annexin V PI. 
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Figure 27: Apoptosis Assay 
The pathways involved in the ribosomal inhibition upon the treatment of SAP and the conjugate. Their 
corresponding downstream genes are highly significant with the microarray results. The caspases activity 
and the histone proteins that regulate the cell cycle process are affected, leading to apoptosis. 
4.2.2 Discussion 
Current cancer treatment protocols are not efficient due to a lack of tumour specificity, 
bio-availability and the frequent dosage that causes severe side effects to normal cells 
that limits the treatment (Sutradhar and Amin 2014). Antibody-based targeted therapy 
has now evolved as a high accuracy treatment for cancer that provides high specificity, 
fewer side effects, increased bio-availability and low dosage levels (Petrelli and 
Giordano 2008). A disadvantage of antibody-based therapy is less permeability of the 
drug molecules into the cancer cells (Lammers et al. 2012), due to a lower availability 
of antigen on the surface of the cell. EpCAM is highly expressed in cancers such as 
breast cancer and gastric cancer and can be of a therapeutic use in treating EpCAM-
positive cancers (Cimino et al. 2010) (Du et al. 2010). The SAP–EpAB conjugate has 
been reported for the utilisation of the photochemical internalisation method to target 
EpCAM-positive cells and to kill MDA-MB-453, MDA-MB-231 and BT-474 cell lines 
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(Lund et al. 2014). In our study, we demonstrate that the SAP–EpAB conjugate 
specifically targets EpCAM-positive eye cancer and breast cancer cells. 
Our results showed that the SAP–EpAB conjugate had efficient binding to the MCF-7 
breast cancer and WERI-Rb1 retinoblastoma cells. The conjugate did not bind to the 
MIOM1 glial cells, indicating the specificity of the conjugate. The MCF-7 cells had 
high expression of EpCAM and showed maximum binding of an antibody (Lund et al. 
2014). 
The microarray analysis suggested evidence of the SAP–EpAB conjugate targeting 
EpCAM-positive cells using by revealing differentially expressed genes involved in the 
anti-tumourogenic process. PRC1 is a mitotic spindle-associated Cdk substrate protein 
that is essential for cytokinesis (Mollinari et al. 2002). It is negatively regulated by p53 
and overly expressed in p53 defective cells (Li, Lin, and Liu 2004), suggesting that the 
gene is tightly controlled in a cancer-specific manner. The PRC1 gene is highly 
expressed in breast cancer tissue (Yun et al. 2008). It is a cell cycle protein that plays an 
essential role in cytokinesis and was observed to be completely down-regulated on 
conjugate treatment, revealing a p53 mediated response in conjugate treated 
cells. Glycosyltransferase 8 domain containing 1 (GLT81) is supposed to be an 
oncogenic protein that is highly up-regulated in cancer conditions. In our study, the 
conjugate treatment of cancer cells down-regulated the expression of the GLT81 
gene. Human hydroxysteroid dehydrogenase like 1 gene (HSDL1) is predominantly 
expressed in most of the tumours (Huang et al. 2001). We observed down-regulation of 
HSDL1 in our study on conjugate treatment. HIST1H2BJ protein is involved in histone 
modification and protein heterodimerisation activity related to mitotic and cell cycle 
pathways. Anaphase-promoting complex (APC) 7 is a multi-unit protein that helps in 
the ubiquitination of cyclin B and mitotic spindle checkpoint that has a negative 
correlation with APC7 activity in ductal breast cancer (Park et al. 2005). The SAP–
EpAB conjugate up-regulated the APC7 gene in the treated cells, thereby preventing 
mitotic spindle checkpoint and inducing the tumour cells to apoptosis. THUMPD2 gene 
is involved in mRNA processing in the ribosomal unit. The conjugate treatment of 
tumour cells resulted in up-regulation of the functional ribosomal unit through 
THUMPD2 gene expression. This result is in agreement with the previous report on the 
effect of SAP on tumour cells by the ch128.1Av/b–SO6 conjugate (Daniels-Wells et al. 
2013). PNPLA8 gene is stimulated via JNK pathways (Lupo et al. 2005) linked with 
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MAP kinase activity. The participation of PNPLA8 has been reported in the clearing of 
apoptotic cells by caspase 3 dependent mechanism (Lauber et al. 2003). PNPLA8 gene 
was highly up-regulated in our microarray studies, indicating caspase 3 dependent 
clearing of apoptotic cells in the conjugate treated cells. We also observed BAG3 
overexpression in conjugate treated cells indicating cell survival through GADD34 
mediated cell response (Hung et al. 2003). Dickkopf-3 (DKK3) protein is known for its 
antagonistic activity against the Wnt signalling pathway in cancer. Cells over-
expressing DKK3 always induce apoptosis and prevent proliferation (Veeck and Dahl 
2012). In our study, DKK3 was up-regulated on the conjugate treatment, suggesting 
apoptosis induction. We observed up-regulation of the MAGOH gene is involved in the 
regulation of the splicing modulation of exon junction complex (EJC) and BCL2L1/Bcl-
X and is mainly involved in the formation of the pro-apoptotic complex (see Figure 27). 
The MAGOH gene was highly up-regulated in our study, revealing complex pro-
apoptotic formation in the conjugate treated cells. 
Based on the microarray study and apoptosis results, we observed that SAP conjugates 
showed more cytotoxicity in MCF-7, WERI-Rb1 and MIOM1 cells than the native 
SAP. The conjugate showed specific binding and cytotoxicity to cancer cells than SAP. 
The flowcytometry-based apoptosis assay revealed that the conjugate had more 
specificity towards EpCAM-positive tumour cells when compared with the native toxin 
alone. The apoptosis assay clearly proved that the cancer cells had undergone early 
apoptosis, with late apoptosis and necrosis in WERI-Rb1 cells and MCF-7 cells. The 
SAP-antibody conjugate yielded a high amount of late apoptosis and necrotic 
populations in IM9 and U266 cell lines, in agreement with Tracy et al. (Daniels-Wells 
et al. 2013). The MTT assay revealed a minimum inhibitory concentration of 0.8 μg–1 
μg of the conjugate targeted tumour cells efficiently. 
4.2.3 Conclusion 
The results show that the EpCAM antibody is a candidate ligand for targeted cancer 
therapy. Conjugation with SAP brings toxicity to cancer cells while excluding the 
normal cells, as the native SAP is not internalised into the cells by itself. The conjugate 
selectively binds to the EpCAM protein on the cancer cells, delivering drug payloads to 
the cells. The promising binding of the conjugate to only tumour cells would provide 
more accurate cancer cell targeted drug delivery. 
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4.3 NCS, Aptamer Conjugates for Targeting EpCAM Positive Tumour 
Cells 
4.3.1 Results 
4.3.1.1 Conjugation and characterisation 
Conjugation of NCS with the EpCAM aptamer (SSEpFi) was performed using Sulfo-
LC-SPDP cross-linker. The reaction was monitored by measuring the absorbance at 340 
nm using a multimode microplate reader. The appearance of the absorption peak at 340 
nm confirmed the release of Pyridine-2-thione that is produced as a by-product 
(Schussler et al. 2009) during the conjugation reaction. The HPLC results indicated that 
NCS was eluted from the Zorbax oligo column at 12.5th minute, whereas the conjugate 
was eluted at 30.0th minute. Measurement of absorbance at 260 nm and 480 nm 
confirmed the presence of the protein and the aptamer, respectively, in the conjugate 
(see Figure 29A). The conjugation was further confirmed by SDS-PAGE (see Figure 
29B). 
 
Figure 28: EpCAM–NCS Conjugates Acting on Cancer Cells 
The conjugate directly attacks the cancer cell by EpCAM aptamer and, by endocytosis, NCS enters and 
travels to the nucleus to cleave the double-stranded DNA, causing cancer cell death. 
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Figure 29: Targeting EpCAM Using EpCAM RNA Aptamer 
(A) The HPLC chromatographs of NCS and NCS–EpCAM aptamer conjugate show confirmation of 
conjugation by the difference in the retention time between the NCS (12.5 minutes at 260 nm and 480 
nm) and the NCS–EpCAM conjugate (30.0 minutes and 30.02 minutes at 260 nm and 480 nm). (B) SDS-
PAGE analysis shows the proof of concept of the conjugation initially with the difference in the bands 
between the NCS and the NCS–EpCAM conjugate with 18% gel stained with Coomassie blue. 
4.3.1.2 Flow cytometry and fluorescence microscopy 
The native aptamer and the conjugate showed better binding profiles in MCF-7 breast 
cancer cells and WERI-Rb1 retinoblastoma cells, compared to MIOM1 Müller glial 
cells. Binding of the native aptamer and the conjugate were found to be 62% and 35%, 
respectively, for MCF-7 cells at the IC50 values (see Figure 30A). The native aptamer 
and conjugate were found to have a binding of 35% and 30%, respectively, for WERI-
Rb1 cells at the IC50 (see Figure 30B). The MIOM1 cells (deprived of EpCAM 
expression) showed a very weak binding of 3% and 10% for aptamer and conjugates, 
respectively, at the IC50 value (see Figure 30C). 
EpCAM positivity was confirmed through an immunofluorescence study that revealed 
that the native aptamer and conjugates were bound to the cell membrane. Both the 
FITC-labelled native aptamer and the aptamer conjugates showed higher levels of 
membrane positivity in the MCF-7 cells (see Figure 30A) than the WERI-Rb1 cells (see 
Figure 30B) and the conjugate did not bind to the MIOM1 cells. These results indicated 
the specificity of the aptamer and conjugate to the EpCAM-positive cells (see Figure 
30C). 
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Figure 30: EpCAM Aptamer Binding 
(A) The MCF-7 cell line showed a significant EpCAM aptamer and NCS–EpCAM conjugate binding to 
the cells with an increase in the concentration of both the aptamer and the NCS–EpCAM conjugate 
through flow cytometry. The fluorescence microscopy revealed the membrane positivity of the aptamer 
and the NCS–EpCAM conjugate. (B) The WERI-Rb1 cell line showed promising binding of both the 
aptamer and the NCS–EpCAM conjugate. The fluorescence microscopy also revealed the membrane 
positivity of the aptamer and the NCS–EpCAM conjugate. (C) The MIOM1 (normal Müller glial cells) 
showed poor aptamer and NCS–EpCAM conjugate binding to the cells. The fluorescence microscopy 
also revealed no binding of the aptamer or NCS–EpCAM conjugate, even with higher concentrations. 
4.3.1.3 Gene expression by microarray analysis 
Microarray analysis was performed using Gene Spring software. From this, 1,714 genes 
were found to be differentially expressed in NCS treated cells and 747 genes in NCS 
conjugate treated cells with a normalised p-value <0.05 and a fold change threshold of 
two against the control sample. The gene entities between the control v. NCS treated 
and control v. conjugate treated cells were overlapped. The overlapped genes revealed 
the participation of considerable transcription factors to show the targeted therapy of the 
NCS (MCF-7). 
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The GO analysis showed the biological processes that are altered in both NCS and NCS 
conjugate treated cells. The differential process observed in NCS treated cells include 
cellular events such as cell cycle phase, mitotic process, regulation of cell cycle, cell 
cycle checkpoint, cell division, apoptotic process, DNA excision, programmed cell 
death, DNA-template transcription and termination and histone exchange. The NCS 
conjugate treatment displayed significant changes in biological processes such as DNA 
replication-independent nucleosome assembly, histone exchange, DNA conformation 
change, cell cycle, protein complex biogenesis, cell morphogenesis involved in 
differentiation, adherens junction organisation and mitotic cell cycle (see Figure 31B). 
The GO analysis showed differential molecular functions in NCS treated cells such as 
protein binding, heterocyclic compound binding, purine NTP-dependent helicase 
activity, ATP-binding, DNA-dependent ATPase activity, helicase activity RNA 
polymerase II carboxyl-terminal domain kinase activity and ARF GTPase activator 
activity (see Figure 31B). The NCS conjugate treatment displayed differential molecular 
functions such as protein binding, molecular function, anion binding, alpha-catenin 
binding, carbohydrate derivative binding, calmodulin-dependent protein phosphatase 
activity and R-SMAD binding. Cell component genes induced by NCS conjugate 
include encode (Encyclopaedia of DNA Elements) for condensed chromosome 
kinetochore, mitochondrial matrix, protein –DNA complex, DNA bending complex and 
DNA packing complex (see Figure 31B). 
The GO analysis of the NCS and NCS conjugate treatments displayed the cell 
component genes encoding for pyruvate dehydrogenase complex, condensed nuclear 
chromosome, centromere region, condensed chromosome, eukaryotic translation 
initiation factor 4F complex, carboxyl-terminal domain protein kinase complex and 
ubiquitin ligase complexes (see Figure 31). The clustering analysis of NCS and NCS 
conjugate treated cells indicated down-regulated genes were involved in apoptotic and 
cell cycle processes. 
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Table 5: Selected Deregulated Genes with a Fold Change of >2.0 Using Gene 
Spring Analysis Based on Normalised Values 






Lectin, galactoside-binding, soluble, 3 binding protein LGALS3BP 2.5568452 down 
DEAD (Asp-Glu-Ala-Asp) box helicase 17 DDX17 3.1946841 down 
Proline-rich coiled-coil 2B PRRC2B 2.7051973 down 
Neurobeachin-like 2 NBEAL2 3.0234184 down 
Spastic paraplegia 7 (pure and complicated autosomal 
recessive) 
SPG7 2.9180033 down 
Glycosylphosphatidylinositol anchor attachment protein 
1 homolog (yeast) 
GPAA1 2.8079553 down 
Coatomer protein complex, sub-unit gamma 1 COPG1 2.5013773 down 
Thioredoxin interacting protein TXNIP 3.1628823 down 
E1A binding protein p400 EP400 3.2239273 down 
Nuclear factor of activated T cells 5, tonicity-responsive NFAT5 3.5761085 down 
FK506 binding protein 10, 65 kDa FKBP10 3.1840112 down 
Chromosome 19 open reading frame 6 C19orf6 3.5370233 down 
Malignant T cell amplified sequence 1 MCTS1 3.1245334 down 
Thioredoxin reductase 2 TXNRD2 2.5721197 down 
Serine/arginine repetitive matrix 1 SRRM1 2.6032836 down 
Protein phosphatase, Mg2+/Mn2+ dependent, 1B PPM1B 2.5592196 down 
Protein kinase C and casein kinase substrate in neurons 3 PACSIN3 2.8217215 down 
dynamin 1 DNM1 2.7908566 down 
F-box and WD repeat domain containing 9 FBXW9 2.9423757 down 
Transmembrane protein 44 TMEM44 2.5677838 down 
Antigen identified by monoclonal antibody Ki-67 MKI67 2.5818971 down 
Mannosidase, alpha, class 2C, member 1 MAN2C1 2.7930863 down 
Solute carrier family 7 (cationic amino acid transporter, 
y+ system), member 1 
SLC7A1 2.7875412 down 
ATP-binding cassette, subfamily A (ABC1), member 3 ABCA3 2.5290477 down 
Ligase I, DNA, ATP-dependent LIG1 2.5790389 down 
Butyrophilin-like 9 BTNL9 2.5389052 down 
EPM2A (laforin) interacting protein 1 EPM2AIP1 3.2607667 down 
Mitochondrial ribosomal protein S25 MRPS25 2.6910046 down 
Transmembrane phosphatase with tensin homology TPTE 2.7242281 down 
Ubinuclein 2 UBN2 2.5980714 down 
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Abelson helper integration site 1 AHI1 2.5695424 down 
Splicing factor 1 SF1 2.6086183 down 
Copine VII CPNE7 2.5966156 down 
Copine VII CPNE7 2.9046967 down 
Beta–1,4-N-acetyl-galactosaminyl transferase 4 B4GALNT
4 
2.8945521 down 
Sodium- and chloride-dependent creatine transporter 1-
like  
SLC6A10P 2.5052253 down 
Zinc finger protein 587  ZNF587 2.5581952 down 
ArfGAP with GTPase domain, ankyrin repeat and PH 
domain 6  
AGAP6 2.8615472 down 
O-linked N-acetylglucosamine (GlcNAc) transferase OGT 2.6030216 down 
CHKB-CPT1B readthrough (non-protein coding)  CHKB-
CPT1B 
3.9068635 down 
RUN and FYVE domain containing 2 RUFY2 2.9833965 down 
CHKB-CPT1B readthrough (non-protein coding)  CHKB 3.2259672 down 
Polymerase (RNA) II (DNA directed) polypeptide J2  POLR2J2 3.5530434 down 
Coiled-coil domain containing 144A  CCDC144A 2.8590381 down 
Coiled-coil domain containing 144A  CCDC144A 2.9187555 down 
Adaptor-related protein complex 1, gamma 2 sub-unit AP1G2 2.8079708 down 
Stromal antigen 3-like 3 STAG3L3 3.1200113 down 
ArfGAP with GTPase domain, ankyrin repeat and PH 
domain 10  
AGAP10 2.7719123 down 
Stromal antigen 3-like 2 STAG3L2 3.4776376 down 
Myeloid/lymphoid or mixed-lineage leukaemia 3  MLL3 2.5650342 down 
Polymerase (RNA) II (DNA directed) polypeptide J2 POLR2J2 3.5970795 down 
Ankyrin repeat domain 36  ANKRD36 2.8232917 down 
Sigma non-opioid intracellular receptor 1 SIGMAR1 2.5128171 down 
Cyclin T1 CCNT1 2.6411932 down 
PHD finger protein 20-like 1 PHF20L1 6.4322852 down 
Paired immunoglobin-like type 2 receptor beta PILRB 3.4961305 down 
Actinin, alpha 1 ACTN1 2.9166229 down 
Actinin, alpha 1 ACTN1 2.8087583 down 
Ligase I, DNA, ATP-dependent LIG1 2.7119608 down 
Mannosidase, alpha, class 2C, member 1 MAN2C1 4.0924285 down 
Nuclear pore complex interacting protein-like nuclear 61E3.4 4.4993873 down 
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pore Complex interacting protein related gene  LOC100132
247 
B double prime 1, sub-unit of RNA polymerase III 
transcription initiation factor IIIB 
BDP1 2.7921912 down 
Golgin A8 family, member A  GOLGA8A 3.4014575 down 
Cyclin L2 CCNL2 2.7555752 down 
Ligase I, DNA, ATP-dependent LIG1 2.7725434 down 
Latent transforming growth factor beta binding protein 4 LTBP4 2.7010207 down 
REV3-like, polymerase (DNA directed), zeta, catalytic 
sub-unit 
REV3L 2.5085416 down 
Glycosylphosphatidylinositol anchor attachment protein 
1 homolog (yeast) 
GPAA1 2.5638845 down 
Splicing factor, suppressor of white-apricot homolog 
(Drosophila) 
SFSWAP 2.8130121 down 
Amyloid beta (A4) precursor protein APP 2.7598193 down 
Ligase I, DNA, ATP-dependent LIG1 2.641188 down 
Solute carrier family 4, sodium bicarbonate 
cotransporter, member 7 
SLC4A7 2.5087512 down 
Glucuronidase SMA5 3.4139633 down 
Thioredoxin interacting protein TXNIP 3.6090052 down 
Thioredoxin interacting protein TXNIP 3.3917687 down 
Glucosidase, alpha; neutral AB GANAB 2.6257985 down 
Ankyrin repeat and LEM domain containing 2 ANKLE2 2.7982814 down 
V-akt murine thymoma viral oncogene homolog 2 AKT2 3.1612883 down 
Amyloid beta (A4) precursor protein APP 2.7726645 down 
Solute carrier family 37 (glucose-6-phosphate 
transporter), member 4 
SLC37A4 2.5171375 down 
Neurobeachin-like 2 NBEAL2 2.5909931 down 
Muts homolog 5 (E. Coli) SAPCD1 3.9692754 down 
Thioredoxin interacting protein TXNIP 2.9724813 down 
FK506 binding protein 10, 65 kda FKBP10 2.6699496 down 
Protein tyrosine phosphatase, receptor type, F PTPRF 2.6272678 down 
Ring finger protein 213 RNF213 2.6890745 down 
Dynamin 1 DNM1 2.5105493 down 
Arfgap with gtpase domain AGAP4 3.5886106 down 
Zinc finger family member 767 ZNF767 2.6693578 down 
Chapter 4: Epcam-Drug Conjugates for Targeted Therapy 
88 






Zinc finger with KRAB and SCAN domains 1 ZKSCAN1 3.0435488 down 
Cyclin L2 CCNL2 2.5346234 down 
Transportin 2 TNPO2 2.7226818 down 
Mannosidase, alpha, class 2C, member 1 MAN2C1 3.2998466 down 
Metastasis associated lung adenocarcinoma transcript 1 
(non-protein coding) 
MALAT1 3.0734236 down 
Nucleoporin 210kda NUP210 4.2865072 down 
Thioredoxin interacting protein TXNIP 3.2396066 down 
Muts homolog 5 (E. Coli)  MSH5, 
MSH5- 
3.2258885 down 
Polymerase (RNA) II (DNA directed) polypeptide J2  POLR2J2 2.5944319 down 
UV-stimulated scaffold protein A UVSSA 2.5388222 down 
Microrna 1304, small nucleolar RNA, H/ACA box 1, 





HNRNPU antisense RNA 1 (non-protein coding) HNRNPU-
AS1 
6.215302 down 
Latent transforming growth factor beta binding protein 4 LTBP4 3.0461078 down 
Homeobox D9 HOXD9 2.6143372 down 
Cleavage and polyadenylation specific factor 6, 68kda CPSF6 2.8033361 down 
Serine/arginine repetitive matrix 2 SRRM2 2.6896882 down 
Cysteine-rich PAK1 inhibitor CRIPAK 2.6890915 down 
CCR4-NOT transcription complex, sub-unit 4 CNOT4 2.8725535 down 
Myeloid/lymphoid or mixed-lineage leukaemia (trithorax 
homolog, Drosophila) 
MLL 3.3418834 down 
RAB12, member RAS oncogene family RAB12 2.9742403 down 
PCI domain containing 2 PCID2 4.5512123 down 
Enah/Vasp-like EVL 2.5605476 down 
Ubiquitin specific peptidase 36 USP36 2.6518903 down 
Ubiquitin specific peptidase 36 USP36 2.5835662 down 
Polo-like kinase 1 substrate 1 PLK1S1 2.7079878 down 
Mucolipin 3 MCOLN3 3.0398474 down 
Zinc finger protein 451 ZNF451 2.6644997 down 
Nuclear receptor-binding SET domain protein 1 NSD1 3.3836284 down 
Nuclear receptor-binding SET domain protein 1 NSD1 4.4906364 down 
Rho guanine nucleotide exchange factor (GEF) 10 ARHGEF10 3.2078502 down 
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Ubiquitin specific peptidase 32 USP32 3.2359056 down 
Polymerase (DNA directed), theta POLQ 5.0514815 down 
BCL2-like 11 (apoptosis facilitator) BCL2L11 2.6989846 down 
Transformer 2 alpha homolog (Drosophila) TRA2A 3.3609042 down 
Poly(A) binding protein, nuclear 1 PABPN1 2.8369732 down 
Poly(rc) binding protein 2 PCBP2 4.0213933 down 
Trna methyltransferase 13 homolog (S. Cerevisiae) TRMT13 2.5334797 down 
Casein kinase 1, alpha 1 CSNK1A1 2.6824126 down 
Poly(rc) binding protein 2 PCBP2 6.1182666 down 
Serrate RNA effector molecule homolog (Arabidopsis) SRRT 3.0508847 down 
NAD(P)H dehydrogenase, quinone 1 NQO1 2.9143357 up 
Glutamate-cysteine ligase, modifier sub-unit GCLM 2.5298219 up 
Chromosome 6 open reading frame 228 C6orf228 2.9446077 up 
Interferon induced with helicase C domain 1 IFIH1 2.5003233 up 
Pantothenate kinase 3 PANK3 2.6540756 up 
Hydroxysteroid dehydrogenase like 1 HSDL1 2.6493126 up 
Fatty acyl coa reductase 1 FAR1 2.5346766 up 
Methyltransferase like 3 METTL3 2.5606947 Up 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 DDX58 2.5925786 Up 
Interferon-induced protein with tetratricopeptide repeats 
1 
IFIT1 3.0005238 Up 
Solute carrier family 35, member G1 SLC35G1 3.4578846 Up 
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Figure 31: Microarray Gene Expression Studies 
(A) The cluster analysis of the NCS–EpCAM conjugate revealed the genes responsible for apoptosis and 
necrosis—strong evidence of DNA damage. (B) GO analysis showed the biological processes, cell 
component processes and molecular functions of the differentially expressed genes between the NCS and 
NCS–EpCAM conjugate treatments with significant p-values that demonstrated the cellular mechanisms 
post treatments. (C) Gene Spring analysis of Natural Language Processing (NLP) showed the network of 
genes and processes involved with NCS and NCS–EpCAM conjugate treatments. 
4.3.2 KEGG pathway analysis and Natural Language Processing networks 
KEGG analysis was performed using the online DAVID software to find the gene 
interaction involved in cancer pathways (Huang da, Sherman, and Lempicki 2009). 
KEGG analysis revealed highly deregulated genes participating in the cell cycle process 
including E2F2, E2F5, CDC20, MYC and genes involved in small lung cancer and 
TGF-beta signalling pathways. The KEGG analysis also helped to understand the 
deregulated genes involved in the treatments of the NCS and the NCS conjugate in 
breast cancer tumour models. In addition, KEGG pathway analysis revealed the 
increased expression of histone molecules such as H2AX, clearly indicating the 
activation of the DNA damage repair mechanism. Cell cycle checkpoint genes including 
BCL2 and cyclins were up-regulated (see Table 6). In the microarray results, NLP 
networks showed the direct biological link between the genes and processes that were 
highly up-regulated and highly down-regulated. The results clearly indicated that the 
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differentially expressed genes upon the NCS–EpCAM conjugate were involved in the 
apoptosis and the necrosis processes (see Figure 31C and Figure 31D). 
Gene expression studies were performed to check the link for the targeted therapy of the 
NCS. The list of genes associated with the EpCAM led us to investigate the effect of the 
conjugate on different cancer cells having EpCAM expression (see Figure 32). 
4.3.2.1 BrdU, H2AX and PARP assay 
The BrdU incorporation assay revealed that the BrdU uptake is higher in untreated cells 
(WERI-Rb1 and MCF-7) than in NCS and conjugate treated cells. indicating a reduction 
in cell proliferation. Consequently, the expression of histone molecule (H2AX), a 
significant regulator of the DNA repair mechanism. was observed to be at elevated 
levels when treated with conjugate (see Figure 32). Cleaved PARP levels increased in 
the conjugate treated cells, as this enzyme recruits the α-H2AX through serine 139 
during DNA repair response, indicating the induction of early DNA damage response. 
4.3.2.2 Cell cycle and apoptosis assay 
The cell cycle assay revealed 78% of G2 phase arrest for the NCS treatment and 86% 
for the NCS conjugate treatment in the MCF-7 cell line (Figure 32). Interestingly, 
WERI-Rb1 cells showed ‘s’ phase elongation leading to the phase arrest of 29% of the 
NCS treatment and 45% of the NCS conjugate treatment (see Figure 32). 
The effect of the toxin and the conjugate on cancer cells was revealed by apoptosis 
assay using PI and annexin. The toxin had a direct effect on DNA damage and, 
consequently, the cells underwent necrosis. The native toxin showed 47% necrosis and 
the conjugates showed 50% necrosis in WERI-Rb1 cells (see Figure 32). Similarly, 
native toxin showed 24% necrosis and the conjugate showed 32% necrosis in MCF-7 
cells (see Figure 32). The NCS and NCS conjugate showed 5.59% and 8.09%, 
respectively, of late apoptosis in WERI-Rb1 cells. NCS and the NCS conjugate caused 
2.4% and 2.1%, respectively, of late apoptosis in the MCF-7 cell line. 
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Figure 32: Aptamer Internalisation and Cellular Effects 
(A) The cell cycle analysis revealed the G2–M phase arrest in the MCF-7 cell line with the NCS and the 
NCS–EpCAM conjugate treatments. The WERI-Rb1 cell line showed the retardation of the ‘s’ phase or 
elongation of the ‘s’ phase leading to phase arrest with the NCS and the NCS–EpCAM conjugate. (B) 
The DNA damage was monitored by an incorporation of BrdU, Anti-PARP and α-H2AX. The intake of 
the BrdU in both the NCS and the NCS–EpCAM treatment was found to be minimal—a reduction in cell 
proliferation. The DNA damage was monitored with the release of PARP enzyme, the release of PARP 
was clearly observed in NCS and NCS–EpCAM conjugate treatment. The overall PARP was highest in 
NCS–EpCAM conjugates compared with NCS. The α-H2AX also revealed increased levels of α-H2AX 
in NCS and NCS–EpCAM conjugate treatments that were recruited by serine 139. (C) Apoptosis revealed 
the highest percentage of positivity of necrosis in both the MCF-7 and WERI- Rb1 cell lines through flow 
cytometry analysis. 
4.3.2.3 Trypan blue cell viability assay 
The trypan blue cell viability assay revealed the IC50 value of 50 nM for the NCS 
conjugate and 150 nM for the NCS in the MCF-7 cells. The IC50 value was found to be 
75 nM and 300 nM for the NCS conjugate and the NCS in the WERI-Rb1 cells. 
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Figure 33: NCS–EpCAM Aptamer Conjugate Inside the Cell 
The conjugate is endocytosed and released into the cytoplasm. The NCS was then carried on to the 
nucleus, breaking non-repairable DNA breaks leading to cell cycle arrest and thereby pausing the cell and 
activation of PARP and H2AX. These molecules trigger the activation of ATM, BCL2 and BAX protein, 
related to apoptosis, to undergo apoptosis and cell death. 
4.4 Discussion 
The selectivity and specificity of aptamers to tumour cells has been reported earlier 
(Simon et al. 2013). Gelonin toxin has been delivered to prostate cancer cells using an 
anti-PSMA aptamer (Chu et al. 2006). In this study, the potent, DNA damaging, 
antitumour, antibiotic protein and NCS have been conjugated with the EpCAM aptamer 
to deliver NCS precisely to the cancer cells. 
Aptamers by themselves are non-toxic and can carry toxic payloads to cancer cells with 
minimal side effects (Blank et al. 2001). We conjugated NCS to the EpCAM aptamer to 
target the EpCAM-positive cells. The ability of the conjugate to induce DNA breaks in 
the cancer cells leading to G2 phase arrest further to the apoptosis and necrosis is in 
agreement with earlier reports (Kang et al. 2012) (Banuelos et al. 2003). Microarray 
analysis revealed the dominant genes that are highly expressed in NCS and conjugate 
treatments in MCF-7 cells. Evidence that the DNA damage response signalling 
pathways were involved is in agreement with earlier studies on targeted tumour therapy 
(Mischel, Cloughesy, and Nelson 2004) (Yamanaka et al. 2006) (Matsumoto et al. 
2009). DNA damage induced by NCS possibly releases reactive oxygen species through 
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an H2AX-Nox1/Rac1 pathway, leading to the repair mechanism for DNA damage 
(Kang et al. 2012). The NQO1 (NAD [P] Quinone oxidoreductase) gene is involved in 
the protection of cytosolic enzymes in adaptive stress conditions and also helps in the 
oxidation of NADH, a crucial component in cellular redox reactions. Moreover, it 
stabilises p53 activity and PARP1 activity (Cresteil and Jaiswal 1991). In our study, 
NQO1 was up-regulated in conjugate treated MCF-7 cells, revealing the stress response 
of the tumour cells. PANK3 is associated with the panthione synthesis pathway and, in 
acetyl-CoA production, facilitates the cellular redox process. Gene IFIT1, PANK3 and 
GCL3 are markers for DNA damage involved in cell proliferation and apoptosis 
(Weichselbaum et al. 2008). We observed that PANK3 and GCL3 are highly up-
regulated, revealing the process of DNA damage response and the induction of 
apoptosis. Most down-regulated genes in our study including AKT2, B4GALNT4, 
ZNF451 and PARP6 are involved in the cell cycle process and DNA damage repair 
mechanism (Tuncel et al. 2012). AKT2 is a thymoma viral oncogene homolog 2 that 
enhances cell migration, invasion and proliferation (Cheng et al. 2007). It has been 
prominently involved in various signalling pathways in cancers such as colorectal, 
pancreatic, prostate, non-small cell lung cancer, myeloid leukaemia and KEGG glioma 
(see Table 6). Mosesson et al. reported that the integrin molecule is transported in the 
direction of cancer invasion by endocytosis of RAB12 (Iida et al. 2005). We found 
RAB12 was highly down-regulated by the conjugate treatment and this may be 
significant in the prevention of cancer invasion. PCB2 is involved in the regulation of 
post-transcriptional and translational processing on stressed conditions (Han et al. 
2013). Complete down-regulation of PCB2 reveals that the conjugate treatment pushes 
the cell to undergo necrosis process. The epigenetic alteration was predicted in the 
conjugate treated cells and is evident by observing the complete down-regulation of the 
gene PHF20L1 that stabilises methyltransferase activity in the genome (Esteve et al. 
2014). Knockdown of the PolQ expression suppresses the DNA repair mechanism 
(Mateos-Gomez et al. 2015). Interestingly, in our study, we witnessed a remarkable 
down-regulation of the PolQ (Ceccaldi et al. 2015) involved in recruiting mitotic 
checkpoint proteins and regulating mitosis process during DNA damage (Nakaya et al. 
2010). In our study, PCID2 is highly down-regulated and this can be correlated to the 
inability of the cells to overcome cell cycle arrest in the mitotic phase. 
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Cell cycle analysis revealed that NCS and the NCS conjugate brought about 78% and 
86%, respectively, G2 phase arrest in MCF-7 cells. Conversely, NCS and the conjugate 
induced 29% and 45%, respectively, ‘s’ phase arrest in WERI-Rb1 cells. The difference 
observed could be due to the variation in the biology of the tumour cells. BRCA1 is a 
significant factor in the DNA repair pathway and helps in tumour suppression. This was 
observed in our microarray data in which BRCA1 is highly expressed (Xu, Chapman, et 
al. 2015) (Roy, Chun, and Powell 2012). The cleaved PARP was found to be more in 
the NCS conjugate treated MCF-7 cells that prove the active participation of DNA 
repair detection and caspase 3 induction. PARP also has a role in detecting double-
strand breaks and immediately activating ATM signalling that increases the H2AX 
activity for the DNA repair mechanism (Xu, Chapman, et al. 2015) (Haince et al. 2007) 
(Bencokova et al. 2009) (Altmeyer et al. 2013). NCS conjugate treated cells showed less 
proliferation, as evidenced by the incorporation of BrdU in both MCF-7 and WERI-Rb1 
cells. The lower levels of incorporation of BrdU in the growing population indicated 
that the conjugate induces DNA damage. The increased expression of H2A histone 
family member X (H2AX) has been reported in DNA-damaged conditions when treated 
with anti-cancer agents such as cisplatin (Lundholm et al. 2013). A higher expression of 
H2AX was evidenced in conjugate treated cells due to DNA damage. Consequently, we 
observed more PARP–1 cleavage in treated cells. Early DNA damage response was 
triggered through the recruitment of H2AX and the toxicity of conjugates that rendered 
lethal damage to the MCF-7 cells. However, in WERI-Rb1 cells we did not observe 
more cleaved PARP1—the apoptosis process was provided by a different, unknown 
mechanism. We observed only a small increase (from 0.04% to 2.56% and 3.40%) in 
the early apoptosis population in WERI-Rb1 cells. A similar profile was obtained for 
the late apoptotic population. More importantly, an increase of up to 50% was observed 
in the necrotic population in conjugate treated WERI-Rb1 cells. A similar pattern of 
necrosis was also obtained for MCF-7 cells when they were treated with conjugates. 
This result is in agreement with the BrdU incorporation and the H2AX recruitment 
assay. Further, cell death was confirmed through the MTT and trypan blue assays. The 
BCL2 family of genes in the apoptosis and the necrosis process were involved in our 
microarray study. The transduction of BCL2 genes releases the cytochrome C, 
enhancing mitochondrial dysfunction leading to apoptosis (Sato et al. 2008). In 
addition, mitochondrial dysfunction is directed by the BCL and the BAX genes that are 
of the BCL2 gene family. The mitochondrial dysfunction has necrosis as well as the 
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apoptosis process (Nakagawa et al. 2005) (Green and Kroemer 2004). This was clearly 
observed from our apoptotic data through Annexin V and PI. 
4.5 Conclusion 
NCS is considered potent DNA damaging antitumour—an antibiotic protein that may 
help in the treatment of cancers. We demonstrated that the EpCAM aptamer and NCS 
can be conjugated using Sulfo-LC-SPDP. The conjugate specifically binds to EpCAM-
positive tumour cells such as MCF-7 and WERI-Rb1. Our results showed that the toxin 
is effective at a lower dosage and brings DNA damage to the tumour cells, arresting the 
cell cycle phase. Gene expression through microarray analysis showed highly down-
regulated genes such as RAB12, PCB2, PolQ, H2AX and PARP1 are involved in 
cellular invasion, post-transcriptional translational regulation and apoptosis induction. 
The microarray result was further confirmed with the validation of H2AX and the 
cleaved PARP in conjugate treated cells by the BrdU incorporation assay. Thus, the 
cancer cells underwent an apoptotic process through PARP1 cleavage in MCF-7 cells 
and a necrosis process. 
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Chapter 5. Nanocarriers as Drug Carriers for Targeted 
Therapy 
5.1 Summary 
For proof of concept, we used aptamer drug conjugates and antibody-drug conjugates in 
retinoblastoma and breast cancer cell line prototypes. The promising results detailed in 
the previous chapters of using NCS–EpCAM conjugates in vitro has led to the 
development of nanoformulations that can be used in liver cancer models. The main 
objective of this study is to treat liver cancer stem cells using LNA EpCAM and LNA 
Ncl aptamer decorated NCs. The reasons for synthesising the NCs are to mask the 
cytotoxicity of the native toxin and deliver the drug payload to the cancer cells. NCS 
has high cytotoxicity levels and the failure of the Phase I and Phase II clinical trials in 
the Japanese population has led to the study of NCS using NCs prepared with sodium 
alginate and chitosan. The effect of the NCS–EpCAM conjugate on the cancer cells was 
promising, as noted in the previous chapter. Therefore, this chapter focuses on 
encapsulating the NCS–EpCAM aptamer conjugate inside the nanoparticle and 
decorating it with LNA EpCAM and LNA nucleolin aptamers to achieve targeting 
efficiency. We synthesised the NPs with different combinations of EpCAM and NCS 
and a void nanoparticle was prepared as the control. The effect of these NPs was 
observed in liver cancer cells that have cancer stem cell markers such as CD44, CD133 
and EpCAM. For this study, Hep3B and HepG2 liver cancer cell lines were used. The 
promising results from the in vitro experimentation have spurred further study on the 
effect of the NPs on liver cancer animal models. In vivo xenograft liver cancer mice 
models were induced with tumours and the effect of these NPs were observed in these 
models. The results were promising—the histopathological investigation proved no 
cytotoxicity to the cells and the bio-distribution was normal. 
5.2 Results 
5.2.1 Physicochemical characterisation of AEC-CP-NCSEpDT3 NCs 
SEM analysis revealed that the morphology of all the NPs was uniform and spherical in 
shape (see Figure 34A). The hydrodynamic size of all the particles was in the range of 
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200 nm–300 nm, as measured by DLS. The void NPs were found to be the smallest in 
size (possibly due to the absence of LNA EpCAM and LNA nucleolin), followed by the 
LNA EpCAM NPs. The chimeric NCS–LNA EpCAM (NLE) NPs were observed to be 
slightly larger than the others (see Figure 34B). The absorption spectra measured by the 
FTIR spectroscopy revealed that the chimeric NLE NPs and the LNA EpCAM NPs 
showed a clear and sharp N–H stretch at 3793 cm–1–3726 cm–1 indicating the presence 
of the LNA EpCAM aptamer in both nanoformulations. The peak at 1633 cm–1 
confirmed the presence of the primary amine group corresponding to the NCS in NCS 
NPs. The peak at 1026 nm further confirmed the presence of sodium alginate and other 
additives present in the nanocapsule synthesis (see Figure 34C). The encapsulation 
efficiency was noted to be 93.8% for the LNA EpCAM NPs, whereas the NCS NPs 
showed 82% encapsulation efficiency and the chimeric NLE NPs showed 92% 
encapsulation efficiency. The statistical analysis revealed that the encapsulation 
efficiency in all the NCs was significant (p<0.001). The release assay for NCS 
confirmed that a burst release was observed in the initial phase followed by a prolonged 
sustained release (see Figure 34D-i). Similar observations were made in the release 
assay of LNA EpCAM, in which a burst release was observed in the initial phase 
followed by a prolonged sustained release (see Figure 34D-ii). 
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Figure 34: Characterisation of NPs 
(A) Scanning electron microscopy confirmed that the void, LNA EpCAM, NCS and chimeric NLE NPs 
were uniform and spherical in morphology. (B) The hydrodynamic size of NPs was measured as 
approximately 250 nm–300 nm using DLS. (C) Encapsulation of NCS and chimeric NLE in AEC-CP 
NPs was confirmed using FTIR analysis. (D-I) and (D-II)-Drug release studies from LNA EpCAM, NCS 
and chimeric NLE NPs revealed an initial burst release followed by a constant slow release of NCS and 
LNA EpCAM. 
5.2.2 In vitro evaluation of AEC-CP-NCSEpDT3 NCs 
The results from the MTT cell viability assay in Hep3B and HepG2 cells revealed that 
void NPs, LNA EpCAM and LNA EpCAM NPs did not induce any significant decrease 
in cell viability when compared to untreated cells (see Figure 35A). Although both NCS 
and NCS NPs induced a significant (p<0.001) decrease in cell viability of the HepG2 
and Hep3B cells, it was observed that the nanoformulation of NCS did not enhance its 
anti-cancer potential. Conversely, nanoformulated chimeric NLE was significantly 
(p<0.01) more effective in reducing the cell viability of both the HepG2 and the Hep3B 
cells when compared to free chimeric NLE. These results suggested that nano-
encapsulation of the chimeric NLE enhanced its anti-cancer potential. To confirm these 
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findings, a clonogenic assay was performed to analyse reproductive cell death. Our 
findings confirmed that both free LNA EpCAM and LNA EpCAM NPs failed to induce 
a significant decrease in the clonogenic potential of the HepG2 and the Hep3B cells. 
Although both NCS and NCS NPs led to a decrease in the clonogenic potential of 
HepG2 and Hep3B cells, this was found to be insignificant. However, chimeric NLE 
NPs were significantly (p<0.01) more effective in reducing the clonogenic potential of 
both the HepG2 and the Hep3B cells compared to the free chimeric NLE (see Figure 
35B). These findings confirmed that the nanoformulation of chimeric NLE enhanced its 
anti-cancer efficacy against cancer cell monolayers. To observe the same in 3D tumour 
spheroid models, a tumour spheroid assay was performed. An insignificant regression of 
the tumour spheroids was noted in LNA EpCAM and LNA EpCAM NPs. However, 
LNA EpCAM NPs were significantly (p<0.05) more effective than the free LNA 
EpCAM in HepG2 spheroids (see Figure 35C). A similar observation was made with 
NCS and NCS NPs in which free NCS led to a significant (p<0.05) regression in tumour 
spheroids. The NCS NPs led to a significantly higher (p<0.001) regression in tumour 
spheroids of HepG2 cells. Both NCS (p<0.01) and NCS NPs (p<0.001) led to a 
significant regression of the tumour spheroids in Hep3B cells. Meanwhile, the chimeric 
NLE NPs showed a more significant regression of tumour spheroids (p<0.01) in HepG2 
and (p<0.001) in Hep3B, compared to the free chimeric NLE (see Figure 35D). The 
chimeric NLE NPs were observed to be the most effective treatment in both the cell 
monolayer assay as well as in 3D tumour spheroids. This confirmed that the conjugation 
of LNA EpCAM with NCS led to an increase in the anti-cancer efficacy and 
nanoformulation of the conjugate, further enhancing its anti-cancer potential. 
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Figure 35: In Vitro Anti-Cancer Efficacy of Chimeric NLE NPs in HepG2 and 
Hep3B Cells 
(A) The MTT cell viability assay confirmed that the NLE chimera was more effective than NCS alone 
and that the nanoformulated NLE chimera was more effective in reducing the cell viability of HepG2 and 
Hep3B cells. (B) The clonogenic assay confirmed that the NLE chimera was more effective than NCS 
alone and that nanoformulated NLE chimera was more effective in inducing reproductive cell death in 
HepG2 and Hep3B cells. (C) and (D) The tumour spheroid assays with HepG2 and Hep3B cells 
confirmed that the NLE chimera was more effective than NCS alone and that the nanoformulated NLE 
chimera was more effective in inducing a regression in the tumour spheroids. (Results = Mean ± SEM) 
p<0.05*, p<0.01** and p<0.001***. 
5.2.3 Anti-cancer activity of AEC-CP-NCSEpDT3 NCs in liver cancer mouse 
xenograft models 
The sorted triple positive (EpCAM, CD44 and CD133) Hep3B cells were able to induce 
tumours in all the groups. The untreated mice were fed a normal diet while the other 
groups were fed a diet of void NPs, LNA EpCAM NPs, NCS NPs and chimeric NLE 
NPs once the tumour had reached 0.5 cm3 (24th day). The diets continued until the 
tumours reached 1.0 cm3 or showed complete regression. The tumour volume reached 
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approximately 1.0 cm3 in untreated mice from the 13th to the 27th day. The tumours in 
the void NPs and the LNA EpCAM NPs treatment groups followed the same trend and 
reached 1.0 cm3 from the 11th to the 32nd day. However, a substantial reduction in the 
tumour volume in NCS NPs and chimeric NLE NPs treatment groups was observed 
within one week (31st day) of feeding (2.5-fold decrease in NCS NPs and 3.5-fold 
decrease in chimeric NLE NPs). A complete regression of tumours was observed in 
both the chimeric NLE NPs on day 47 and the NCS NPs on day 51. From day 52, six 
out of the 12 mice (three males and three females) were fed with a normal diet until day 
60, to check the tumour recurrence. No tumour recurrence was observed until the 60th 
day (see Figure 36A). The mice were checked for any signs of abnormality and 
discomfort and body weight was measured every alternate day. Our findings revealed 
that the mice that were fed on NPs diets did not show any signs of toxicity or discomfort 
and insignificant changes were observed in body weight compared to the untreated mice 
(see Figure 36B). After the mice were humanely killed, we performed an histological 
analysis of key organs including the tumour, kidney, brain, liver, spleen and intestine 
with haemotoxylin and eosin (H&E) staining to observe any signs of toxicity or 
abnormality (see Figure 36C). The tissues from the various parts of mice fed on the NPs 
diet did not show any change or abnormality when compared to tissues from the normal 
mice. A blood analysis was also performed to detect any signs of toxicity. Our findings 
revealed that the WBC count was decreased by 3.06-fold and the RBC count was also 
found to have reduced by 1.46-fold in the NCS NPs when compared to the void NPs 
(see Table 7). Insignificant changes were observed in the chimeric NLE NPs-fed mice. 
However, the platelet count was found to be substantially lowered by both the NCS NPs 
(3.73-fold) and the chimeric NLE NPs (1.46-fold). 
Chapter 5: Nanocarriers as Drug Carriers for Targeted Therapy 
105 
 
Figure 36: Tumour Suppressive Efficacy of Chimeric NLE NPs in Mice with 
Xenograft Stem Cell (CD133+, CD44+ EpCAM+) Tumours 
(A) A complete regression of tumours in all mice fed a diet containing NCS NPs and chimeric NLE NPs 
was observed. (B) An analysis of the body weight in mice showed no significant differences among the 
treatment groups suggesting no signs of abnormality or toxicity. (C) The histological analysis from key 
organs confirmed the absence of unwanted cytotoxicity in mice fed on NPs. 
5.2.4 Live imaging confirmed the target specific binding using NIRF 
The theranostic potential of AEC-CP-NCSEpDT3 NCs was studied using NIRF. The 
results were measured using IVIS and the fluorescent measurements were obtained as 
relative fluorescence units (RFU). The results were compared to the control diets v. the 
AEC-CP-NCSEpDT3 targeted diet. The fluorescence intensity of the targeted NCs was 
high in the AEC-CP-NCSEpDT3 targeted and corresponding tumours. The presence of 
NCs was observed in organs including the gut, buccal cavity, stomach, intestines and 
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other parts of the body. The imaging was done with the extracted organs individually, 
after humanely killing the animals. A high intensity of fluorescence showed in the skin 
around the tumour followed by the stomach, spleen, intestine, brain, tumour and 
kidneys. These studies have confirmed an efficiently targeted cancer therapy using LNA 
aptamer ligands (see Figure 37). 
 
Figure 37: Tumour Targeting Potential and Bio-Distribution of Chimeric NLE 
NPs 
(A) The NIRF images revealed a high localisation of NPs in the tumour site compared with the void NPs 
that did not contain LNA aptamers for tumour targeting. (B) The NIRF images showing the bio-
distribution of the chimeric NLE NPs in various organs. (C) Histogram showing comparative distribution 
of NPs in tumours and other organs of mice that were fed NP diets. 
5.2.5 Apoptotic array and anti-cancer effects of AEC-CP-NCSEpDT3 targeted 
The apoptosis array revealed the relative expression of 36 key proteins involved in the 
pro- or anti-apoptosis process. The treatment tumours including AEC-CP-EpDT3 
targeted, AEC-CP void and the control diet were chosen for this study. There were no 
tumours in the remaining two groups. The array showed differential expression in the 
untreated group and the treated groups with the LNA EpCAM NC and void NCs. The 
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level of expression of Bcl-2 in the groups void and LNA EpCAM NC, respectively, was 
2.5-fold and 1.2-fold in targeted, Bad showed 1.4-fold and 0.7-fold, clusterin showed 3-
fold and 2.5-fold, survivin showed 1.2-fold and 2.5-fold, catalase showed 2-fold and 2-
fold and X-linked inhibitor of apoptosis protein (XIAP) showed 2.2-fold and 4-fold. 
The expression was considered relatively high in recurring tumours in these groups. The 
pro-apoptotic protein expression was found to be Pro-Caspase 5-fold and 3.5-fold, 
cytochrome c 4.5-fold and 2.7-fold, BAX 2.7-fold and 1.5-fold, FADD 1.75-fold and 
0.5-fold, HSP-27 7-fold and 1.5-fold, TRAIL R2 2.5-fold and 5-fold, HSP-60 2.5-fold 
and 0.1-fold, HSP-70 5-fold and 2.1-fold, Phospho-p53 2.2-fold and 2-fold, phosphor 
p53 0.1-fold and 0.5-fold, HTRA 6.2-fold and 3.8-fold and SMAC 6.1-fold and 3.5-
fold. The rest of the proteins were found to be non-significant (see Figure 38). 
5.2.6 Stem cell array 
Stem cell array was performed on the tumours isolated from the void, LNA EpCAM NC 
and the control mice. The relative expression of 15 key proteins, or key molecules of 
pluripotent stem cell markers, were analysed. The results showed that the relative 
expression of E-cadherin was 4-fold and 3.5-fold in the void and LNA EpCAM NC 
groups when compared to all other markers in the array. Further analysis revealed a 
decreased expression in recurring tumours in the ά-Fetoprotein of 3.5-fold and 1.5-fold, 
the hepatocyte nuclear factor (HNF3β) of 4-fold and 2-fold, the SOX17 of 4-fold and 
2.1-fold, the pancreatic and duodenal homeobox 1 (PDX–1) of 5-fold and 3.5-fold, the 
tumour protein P63 (TP63) of 3.5-fold and 1-fold, the orthodenticle homeobox 2 (Otx2) 
of 3-fold and 1.5-fold and the vascular endothelial growth receptor 2 (VEGFR2) of 3-
fold and 1.5-fold, respectively. All other proteins were considered insignificant (see 
Figure 38). 
5.2.7 Human angiogenesis array and mouse cytokine array studies 
An angiogenesis array was performed with the control, void and the LNA EpCAM NC 
tumour samples. Ten of the 55 angiogenic markers were found to be expressing. The 
markers included angiopoietin–1, angiopoietin-2, artemin, DPPIV, endothelin–1, FGF-
acidic, FGF-basic, persephin, serpin E1 and thrombospondin–1. A reduction in fold 
expression of activin A, ADAMTS–1, Endostatin FGF-4, 7, HGF, PDGF-AB and 
vasohibin was observed in the void and LNA EpCAM NC tumour samples, compared 
Chapter 5: Nanocarriers as Drug Carriers for Targeted Therapy 
108 
with the control sample. The reduced fold change was observed to be more than 2-fold 
and the p-value was found to be p<0.05 (see Figure 38). 
The cytokine array showed the expression of 40 important mouse cytokines in the 
serum of untreated mice, void and the LNA EpCAM NC-fed mice. The expression of 
complement component 5 (C5/C5a) was observed, even in athymic mice. The 
expression of IFN-gamma, IL-13, IL-23 and serpin-E1 was increased in the untreated 
and void samples. The expression slightly decreased (by 1-fold) in LNA EpCAM NC. 
The expression of the other proteins including IL-alpha, MIF and MIP-alpha were 
decreased in untreated and void samples and the expression of the same proteins were 
observed to be increased (see Figure 38). 
 
Figure 38: Protein Expression of Apoptosis, Angiogenesis, Stem Cell and Cytokine 
Arrays 
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(A) Apoptosis array showing 35 key proteins involved in the apoptosis pathway. The figure clearly 
illustrates the increased expression of Bcl-2, Bad and XIAP protein in the tumour recurrence, the relative 
fold change and expression of 15 key proteins involved in the apoptotic pathway. The results showed 
specifically that the down-regulation of E-cadherin, a tumour suppressor protein, was up-regulated. 
p<0.05* is significant, p<0.01** is highly significant and p<0.001*** is very highly significant. (B) 
Angiogenesis array showing 55 key proteins involved in angiogenetic pathways. The figure illustrates the 
angiogenesis array that includes the increased expression of angiopoietin-1, angiopoietin-2, artemin, 
DPPIV, endothelin-1, FGF-acidic, FGF-basic, persephin, serpin E1 and thrombospondin-1. A reduction 
in fold expression of activin A, ADAMTS-1, Endostatin FGF-4,7, HGF, PDGF-AB and vasohibin was 
observed in the void and EpCAM tumour samples when compared with the control samples. (C) The stem 
cell array showing the differential expression of 15 key stem cell markers, the relative fold change and 
expression of 15 key proteins involved in the apoptotic pathway. The results showed specifically that the 
down-regulation of E-cadherin, a tumour suppressor protein, was up-regulated. p<0.05* is significant, 
p<0.01** is highly significant and p<0.001*** is very highly significant. (D) The cytokine array revealed 
the expression of IFN-gamma, IL-13, IL-23 and serpin-E1 was increased in the untreated and void 
samples and slightly decreased by 1-fold in the EpCAM. p<0.05* is significant, p<0.01** is highly 
significant and p<0.001*** is very highly significant. 
5.2.8 Chimeric NLE NPs modulate gene expression to induce apoptosis in Hep3B 
cells 
Gene expression studies were performed in Hep3B cells for the analysis of survivin 
splice variants, apoptosis markers, stem cell markers and key signalling genes. It was 
observed that both void NPs and LNA EpCAM NPs led to a significant (p<0.01) 
increase in survivin gene expression. The NCS NPs led to an insignificant decrease in 
survivin, whereas the chimeric NLE NPs led to a significant (p<0.05) decrease in 
survivin gene expression. A similar finding was made in survivin 2B, in which void 
NPs led to a significant (p<0.001) increase and the chimeric NLE NPs led to a 
significant (p<0.05) decrease in the survivin 2B gene expression. In survivinΛEX3, the 
void NPS and LNA EpCAM NPs (p<0.01) and the NCS NPs (P<0.001) led to a 
significant increase, while the chimeric NLE NPs led to a significant (p<0.05) decrease 
in the expression. No significant change was observed in survivin 3B with chimeric 
NLE NPs, while the survivin 2α expression was significantly increased (p<0.001) by 
void NPS, LNA EpCAM NPs and NCS NPs and significantly decreased (p<0.01) by 
chimeric NLE NPs (see Figure 39A). 
The pro-apoptotic genes such as p53 (p<0.05), caspase-3 (p<0.001), cytochrome c 
(p<0.001) and FAS (p<0.001) were found to be significantly up-regulated in the 
chimeric NLE NPs treatments. A significant increase in gene expression of caspase-3-
void NPs (p<0.001) and NCS NPs (p<0.05), cytochrome c-void NPs (p<0.01), FAS-
void NPs (p<0.001) and NCS NPs (p<0.01) was also observed (see Figure 39B). In stem 
cell markers, the gene expression of CD133 was significantly increased by void NPs 
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(p<0.001) and decreased (p<0.01) by chimeric NLE NPs. The gene expression of CD44 
was found to be significantly (p<0.01) reduced by NCS NPs and the gene expression of 
EpCAM was found to be significantly reduced by LNA EpCAM NPs (p<0.01) and 
NCS–EpCAM NPs (p<0.05). In signalling markers, insignificant changes were 
observed in the gene expression of Akt, PI3K, mTOR and ERK1 with chimeric NLE 
NPs. However, void NPs led to a significant (p<0.01) increase in Akt. EpCAM NPs led 
to a significant (p<0.01) decrease in mTOR and a significant increase (p<0.001) in 
ERK1 gene expression (see Figure 39D). 
Figure 39: Gene Expression Analysis for Apoptotic, Stem Cells and Signalling 
Molecules 
(A) Change in gene expressions of survivin splice variants-survivin, survivin 2B, survivinΛEX3, survivin 
3B and survivin 2a. (B) Expression of key pro-apoptotic markers. (C) Gene expression of stem cell 
markers CD133, CD44 and EpCAM. (D) Gene expression levels of signalling markers AKT, PI3K, 
mTOR and ERK1 post-treatment with void NPs, LNA EpCAM NPs, NCS NPs and chimeric NLE NPs. 
(Results = Mean ± SEM) p<0.05*, p<0.01** and p<0.001***. 
Chapter 5: Nanocarriers as Drug Carriers for Targeted Therapy 
111 
 
Figure 40: The Anti-Cancer Mechanism of Chimeric NLE NPs in Liver Cancer 
Stem Cells 
A chimera of LNA EpCAM and NCS was created. The chimeric NLE NPs were synthesised and targeted 
using LNA EpCAM and nucleolin. Upon oral feeding, the NPs were found to be located mainly in the 
tumour. A complete regression of tumours in all mice fed on diets containing NCS NPs and chimeric 
NLE NPs was observed in vivo. No signs of cytotoxicity were observed by morphological, body weight 
and blood analysis of mice. Pro-angiogenic markers such as Angiogenin-1, EGF, IGFBP-3 and HGF were 
significantly down-regulated, whereas the anti-angiogenic protein IGFBP-1 was up-regulated. Tumour 
promoting cytokines I-309, IL-13 and SDF-1 were significantly down-regulated. Anti-apoptotic proteins 
such as survivin, clusterin and HIF-1a were down-regulated, while pro-apoptotic proteins such as 
phosphor-Rad 17 and p-27/Kip1 were significantly up-regulated. NCS leads to single-strand breaks in 
DNA at adenine and thymine (A–T) sequences. DNA damage by NCS leads to an increase in ROS levels 
due to an overexpression of histone H2AX, leading to apoptosis and cell death. 
5.2.9 Histology and blood analysis 
The tumours were sectioned and the slides were stained with H&E for the organs, 
tumour, kidney, brain, liver, spleen and intestine sections. The results confirmed that 
there was no difference between the sections taken from the void and the AEC-CP-
Chapter 5: Nanocarriers as Drug Carriers for Targeted Therapy 
112 
EpDT3 treated mice. The cells were as healthy as the control tissue sections and no 
cytotoxicity was observed. The sections also revealed the presence of more blood 
vessels in the recurring tumour sections (see Figure 39). 
The blood analysis revealed the levels of blood components in the treated mice. The 
RBC count visibly increased 2-fold and the WBC count increased 1.58-fold. The 
haemoglobin content increased 1.5-fold and the hematocrit levels 1.2-fold (see Table 7). 
The untreated mice showed comparatively higher mean corpuscular haemoglobin 
concentration and good platelet count compared to the control. 





Void NC EpCAM NC NCS NC EpCAM–NCS 
NC 
1 WBC (103/mm3) 9.20 ± 2.20 10.90 ± 0.50 3.00 ± 7.50 7.60 ± 3.10 
2 RBC (106/mm3) 15.86 ± 0.75 14.30 ± 0.17 10.80 ± 1.70 14.77 ± 0.10 
3 HGB (g/dl) 25.80 ± 6.50 23.40 ± 0.07 21.80 ± 1.90 25.80 ± 0.60 
4 HCT (%) 80.40 ± 2.25 70.60 ± 0.10 53.80 ± 6.30 74.90 ± 2.20 
5 MCV (μm3) 51.00± 0.70 49.00 ± 2.10 49.00 ± 1.10 51.00 ± 1.50 
6 MCH (pg) 16.20 ± 6.50 16.30 ± 5.90 20.10 ± 7.10 17.40 ± 8.10 
7 MCHC (g/dl) 32.00 ± 45.01 33.10 ± 30.97 40.60 ± 12.10 34.40 ± 12.20 
8 PLT (103/mm3) 679.00 ± 1701.50 932.00 ± 125.00 182.00 ± 1056.00 464.00 ± 1101.00 
*WBC = white blood cells, RBC = red blood cells, HGB = haemoglobin, HCT = hematocrit, MCV = 
mean corpuscular volume, MCH = mean corpuscular haemoglobin, MCHC = mean corpuscular 
haemoglobin concentration, PLT = platelets. 
5.3 Discussion 
The nanocarrier used in this study contains calcium phosphate coated with chitosan and 
an outer alginate cover added, as described by the earlier reports on different cancer 
types (Barrere, van Blitterswijk, and de Groot 2006) (Gades and Stern 2005) (Tugcu-
Demiroz et al. 2007). This material was chosen for the NC preparation due to its 
potential nil cytotoxicity, established biodegradable nature and health benefits (Barrere, 
van Blitterswijk, and de Groot 2006). Chitosan reduces cholesterol and has other 
positive health effects (Gades and Stern 2005). Sodium alginate was one such chemical 
that was declared safe by World Health Organization and its benefits included good 
digestion. Sodium alginate was said to be safe by the US Food and Drug Administration 
in 1973 (Tugcu-Demiroz et al. 2007). Chitosan also helps in receptor-mediated 
endocytosis and transcytosis (Kanwar et al. 2015), as the polymer has a mucoadhesive 
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property. Reports state that the alginate coating is resistant to the acidic pH in the 
stomach that helps to protect the NCS from degrading (Roy, Kanwar, and Kanwar 
2015). The NCs pass from stomach to the intestine, where the basic pH will degrade the 
NCS and expose the chitosan layer. The nature of the chitosan polymer means it will be 
absorbed by the intestinal cells (Kanwar et al. 2015). The stability of the NCs was 
confirmed by exposing the NCs to high pH and low pH. The NCs were exposed to pH2 
and pH 8 and were found to be stable. Sustained release of the drug molecule was 
observed in the media through ultraviolet–visible spectroscopy and confirmed the 
release kinetics of the NCs at different pH. Most of the drug (approximately 80%) was 
released between 24 hours to 48 hours (Kanwar et al. 2015). 
Our group has previously conducted studies on the efficiency of these NCs in microbial 
infections (Gupta et al. 2015), osteoarthritis (Samarasinghe, Kanwar, and Kanwar 2014) 
and colon and breast cancer models (Kanwar et al. 2008) (Gades and Stern 2005). A 
comparison of blood samples was conducted to estimate the count of WBCs and RBCs 
in the treatment group. The NC treated mice were healthy and could improve their 
blood count (Kanwar, Mahidhara, and Kanwar 2012; Kanwar et al. 2015) (Mahidhara et 
al. 2015). In histopathological investigations, no cytotoxicity was observed in the brain, 
heart, kidney, liver or spleen (see Figure 5E). Vibrations in the chemical bonds that 
include the N–H stretch, C = O and the NH bend confirm the presence of constituents in 
the NCs and showed no nanotoxicity (Kanwar, Mahidhara, and Kanwar 2012) (see 
Figure 1A). Imaging using the NIRF also helped in the live monitoring of the tumours 
and bio-distribution of NCs in the organs (Shah and Weissleder 2005). 
In this study, for the in-vitro evaluation of NCs we used HepG2 and Hep3B as they are 
triple positive (Shah and Weissleder 2005) for stem cell markers (CD44, CD133 and 
EpCAM). The liver cancer xenograft models (nude mice) were used to study the in-vivo 
efficiency of the NCs (Yamashita et al. 2009) (Han et al. 2015) (Rountree et al. 2009). 
Hep3B was sorted for all three stem cell markers and the cells were used to induce 
tumours. Previous studies have found antitumour properties of CD133, CD44 and 
EpCAM using Fe-bLf NCs. Similar studies were performed and the NCs were 
synthesised by decorating with LNA EpCAM and LNA nucleolin aptamers for double 
target efficiency. These markers are well-established surface receptor proteins in 
cancers (Liu et al. 2014) (Pavsic et al. 2014) and overexpressed in most of the solid 
tumours (Imrich, Hachmeister, and Gires 2012) (Spizzo et al. 2011a). The mice were 
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continuously fed with NCs with different treatments and the tumour volumes were then 
noted. Half of the mice population in all the treatment groups was fed with an AIN93G 
diet for the next 30 days to check the tumour progression. In vivo analysis revealed that 
the NCs with the coupled NCS–EpCAM conjugate showed a tumour regression of 
about 95% that is directly related to the anti-cancer efficiency of the NCs. The NCs with 
NCS and NCS–EpCAM treatments showed the ability to completely regress the tumour 
without any side effects. 
NIRF imaging confirmed the tumour targeting potential of the NCs. The NCs 
containing LNA probes showed a high intensity of fluorescence in tumour localisation. 
In all other organs the intensity of the fluorescence demonstrated good bio-distribution 
of the NCs. The NCs accumulated in the tumours showed the targeting potential of the 
EpCAM and the Nucleolin, enhancing the therapeutic efficiency of the NCS. The NCs 
had not altered the blood circulation, but had altered the absorption process making the 
NCs biodegradable. 
H&E staining indicated that there was no cytotoxicity of the tissue specimens. The 
blood analysis also confirmed that the treatment groups had shown the blood 
components to be in the normal range and no adverse effects were found (Yamashita et 
al. 2009) (Han et al. 2015) (Rountree et al. 2009). The histopathological specimens 
clearly indicated no necrosis or tissue damage in all the organs, suggesting that the NCs 
do not alter the normal function of the other organs and are localised only to the tumour 
site. 
To depict the anti-cancer mechanism of NCS–EpCAM NCs, apoptosis and stem cell 
arrays were performed. The tumours from void, EpCAM and control were collected and 
the lysates were also collected. The apoptosis array showed the same changes in the 
void, EpCAM treated and control-diet mice. The expression of pro-apoptotic markers 
such as TRAIL R2, Pro-Caspase-3, cytochrome c, Bad, HSP27, FADD, HSP70 and 
HSP60 phosphor p53 (s15&s392) was higher in EpCAM NCs when compared with the 
other two treatments. The expression of TRAIL, Fas and FADD was high. These 
molecules are called ‘death receptors’ and lead to the activation of caspase-8 and 
caspase-3, reported in bLf treatment in azoxymethane-treated rats (Fujita et al. 2004). 
The stem cell array also revealed the expression of key 15 molecules. The inhibition of 
expression of EpCAM, CD44 `and CD133 was clearly observed. The use of NCs with 
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LNA EpCAM and LNA nucleolin has shown promising results in inhibiting the tumour 
progression, further helping to kill the entire tumour volume. The LNA modified 
EpCAM and nucleolin had a promising targeting effect, as was observed in previous 
reports (Roy et al. 2015). The inhibition of some of the important stem cell markers was 
also observed, such as PDX–1 (imparts tumour initiating metastatic capacity) (Ischenko, 
Petrenko, and Hayman 2014). The key molecules not expressed included ά-fetoprotein 
(Dudich et al. 1998) (stimulates tumour growth), Otx2 (Adamson et al. 2010) (maintains 
and progresses cancer), SOX 17 (Yang et al. 2013) (promotes tumour angiogenesis and 
destabilises tumour vessels), TP63 (Di Como et al. 2002) (tumour growth and 
migration), HCG (Cole 2012) (invasion and malignancy of tumour) and VEGF R2 
(Chatterjee et al. 2013) (promotes angiogenesis). E-cadherin was overexpressed in 
tumours that were involved in the β-catenin signalling pathway and suppresses tumour 
cell growth (Lau, Klausen, and Leung 2011). The human angiogenesis array showed the 
significant expression of DPPIV, angiopoietin–1, 2, endothelin–1, persephin and 
thrombospondin–1 was observed in the void and EpCAM treated cells. The FGF 
expression was included in mitogenic and cell survival activities such as tissue repair, 
tumour growth, cell growth, morphogenesis and invasion (Kwabi-Addo, Ozen, and 
Ittmann 2004). The cytokine profiling of the expression of C5/C5a was found to be 
significant in untreated, void and EpCAM samples. The complement component 5 leads 
to the cleavage C5a and C5b (Boshra et al. 2004). The IL-12 and IL-27, products of 
activated monocytes/macrophages and dendritic cells, were expressed in almost all the 
samples, as with previous reports (Liu, Guan, and Ma 2007). 
Survivin, as a key molecule involved in apoptosis, regulated the cell division in the 
MAPK signalling and Wnt/β catenin signalling pathway (Carter et al. 2006) (Zhang, 
Yan, et al. 2013). The q-RT PCR studies clearly indicated that the expression of 
survivin and survivin 2B was up-regulated with the NCS NC and NCS–EpCAM NC 
treatments. mTOR was observed as up-regulated in EpCAM–NCS NC treated samples. 
The PCR study also revealed that apoptotic genes such as BCL2, BAX and other related 
genes were involved in the pro-apoptosis process of cancer stem cells. PI3K and ERK 1 
are the signalling molecules involved in the migration and cell proliferation was highly 
expressed in the treatments. This is in agreement with the previous report in which the 
PI3K and ERK 1 activation can lead to invasion and migration in primary HCC (Saxena 
et al. 2007). The ERK signalling does not affect the cell cycle and the normal cell 
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process remains normal (Matsumoto, Okano, and Murawaki 2005). The fate of 
apoptosis depends on BCL2 and other related genes involved in apoptosis, is in 
accordance with the previous reports (Yan et al. 2014) (Shafagh, Rahmani, and Delirezh 
2015) (Roy et al. 2015) (Figure 6). In summary, HCC is one of the worst cancers. There 
are new treatment technologies under clinical trials that include nucleic acid-based anti-
HCV therapeutics (Lee, Kim, and Lee 2013). The antisense oligonucleotide binds to the 
complementary RNAs to suppress access to the cellular mechanism, thereby inhibiting 
the expression of the targeted RNAs (Gebbing et al. 2015). Recent studies have shown 
the new approach of nucleic acids in therapy under clinical trials with SPC3649 
(formerly Miravirsen), an LNA modified antimiR–122, for the treatment of HCV (Lee, 
Kim, and Lee 2013). Transplantation is one of the best options for HCC; however, the 
supply and availability of high quality donor organs is a limitation. The alternative 
treatments include resection, systemic therapy using sorafenib and radiofrequency 
ablation (RFA). These therapies have significant systemic or local side effects. Thus, 
the reason for this study is to suggest targeted therapy to reduce the side effect profile 
and to increase clinical efficacy. In this study we modify RNA/DNA based aptamers 
specific to HCV with LNA technology, to find the nucleic acid-based nano-therapeutics 
that target the HCV RNA genome or HCV-encoded proteins. Moreover, we will find 
their mechanisms of action and the prospects for their future application to the treatment 
of chronic HCV infections. The NCS encapsulated NCs decorated with LNA EpCAM 
and LNA nucleolin help to directly deliver the drug payloads to the cancer tissues, 
sparing the normal cells and tissues. This study revealed the decrease in the tumour 
volume of the HCC xenograft models. The clear histopathological investigations 
suggested no cytotoxicity of the tissues. The real-time PCR analysis has clearly shown 
the evidence of cell death by NCS by apoptosis pathways. The anti-cancer effect was 
clearly observed through death receptors such as FADD, TRAIl and Fas. Their 
activation leads to the activation of phosphor p53 by inhibiting the notch pathway to 
induce the activation of Bad. The induction of Bad leads to the depolarisation of 
mitochondria, leading to the release of SMAC/DIABLO and cytochrome c. Further, the 
induction of apoptosis was observed by inhibiting the Akt pathway and the activation of 
cytokines released from dendritic cells and macrophages (IL-27). 
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5.4 Conclusion 
This study showed the potential benefits of targeted therapy for primary liver tumours. 
The same system of NPs could be used with any other drug molecules to reduce the side 
effect profile and to increase clinical efficacy. The nanoformulated NCS and the NLE 
chimera decorated with LNA EpCAM and LNA nucleolin led to complete tumour 
regression, due to tumour-specific targeting. The histopathological and blood 
investigations suggested no signs of cytotoxicity. This proof of concept study 
successfully demonstrated that the chimerisation of NCS using LNA EpCAM was more 
successful and that nanomedicine-based technology enhanced the anti-cancer efficacy 
of the treatments. These NPs can be further characterised for their affinity and for their 
therapeutic potential in primary liver cancer cells, as well as liver cancer stem cells 
isolated from real human HCC patients for further validation and translational research. 
5.5 Future Perspectives 
1) In the current study, in vitro characterisation of two main conjugates was 
conducted and the best oligo conjugate was tested in vivo in liver cancer models. 
In future, to target different cancer tissues a molecule other than EpCAM could 
be studied. 
2) The function of NCS was revealed through the present study. In future, the 
internal mechanism of how NCS acts on internal organelles could be studied to 
obtain information on how NCS kills cancer cells. 
3) Interestingly, EpCAM expression was found in RB, breast and liver cancers. 
This study aimed at targeting these cancers using NCS. Future studies could use 
a different target ligand to conjugate NCS for better therapeutic effect. 
4) The conjugation of NCS with EpCAM was shown in this study. In future, the 
better biomarker could be chosen for the best optimised therapeutic levels. 
5) Bio-availability studies could be performed to reduce the cytotoxicity levels of 
the nano-conjugates. 
6) These novel conjugates could be investigated in other cancer types and used in 
clinical trials for further investigation. This could be a promising therapeutic 
molecule. 
7) The NCS encapsulated NCs decorated with bi-specific LNA EpCAM and LNA 
nucleolin have shown promising results with the CD133, CD44 and EpCAM 
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sorted HCC xenograft mice models. These NPs could be further characterised 
for their affinity and for their therapeutic potential. The NPs could be tested in 




Table A.1: List of Chemical Composition 
Serial No. Chemical Composition 
1 0.1% HCL 1 mL concentrated Hydrochloric acid 
999 mL milliQ 
2 4% (APES) 4 mL aminopropyl ethoxy silane 
96mL milliQ 
3 10 mM citrate buffer, pH 6.0 0.1 M trisodium citrate 41 mL 
0.1 M citric acid 9 mL 
Adjust the pH to 6.0 with conc. HCL 
Made up to 500 mL with milliQ 
4 1X Tris Buffered Saline 
(TBS), pH 7.6 
1.517 gm Tris buffer 
2.175 gm sodium Chloride 
Adjust pH to 7.6 
Made up to 250 mL with milliQ 
5 FACS Buffer 1X Phosphate buffered saline 
10% FBS 
1% sodium azide 
6 RadioImmunoPrecipitation assay 
(RIPA) lysis buffer 




1 mM EDTA 
150 mM sodium chloride 
1% PMSF 
250 μL of l mg/mL Protease Inhibitor 
Cocktail 
7 10X Running Buffer 144 gm Glycine 
30 gm Tris buffer 
10 gm Sodium Dodecyl sulphate 
Made up to 1000 mL 
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Serial No. Chemical Composition 
8 Sample loading buffer (4X, 10 
mL) 
2.0 mL 1 M Tris HCL, pH 6.8 
0.8 g SDS 
4.0 mL 100% glycerol 
4.0 mL 14.7 M β-mercaptoethanol 
1.0 mL 0.5 M EDTA 
8.0 mg bromophenol blue 
2.6 mL H2O 
9 30% acrylamide (100 mL) 29 gm acrylamide 
1 gm bisacrylamide 
Made up to 100 mL with milliQ 
10 1.5 M Tris, pH 8.8 (250 mL) 45.43 gm Tris base 
Adjust the pH to 8.8 
Made up to 250 mL 
11 1 M Tris, pH 6.8 (50 mL) 6.06 gm Tris base 
Adjust the pH to 6.8 
Made up to 50 mL 
12 10% SDS (50 mL) 5 gm SDS 
Made up to 50 mL 
13 5% skimmed milk (50 mL) 2.5 gm skimmed milk 
Made up to 50 mL with 1XTBS-T 
14 0.1 M CaCl2 Solution 0.74 gm CaCl2 
Made up to 50 mL with milliQ 
15 1X TE Buffer, pH 8.0 10 mM Tris HCL, pH 8.0 




Table A.2: List of Instruments 
Serial No. Instrument Model Company 
1 SDS-PAGE Setup Powerpac Hc Bio-Rad 
2 Biosafety Cabinet Safemate 1.2 Laftechnologies 
3 5% CO2 Incubator Heracell 150i Thermo Scientific 
4 Chemidoc XRS XRS Bio-Rad 
5 Gel Electrophoresis Setup Major science MP 300N 
6 pH Meter – Labchem pH 
7 Confocal Microscope LASaf Leica 
8 Inverted Microscope – Prism Optical 
9 Sonicator Vibra-Cell Sonics 
10 Microplate Reader SH–1000 Corona Electric 
11 Fluorescent Reader MTO-601F Corona Electric 
12 Flow Cytometer CantoII BD Bioscience 
13 Centrifuge 5804 Eppendorf 
14 Real-Time PCR AB 2500  Applied Biosystems 
15 Sample Heater HB-2 Wealtec Corp 
16 Dynamic Light Scattering Nano-2S Malvern Instruments 
17 Shaking Incubator LT Orbitek 
18 FTIR TENZOR 27 series Bruker 
19 UV Transilluminator 3UV UVP Company 
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Table A.3: List of Chemicals 
Serial No. Reagent/Chemical/Antibody/Buffers Company 
1 Acetone Chem Supply 
2 Acetonitrile Sigma-Aldrich 
3 Acrylamide Sigma-Aldrich 
4 Agarose Sigma-Aldrich 
5 Ammonium bicarbonate Sigma-Aldrich 
6 Ammonium persulfate Sigma-Aldrich 
7 Annexin V Staining kit BD Bioscience 
8 Anti-mouse IgG-FITC (F0257, Sigma-Aldrich) 
9 Anti-mouse IgG-horse radish peroxidase (A9044, Sigma-Aldrich) 
10 Bisacrylamide  Sigma-Aldrich 
11 Bradford-Coommassie plus protein assay reagent Thermo Scientific 
12 Bovine serum albumin Sigma-Aldrich 
13 Bromophenol blue Sigma-Aldrich 
14 Chloroform  Sigma-Aldrich 
15 Dithiothreitol (DTT) Sigma-Aldrich 
16 Dimethyl sulfoxide (DMSO) Sigma-Aldrich 
17 DMEM (high glucose) Life Technologies 
18 DNA ladder Fermentas 
19 Ethanol Chem Supply 
20 EDTA Sigma-Aldrich 
21 FBS Life Technologies 
22 DAPI Sigma-Aldrich 
23 Glacial acetic acid Panreac 
24 Glycerol Sigma-Aldrich 
25 Glycine Sigma-Aldrich 
26 Haematoxylin HiMedia Laboratories 
27 Isopropyl alcohol Chem Supply 
28 Methylene blue Sigma-Aldrich 
29 Mouse anti-EpCAM monoclonal antibody Cell Signaling Technology 
30 Paraformaldehyde Sigma-Aldrich 
31 Protein marker, wide range Bio-Rad 
32 Propidium Iodide stain Sigma-Aldrich 
33 Protease inhibitory cocktail Sigma-Aldrich 
34 RNase OUT Life Technologies 
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Serial No. Reagent/Chemical/Antibody/Buffers Company 
35 RPMI media Life Technologies 
36 Sodium azide Sigma-Aldrich 
37 Sodium Chloride Sigma-Aldrich 
38 Sodium citrate Sigma-Aldrich 
39 SDS Sigma-Aldrich 
40 Superscript III Life Technologies 
41 SYBR green premix Life Technologies 
42 Tis base Sigma-Aldrich 
43 Triton X–100 Sigma-Aldrich 
44 TRIzol reagent Life Technologies 
45 Trypan blue  Sigma-Aldrich 
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